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Abstract
Posttranslational modification to proteins represents a fundamental mechanism by
which protein function is extended and elaborated.  In the brain, modifications such as
phosphorylation play critical roles in mediating neuronal communication and
development. Unique among carbohydrate modifications is the addition of a single
monosaccharide, N-acetyl-D-glucosamine, to serine and threonine residues of proteins
(O -GlcNAc glycosylation). The modification shares intriguing features with
phosphorylation, including its intracellular and dynamic nature.  The enzyme responsible
for adding the modification to proteins is necessary for life at the single cell level and O-
GlcNAc glycosylation has been linked to nutrient sensing, gene expression, and in the
brain, to neurodegeneration.  Despite tantalizing evidence for the modification’s
importance, understanding O-GlcNAc glycosylation has been hampered by insufficient
strategies to study it at single-protein level as well as across the proteome.  Here we
describe the development of a new, chemoenzymatic strategy to facilitate the discovery
of O-GlcNAc proteins, as well as the first studies aimed at understanding O-GlcNAc
proteome-wide, in the brain. 
Our approach capitalizes on an engineered enzyme and synthetic unnatural
substrate to specifically ‘tag’ O-GlcNAc-modified proteins for rapid and sensitive
detection.  We applied the methodology to the discovery of low-abundance, endogenous
O-GlcNAc proteins from cells. We also combined the approach with mass spectrometry
for the isolation of O-GlcNAc peptides and the mapping of glycosylation sites, the first
step toward functional analysis of the modification.  Overall, our efforts led to the
identification of nearly fifty new O-GlcNAc proteins, several of which serve as targets
for mechanistic study.  Many of the proteins function in the control of transcription and
translation, highlighting the proposed role for O-GlcNAc in regulating gene expression.
Additionally, we provide evidence that O-GlcNAc glycosylation is particularly prevalent
on proteins at the nerve terminal, or synaptosome, where it may function to control
vesicle cycling and neurotransmitter release.  Finally, our work has also led to the first
bioanalytical, quantitative assays for O-GlcNAc dynamics in both cells and tissue.  We
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have shown that O-GlcNAc is reversible in neuronal tissue and can respond rapidly and
robustly to neuronal stimulation in vivo.
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Chapter 1
Introduction:  O-GlcNAc Glycosylation in the Brain
1.1 Post-Translational Modifications as Critical Regulators of Neuronal Function
One of the most intriguing revelations of the human genome sequencing project,
completed in 2003,1 was the discovery of the relative paucity of genes encoding all the
proteins necessary for human development and functioning.  That number, now estimated
at 20-25,000 genes,1 is barely larger than the genome of far simpler organisms such as the
nematode Caenorhabditis elegans (19,000 genes).2  While genomics has revealed the
genes in various organisms, it tells us little about the actual gene products, the proteins,
produced in physiological settings.  Because these proteins are so essential for cellular
function, ‘decoding’ their interrelationship will be as critical as sequencing the genome to
understanding normal and pathological organismal function.  One of the fields that has
emerged to tackle this challenge is that of proteomics.3  As a counterpart to genomics,
proteomics asks which proteins are expressed in specific cellular states, how these
proteins interact in networks to govern cell function, and how these
expressions/interactions change in response to physiological stimulation.  The number of
proteins far outnumbers genes due to alternative transcript formation, proteolytic
processing, and the addition of chemical groups to protein side chains, referred to as post-
translational modifications (PTMs).  As such, the study of protein regulatory networks
represents a formidable task.3
Perhaps nowhere is complexity more clearly displayed than in the human brain,
which is composed of over 1011 neurons and over 10-fold more supporting glial cells.3
The proteins within each of these cells are responsible for dictating neuronal
22
communication, growth during development, and degradation. Moreover, aberrations in
protein function are hallmarks of debilitating neurodegenerative diseases such as
Alzheimer’s and Huntington’s disease.  One mechanism that has evolved to orchestrate
protein behavior is the post-translational modification (PTM) of protein side chains.
PTMs extend and elaborate the standard 20 amino acids,4,5 and can serve as molecular
‘signals’ to modulate protein activity and interactions.  One of the best characterized
PTMs is the addition of a phosphoryl group to serine, threonine, and tyrosine residues of
proteins.  Over 500 members of the human genome are kinases, highlighting the
necessity for this type of modification.6 Moreover, fifty years of research has
demonstrated that phosphorylation represents a central mechanism by which proteins
transmit intracellular signals in response to external cues, assemble in macromolecular
complexes, undergo degradation and drive a host of processes such as gene expression.6,7
In the neuronal junctions that mediate communication, known as synapses,
phosphorylation signaling events underlie the proposed molecular basis of learning and
memory (Figure 1.1).  For example, presynaptically, phosphorylation regulates synaptic
vesicle exocytosis and the release of neurotransmitter.8  Postsynaptically,
phosphorylation modulates  glutamate receptor conductance, receptor trafficking to and
from the membrane, as well as the complexation and degradation of  cytoskeletal-
remodeling proteins necessary for proper synapse function.9-11 In fact, one of the most
abundant components of neuronal synapses is the protein kinase Ca2+/calmodulin-
dependent protein kinase II (CaMKII).  CaMKII is a well-characterized molecular
‘switch’ whose activity is necessary for the activity-induced strengthening of synapses
(long-term potentiation (LTP)).  At synapses, CaMKII mediates the induction of LTP
33
both by directly phosphorylating α-amino-3-hydroxy-5-methyl-4-isoxazole propionic
acid receptors (AMPA-R), thus increasing their conductance, and modulating AMPA
receptor trafficking to the cell surface by phosphorylating their associated proteins.12,13
Figure 1.1.  Protein phosphorylation regulates numerous facets of neuronal communication, such
as the release of neurotransmitter presynaptically, trafficking of ionotropic glutamate receptors
into the membrane, and ion channel conductance.  Signal transduction via phosphorylation is also
necessary for gene transcription and de novo protein synthesis, which are required for long-term
memory formation.
Among its varied roles, phosphorylation mediates the molecular changes
characteristic of long-term memory formation.   Elegant work by Eric Kandel and others,
beginning in the nineteen-sixties, demonstrated that long-term memory formation was
dependent on transcription and translation of new proteins.   In particular, they showed
that long-term facilitation of the gill-withdrawal reflex in Aplysia was dependent on
transcription mediated by cAMP-response element binding protein (CREB).14 Related
work demonstrated  that LTP, a molecular model for long-term memory, was dependent
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P
P
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on phosphorylation pathways mediated by the cAMP-dependent kinase PKA.  As PKA is
one of the major kinases acting on CREB, regulated phosphorylation of CREB has been
implicated as a molecular marker of long-term memory storage.15-17  As such, CREB and
the phosphorylation pathways that act on it have become targets for drug development to
improve cognitive deficits.14
In addition to phosphorylation, numerous other PTMs play critical roles in protein
function in the brain and other tissue.  Currently, over 200 distinct PTMs have been
identified, comprising diverse groups of molecules such as lipids, acetates, and
polypeptides (Figure 1.2).4,5
Figure 1.2. Diverse molecules serve to modify proteins posttranslationally.  PTMs are critical for
all aspects of cellular function including protein turnover and localization, gene expression, and
cell-cell communication.
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Lipid modifications, such as farnesylation, drive protein translocation and association
with the membrane.  In the brain, farnesylation has been shown to affect localization of
the protein transducin, in the retina, which is critical for  light adaptation.18  At the post-
synaptic density (PSD) of the synapse, polyubiquitination (the addition of multiple 76-
amino acid ubiquitins to lysine residues) has been shown to promote degradation of
critical scaffolding proteins in a manner dependent on neuronal activity.19,20 Recent
efforts to understand PTMs have focused on understanding not just individual
modifications, but how networks of modifications drive particular cellular function.  One
example of such PTM networks exists along the N-terminal ‘tails’ of histones, the
proteins that coil around DNA, and serve as important determinants of transcriptional
activation.  The distinct network of histone modifications, ranging from lysine acetylation
to phosphorylation to methylation, has been proposed to serve as a ‘code’ that marks
dynamic transitions between transcriptionally active or repressed chromatin states.21
While some PTMs, like phosphorylation and acetylation, are dynamically
regulated, others function stably over the course of a protein’s lifetime.  One of the most
classical of these modifications is the addition of carbohydrate moieties to proteins
(glycosylation).  Estimates suggest that nearly half of all proteins are glycosylated,
making this the most common form of protein modification in vivo.22 N-linked
glycosylation, via the consensus sequence Asn-X-Ser/Thr, (where X can not be proline)
is characterized by extraordinarily long chains of carbohydrates.5,23  O - l i n k e d
glycosylation, which lacks a consensus motif, is often restricted to just a few
carbohydrate units but may be elaborated to great lengths and structural diversity as
exemplified by the glycosaminoglyan proteoglycans.24,25  The enzymes of glycosylation
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are largely restricted to the endoplasmic reticulum and Golgi apparatus, where they
modify proteins destined for membrane insertion or secretion.5  As with kinases, the great
number and diversity of glycosyltransferases (~250 in the human genome) highlights the
essential role of this PTM for cell function.26
Studies have implicated carbohydrate modifications in a number of processes,
including proper protein folding, protein targeting to subcellular compartments and
receptor-ligand binding.23,24,27  On a cellular level, these modifications are important for
cell-cell communication and cell growth and division.28 One of the most well-
characterized roles of glycosylation is in the immune response and inflammation.29  In
humans, red blood cells display one of three glycosphingolipids on the cell surface that
differ by a single monosaccharide residue, forming the basis of the so-called A, B or O
blood groups. The antibodies generated against the nonnative carbohydrate antigen
prohibit blood transfusion among those with different blood types.24
In the nervous system, glycosylation plays a vital role in cytokine and growth
factor-receptor interactions.24,28  For example, the cell surface heparan sulfate (HS)
proteoglycans are necessary to mediate the interaction of the secreted slit protein and its
cell-surface receptor robo.  Slit functions as a repulsive guidance cue for growing axons
and removing the carbohydrates from HS proteoglycans ablates its chemorepulsive
effect.30  Glycosylation also mediates neurite and axonal outgrowth in the spinal cord,
where studies have shown that chondroitin sulfate proteoglycans specifically prevent
neuronal regeneration after spinal cord injury.31 Interestingly, deglycosylation of the
proteoglycans ‘disinhibits’ neurite outgrowth,32 highlighting the potential benefits of
targeting protein glycosylation for therapeutic gain.
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1.2 O-GlcNAc Glycosylation
Unique to carbohydrate protein modifications is the addition of a monosaccharide
β-N -acetylglucosamine to serine and threonine residues of proteins (O-GlcNAc
glycosylation) (Figure 1.3).33-35
Figure 1.3.  O-GlcNAc glycosylation is a unique carbohydrate modification to proteins.
Mediated by two soluble, intracellular enzymes, O-GlcNAc is dynamic and ubiquitous, sharing
more in common with phosphorylation than traditional forms of glycosylation.
First identified by Hart and Torres in 1984 in lymphocyte cells,36 O-GlcNAc is
distinguished from other carbohydrate modifications by occurring predominantly on
intracellular proteins rather than those sequestered to membrane compartments.37
Moreover, unlike classical forms of glycosylation, O-GlcNAc appears to be dynamically
regulated.  Pulse-chase experiments including [3H]-GlcNAc have shown that for certain
protein substrates, the half-life of the O-GlcNAc modification is on the order of hours
compared to days for the protein backbone.38  Moreover, recent studies have shown that
O-GlcNAc levels are strongly upregulated in response to a number of cell stress stimuli.39
In neutrophils (white blood cells), O-GlcNAc can respond directly to ligand binding
within minutes.40
In the twenty years since its discovery, O-GlcNAc has been identified in all
higher eukaryotic organisms, from C. elegans to humans33 and found to modify
~100 proteins.39  The enzymes responsible for catalyzing the modification have been
cloned and characterized.41  Demonstrating that there is no compensatory mechanism for
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O-GlcNAc in mammals, an O-GlcNAc transferase  (OGT) knockout is lethal at the
embryonic stem cell level.42,43  OGT shares little to no homology to traditional
glycosyltransferases.  Moreover, unlike these enzymes, which are restricted to the ER and
Golgi,  OGT is a soluble, alternatively spliced, multimeric protein found predominantly
in the nucleus and cytoplasm, with additional limited distribution in the mitochondria.41
Interestingly, unlike enzymes that govern well-characterized modifications, such as
phosphorylation, there is only one known OGT gene.  While there is no consensus
sequence for glycosylation,  OGT may modulate its substrate specificity through protein-
protein interactions with its tetratricopeptide N-terminal repeat domain (TPR).44
Recently crystallized, the OGT TPR bears significant similarity to that of importin-α, in
which the TPR serves as a protein-interaction domain.45  Indeed, several binding partners
of OGT have been identified,46,47 and may function to govern its subcellular localization
or substrate targeting in a manner analogous to the A-kinase anchoring proteins (AKAPs)
associated with the cAMP pathway and PKA.48
Interestingly, the β-N-acetylglucosaminidase (O-GlcNAcase) that removes O-
GlcNAc has also been cloned and is distributed to the cytoplasm and nucleus.49,50  Unlike
classical hexosaminidases that reside in the lysozome and function largely to degrade
membrane glycoproteins, O-GlcNAcase has a pH optimum near neutral, coincident with
its non-lysosomal activity.49  The O-GlcNAcase appears to be a bifunctional enzyme, as
it shares sequence homology with acetyltransferases, and recent studies have shown that
it can behave as an acetyltransferase in vitro.51  In dividing cells, targeted
pharmacological disruption of the O -GlcNAcase induces growth arrest, whereas
overexpression induces early mitotic exit and severe perturbations in mitotic
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phosphorylation.52
The intriguing features of O-GlcNAc led many groups to posit that this
modification may function similarly to phosphorylation in the cell.53  Like
phosphorylation, O-GlcNAc is intracellular, dynamic and targets serine and threonine
residues.  Moreover, recent studies have identified proteins with lectin-like properties for
O-GlcNAc, (such as the heat shock protein 70).  These lectins may behave analogously to
known proteins baring phosphorylation-binding domains such as  the WW superfamily.54
Additionally, several studies highlight the apparent antagonism between O-GlcNAc
glycosylation and phosphorylation.  For example, O-GlcNAc modifies the carboxy-
terminal domain (CTD) of RNA polymerase II (RNAP II)  in vivo.  However, this form
of RNAP II lacks the phosphorylation  necessary for transcriptional initiation, elongation
and termination and thus is transcriptionally inactive.55,56  Moreover, synthetic peptides
that are glycosylated cannot be phosphorylated by the CTD TFIIH kinase CDK7,
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phosphorylated peptides are no longer substrates for OGT, even though the two primary
sites of modification are distinct.  In other examples, O-GlcNAc and phosphate compete
for the same site of modification.  This is the case with the oncogene c-myc, in which the
lymphomal hotspot Thr58 can be interchangeably modified depending on extracellular
conditions,57 as well as the transcription factor estrogen receptor β (ER-β), in which
glycosylation and phosphorylation may have opposing effects on protein stability.58
These studies support what has been characterized as a ‘yin-O-yang’ between O-GlcNAc
and phosphorylation.  Nonetheless, in the case of  certain proteins, such as the signal
transducer and activator of transcription 5 (Stat5), O-GlcNAc and phosphorylation are
not mutually exclusive59 and may behave cooperatively to regulate function. Moreover,
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establishing the interplay between the two modifications on complex networks of
proteins, if it exists, has proved challenging, in part because the function of O-GlcNAc
was, for many years, not well understood.
 Initial efforts to understand the role of O-GlcNAc glycosylation centered on
identifying modified proteins.  Nearly one hundred O-GlcNAc proteins were individually
identified, during a twenty-year period.39  These proteins include transcription factors
such as Sp1and CREB, the 26S cap of the proteasome, cytoskeletal proteins such as the
neurofilament proteins H, M, L, and proteins involved in glucose metabolism, such as
glycogen synthase.60-63
In part due to the challenges in identifying O-GlcNAc targets,64 the functional
significance of O-GlcNAc modification remains elusive.  Nonetheless, in recent years,
several intriguing hypotheses have emerged as to the role of O-GlcNAc, including
nutrient sensing and transcriptional repression (Figure 1.4). 33,35
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Figure 1.4.  O-GlcNAc glycosylation plays a role in many aspects of cell function
including transcriptional repression and nutrient sensing.  The substrate for the O-GlcNAc
transferase (OGT), UDP-GlcNAc, is a product of the hexosamine biosynthesis pathway and
OGT’s unique sensitivity to it can tune O-GlcNAc levels in response to extracellular glucose.
Upregulation of O-GlcNAc on transcriptional machinery can inhibit gene transcription in
response to changes in glucose or other stimuli.
Roughly 3% of all glucose that enters cells is shuttled into the hexosamine
biosynthesis pathway62  of which the primary product is uridine-diphospho-N-actetyl-D-
glucosamine (UDP-GlcNAc), the substrate of OGT.  Interestingly, UDP-GlcNAc levels
are known to fluctuate significantly, depending on cell state.65  Moreover, OGT has 3
apparent Kms for UDP-GlcNAc (6, 35 and 217 µM) toward peptide acceptor substrates,
and its activity toward those substrates changes with increasing UDP-GlcNAc
concentration.66  These and other findings suggest that  glucose levels may be able to
fine-tune the O-GlcNAc modification in a highly sensitive manner,67 which prompted
many groups to propose that O-GlcNAc functions as a nutrient sensor in the cell.  Several
studies support this hypothesis, demonstrating that GlcNAc levels, both globally and on
individual proteins, are responsive to varying glucose concentrations in a number of cell
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types.68-70  Because aberrantly high levels of glucose can affect O-GlcNAc levels, it has
been proposed that the modification contributes to type II diabetes, a hallmark of which is
hyperglycemia-induced insulin resistance.  In support of such a role, Hart and colleagues
demonstrated that treatment of 3T3-L1 adipocyte cell lines with the O-GlcNAcase
inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate
(PUGNAc) decreased insulin-stimulated glucose uptake and interfered with insulin-
activated phosphorylation signaling cascades.71  A similar finding was reported for
skeletal muscle.72  Others have demonstrated that overexpression of OGT induces insulin
resistance in both adipocyte and skeletal tissue.73  Finally, a C. elegans OGT knockout,
while not lethal, induces significant changes in metabolite storage and suppresses the
conversion to the dauer form of the nematode, suggesting that O-GlcNAc plays a
significant role in C. elegans nutrient storage and longevity.74
In addition to nutrient sensing, O-GlcNAc also appears to figure prominently in
the control of transcription.  These two roles for O-GlcNAc are likely interrelated as it is
well known that nutrient cues from the extracellular environment can initiate particular
patterns of gene expression in numerous cell types.35  Recent efforts in the field have
focused on the role of O-GlcNAc in transcriptional repression, although it should be
noted that for several molecular targets such as nuclear factor kappa B (NFκB), O-
GlcNAc serves to upregulate transcriptional activity.35  Consistent with a role in
repression, OGT was found to stably interact with the corepressor mSin3A, a member of
the histone deacetylase complex, where it was shown to be involved in synergistic
transcriptional repression along with histone deacetylation.75  Recently, mSIN3A and
OGT interactions were tied to yet another PTM, the nonenzymatic addition of
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methylglyoxal, a product of glycolysis, to arginine residues of proteins.  Methylglyoxal
modification is associated with aging, inflammation, and a host of pathologies including
diabetes.  Methylglyoxal modification of mSin3A in response to high glucose led to
enhanced recruitment of OGT and increased O-GlcNAc modification of the transcription
factor Sp3.  The resultant elevation in O-GlcNAc led to an increase in expression of the
angiopoeitin-2 gene, one of several genes whose proliferative function is associated with
late stages of various diseases, including diabetic retinopathy.76
In addition to its interaction with mSin3A, O-GlcNAc glycosylation has been
shown to be associated with transcriptionally silenced areas of euchromatin.77  Moreover,
Kudlow and colleagues demonstrated a negative effect on Sp1 transcription factor
activity in response to glycosylation78.   Our group identified CREB as a new target of O-
GlcNAc modification, and showed that CREB-mediated transcription is likewise
downregulated in response to glycosylation.60  Finally, OGT colocalizes with  RNAP II
in cells,46 and as described earlier, is associated with transcriptionally inactive forms of
the RNAP II holonenzyme.55
1.3 O-GlcNAc Glycosylation in the Brain
Given the similarities and potential interplay between phosphorylation and O-
GlcNAc glycosylation and the essential role phosphorylation plays in brain function, we
became interested in the role of O-GlcNAc in the nervous system.   In particular, we were
interested in the molecular targets of O-GlcNAc glycosylation and the ensuing effect of
O-GlcNAc on brain function.  In addition, we were intrigued by the dynamic nature of
the modification and sought to understand O-GlcNAc regulation in neuronal tissue.
A number of studies suggested that O-GlcNAc plays an important role in the
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brain.  Both OGT and O-GlcNAcase mRNA and protein expression are highest in brain
and pancreas.79 A neuron-specific OGT conditional knockout in the mouse produced
viable pups who failed to nurse, had significant motor deficiencies and died within
several days.42  Further supporting a ‘yin-O-yang’ between phosphorylation and O-
GlcNAc, OGT was found to form stable complexes with protein phosphatase 1 in the
brain.80
Prior to our work, only a handful of O-GlcNAc-modified proteins from the brain
had been identified.  Among these proteins were the synaptic vesicle associated protein
synapsin, β-synuclein, neurofilament proteins H, L, M,  the collapsin response mediator
protein-2 (CRMP-2), the amyloid precursor protein (APP) and the microtubule associated
protein tau.81  Hyperphosphorylated tau and aberrantly processed APP are hallmarks of
Alzheimer’s disease, which has been linked  to insufficient glucose uptake in the aging
brain,82 suggesting that O-GlcNAc may play a role in neurodegeneration.  Indeed, the
OGT conditional mouse knockout showed hyperphosphorylated tau,42 and studies on
hippocampal slices from adult rat have shown aberrant phosphorylation of tau in response
to treatment with the O-GlcNAcase inhibitor PUGNAc.83  Interestingly, O-GlcNAc is an
endogenous inhibitor of the proteasome, and corollary studies suggested that aberrant O-
GlcNAc glycosylation in the brain induced proteome malfunction and neuronal
apoptosis.83
Whether O-GlcNAc plays a role in neurodegeneration remains unclear, but even
more fundamentally, its contribution to non-pathological brain function is still unknown.
Specifically, although found throughout the neuron, OGT is particularly abundant in
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synaptosomes, especially in the cytosol of the axon terminal  and around dendritic
microtubules, consistent with  O-GlcNAc modification of several microtubule-associated
proteins.81,84  Both enzymes are found throughout brain substructures, but are most
prevalent in the hippocampus and the Purkinje neurons of the cerebellum.83,84  Indeed, a
study from 1999 identified a panel of phosphatase and kinase inhibitors that had
significant effects on O-GlcNAc levels in the cytoskeletal fractions of cultured cerebellar
neurons suggesting that, as in other tissues, O-GlcNAc can be dynamic in the brain.85
One possible role for O-GlcNAc in the brain may involve glucose sensing in
active brain areas.  The brain consumes a disproportionally large amount of glucose and
oxygen compared to the rest of the body.86  Contrary to the prevailing model of relatively
invariant glucose uptake in the brain, recent studies suggest that glucose levels increase in
specific regions of the adult brain, in response to high levels of activity.86   For example,
in rodent hippocampi, glucose uptake from the cerebrospinal fluid was shown to increase
significantly in response to maze-learning paradigms.86  Because of its exquisite
sensitivity to glucose, one physiological role for O-GlcNAc may be as a mechanism to
tag or mark neurons or neuronal networks with high metabolic rates, in turn affecting
diverse processes such as axonal outgrowth or synaptic vesicle cycling.   In addition to
glucose, other factors may contribute to O-GlcNAc regulation and function in the brain.
For example, OGT appears to be tyrosine phosphorylated87 and may respond to
extracellular cues through tyrosine kinase/phosphatase signaling cascades.  Finally, O-
GlcNAc levels are known to respond to stress, and protect cells from stress-induced
apoptosis.88  In neurons, O -GlcNAc may serve analogously to protect cells from
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apoptosis (in response to excitotoxicity, for example) potentially in both a UDP-GlcNAc
dependent and independent manner.
1.4 Methodologies to Study O-GlcNAc
Despite emerging evidence for its significance in the brain, identifying O-GlcNAc
glycosylated proteins in neurons or understanding the regulation of O-GlcNAc in the
brain has proven challenging.  Methodologies to detect the O-GlcNAc modification
endogenously have traditionally suffered from both lack of selectivity and sensitivity
(discussed in more detail in Chapter 2).  The first tool to study O-GlcNAc harnessed the
selectivity of the enzyme β1,4-galactosyltransferase to  catalyze the transfer of galactose
to terminal GlcNAc sugars.36  Highly selective for GlcNAc, the enzyme was shown to
effectively transfer UDP-[3H]-galactose to GlcNAc-modified proteins for detection by
autoradiography.37  However, compared to other commonly used radioisotopes such as
[32P], UDP-[3H]-galactose has low specific activity, such that it can take weeks or months
to detect even the most highly abundant glycosylated proteins.64,89  This limitation led to
the development of several antibodies for O-GlcNAc.  Specifically, the RL-2 antibody
was raised against O-GlcNAc modified nuclear pore proteins, and was demonstrated to
show good selectivity for O-GlcNAc.90  However, because it was raised against particular
O-GlcNAc glycosylated peptides, the antibody also recognizes peptide determinants and
either fails to detect certain O-GlcNAc proteins entirely, or requires a higher
concentration of protein  than found endogenously for detection.64,90  Hart and colleagues
developed an O-GlcNAc-specific antibody shown to bind selectively to O-GlcNAc
peptides with no cross-reactivity for O-linked  N-acetyl-d-galactosamine (O-GalNAc)
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peptides or peptides lacking the GlcNAc sugar.89  While this CTD110.6 antibody has
been employed as a strategy to assess global O-GlcNAc glycosylation, it still fails to
detect many O-GlcNAc-modified proteins, and often exhibits weak binding affinity by
Western blotting.64
 The traditional strategies are further limited by their inability to identify specific
amino acid sites of O-GlcNAc glycosylation on proteins of interest, which is a
prerequisite for understanding the functional role of the modification on individual
targets.  Because OGT lacks a consensus sequence for glycosylation79 and because the O-
GlcNAc moiety is highly labile during mass spectrometry,91 predicting sites of
glycosylation or identifying sites analytically has proven challenging.
1.5 Chemical Biology and Bioanalytical Approaches to Study Proteins and PTMs
The study of PTMs, as exemplified by O-GlcNAc, poses a number of challenges.
They are not genetically encoded, (often with no consensus amino acid sequence for
modification), present at substoichiometric amounts or on low-abundance proteins, are
dynamic in the cell, and often labile during protein analysis.  As such, the PTM field has
spurred the development of many new and exciting chemical biology and bioanalytical
techniques, greatly enhancing our ability to understand this rich area of biology.
PTM analysis in recent years has benefited greatly from the application of well-
established chemical strategies to study the biophysical and biochemical properties of
proteins.  In particular, synthetic chemistry and molecular biology have been used to
design non-canonical, unnatural amino acid analogues for incorporation into proteins in
vivo.92  For example, site-specific incorporation, via nonsense suppression, has been used
to perturb ligand binding sites in receptor proteins and ion channels to glean molecular
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insights into ion channel properties.93  Residue-specific incorporation, via global
replacement of a given amino acid, has been used in protein engineering contexts to
modulate protein-fold and protein-protein interactions.92  Unnatural amino acids have
also been used as bioorthogonal chemical handles, to permit ready detection and isolation
of proteins from cells.94   In a related vein, chemical strategies have been used to expand
the scope of traditional peptide synthesis in order to gain access to large polypeptides or
even proteins in vitro for functional analysis.95  Importantly, approaches like native
chemical ligation, (which uses transthioesterification to couple peptides) have allowed
chemists to build proteins with nonnatural amino acids, such as fluorescent tags.95  Native
chemical ligation and related techniques are particularly attractive strategies for the
creation of post-translationally modified proteins in vitro.  They can be used to create
homogenously modified proteins for biological studies as exemplified by the generation
of the O-linked glycosylated protein, and antimicrobial agent, diptericin96.
Bertozzi and colleagues elegantly applied the principles of unnatural analogue
incorporation to the study of carbohydrates.  In particular, they have demonstrated that
carbohydrates with bioorthogonal functionalities such as ketones or azides can be
incorporated in cells, and even in a limited subset of  animal tissues in vivo.97  The
bioorthogonal functionality on these sugars can  be used as a tag to identify cell surface
expression of such molecules, which may be aberrant in certain disease states, such as
cancer.98
Other synthetic approaches have been geared toward the study of
phosphorylation. For example, the ‘bump-hole’-type strategies have been used to
incorporate unnatural adenosine triphosphate (ATP) analogues into mutant kinases in
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order to identify new physiological targets of such kinases.6  Moreover, lipid
modifications, specifically farnesylation, have been the targets of azido analogues
incorporated in cells for the identification of new, modified proteins from cell culture.99
Such synthetic approaches have developed in tandem with analytical techniques
for the discovery of PTMs.  The last twenty years have seen the robust expansion of mass
spectrometry, not just in the identification of isolated proteins, but in the evaluation of
whole-cell proteomes, and the discovery of corresponding sets of PTMs.100  For example,
multidimensional protein identification technology (MudPIT), which uses multiple
chromatographic steps coupled to mass spectrometry, has enabled global studies of
posttranslationally modified proteins in yeast.101  Chemical derivitization methods for a
number of PTMs, such as phosphates and N-linked carbohydrates, as well as techniques
such as metal ion affinity chromatography have facilitated the enrichment of low-
stoichiometry modified peptides and the sequencing of modification sites.102,103,104 In
another example, Dietrich and colleagues used the incorporation of an unnatural
methionine analogue, with azide functionality, in order to specifically isolate and identify
newly translated proteins from cell culture.105  Finally, emerging strategies in mass
spectrometry have involved not just the identification of proteomes and PTMs, but the
quantification of changes in both protein expression and PTMs in response to cellular
stimulation.  In the best-characterized strategies such as stable isotope labeling with
amino acids in cell culture (SILAC)106 or isobaric tags for relative and absolute
quantification (iTRAQ),107 cells or cell extracts are labeled with stable isotopes and the
ratio of signal intensities of differentially labeled, but essentially chemically identical,
peptides are used to determine relative abundance (Figure 1.5).
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Figure 1.5. Mass spectrometry (MS)-based approaches for quantitative proteomics.  (A) In
methods such as stable isotopic labeling with amino acids in cell culture (SILAC), differential
isotopes of amino acids such as arginine are added to two or more different populations of cells.
Samples are mixed and proteolytically digested.  Relative signal intensities of mass differentiated
but chemically identical peptides are used to determine relative abundance. (B) In another
method, isobaric tags for relative and absolute quantification (iTRAQ), cell lysates from two or
more different cell populations are proteolytically digested.  Peptide n-terminal amines (and ε-
amines from lysine residues) are subsequently labeled with isobaric mass tags.  The tags are
cleaved during tandem MS (MS/MS) allowing mass differentiation, and the differences in signal
intensity between portions of the tags are used to determine relative abundance.
In order to monitor quantitative changes in PTMs, techniques such as SILAC have been
coupled to enrichment strategies, as in the case of a recent study that used antityrosine
antibodies to specifically capture SILAC-labeled  tyrosine-modified proteins.  In this
case, the authors were able to monitor temporal changes in tyrosine phosphorylation in
response to cell stimulation.108
Overall, the wealth of techniques that have recently emerged to study protein and
PTM networks should prove fruitful as the field moves from identifying modified
proteins toward addressing the more challenging questions of how PTMs are regulated,
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spatially and temporally, and in turn, how they modulate ‘proteome’ and cellular
function.
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1.6 Conclusion
The covalent attachment of post-translational modifications to protein side chains
is a critical means by which protein function is elaborated, and by which key cellular and
organismal processes are controlled.  In the brain, well-characterized phosphorylation
signaling cascades mediate molecular changes proposed to form the basis of learning and
memory.  More recently, other PTMs such as ubiquitination and acetylation have come to
be recognized for their contribution to neuronal function.  One emerging PTM is O-
GlcNAc glycosylation, the covalent attachment of the single monosaccharide, N-acetyl-d-
glucosamine to serine/threonine residues of proteins.  Unique among carbohydrate
modifications, O-GlcNAc is both intracellular and dynamic.  The enzymes responsible
for the modification are necessary for life at the single cell level and are particularly
abundant in the brain and pancreas.  Although it may serve global functions in nutrient
sensing and transcriptional repression, the role of O-GlcNAc in the brain and the brain-
specific proteins it modifies are largely unknown.  Owing to the difficulty in detecting the
modification and identifying O-GlcNAc modification sites, this PTM has proven
challenging to study.  As such, the development of sensitive techniques for both the
discovery of O-GlcNAc proteins and the identification of stimuli that regulate O-GlcNAc
in the brain are critical.  In this regard, emerging strategies involving synthetic chemistry,
chemical biology and analytical chemistry should prove to be powerful tools to
understand not just O-GlcNAc but the complex regulatory network of PTMs that underlie
brain function.
23
23
References
1. International Human Genome Sequencing Consortium. Finishing the euchromatic
sequence of the human genome. Nature 431, 931-45 (2004).
2. The C. elegans sequencing consortium. Genome Sequence of the Nematode C.
elegans: A Platform for Investigating Biology. Science 282, 2012-18 (1998).
3. Becker, M., Schindler, J. & Nothwang, H. G. Neuroproteomics - the tasks lying
ahead. Electrophoresis 27, 2819-29 (2006).
4. Khidekel, N. & Hsieh-Wilson, L. C. A 'molecular switchboard'--covalent
modifications to proteins and their impact on transcription. Org Biomol Chem 2,
1-7 (2004).
5. Walsh, C. T., Garneau-Tsodikova, S. & Gatto, G. J., Jr. Protein posttranslational
modifications: the chemistry of proteome diversifications. Angew Chem Int Ed
Engl 44, 7342-72 (2005).
6. Johnson, S. A. & Hunter, T. Kinomics: methods for deciphering the kinome. Nat
Methods 2, 17-25 (2005).
7. Cohen, P. The origins of protein phosphorylation. Nat Cell Biol 4, E127-30
(2002).
8. Turner, K. M., Burgoyne, R. D. & Morgan, A. Protein phosphorylation and the
regulation of synaptic membrane traffic. Trends Neurosci 22, 459-64 (1999).
9. Esteban, J. A., Shi, S. H., Wilson, C., Nuriya, M., Huganir, R.L. & Malinow, R.
 PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking
underlying plasticity. Nat Neurosci 6, 136-43 (2003).
10. Derkach, V., Barria, A. & Soderling, T. R. Ca2+/calmodulin-kinase II enhances
channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate
type glutamate receptors. Proc Natl Acad Sci USA 96, 3269-74 (1999).
11. Pak, D. T. & Sheng, M. Targeted protein degradation and synapse remodeling by
an inducible protein kinase. Science 302, 1368-73 (2003).
12. Lisman, J., Schulman, H. & Cline, H. The molecular basis of CaMKII function in
synaptic and behavioural memory. Nat Rev Neurosci 3, 175-90 (2002).
13. Tomita, S., Stein, V., Stocker, T. J., Nicoll, R. A. & Bredt, D. S. Bidirectional
synaptic plasticity regulated by phosphorylation of stargazin-like TARPs. Neuron
45, 269-77 (2005).
14. Carlezon, W. A., Jr., Duman, R. S. & Nestler, E. J. The many faces of CREB.
Trends Neurosci 28, 436-45 (2005).
15. Bito, H., Deisseroth, K. & Tsien, R. W. CREB phosphorylation and
dephosphorylation: a Ca(2+)- and stimulus duration-dependent switch for
hippocampal gene expression. Cell 87, 1203-14 (1996).
16. Barco, A., Alarcon, J. M. & Kandel, E. R. Expression of constitutively active
CREB protein facilitates the late phase of long-term potentiation by enhancing
synaptic capture. Cell 108, 689-703 (2002).
17. Nguyen, P. V. & Woo, N. H. Regulation of hippocampal synaptic plasticity by
cyclic AMP-dependent protein kinases. Prog Neurobiol 71, 401-37 (2003).
18. Kassai, H., Aiba, A.,  Nakao, K., Nakamura, K.,  Katsuki, M.,  Xiong, W. H.,
Yau, K. W., Imai, H., Shichida, Y., Satomi, Y., Takao, T., Okano, T. &
24
24
Fukada, Y.  Farnesylation of retinal transducin underlies its translocation during
light adaptation. Neuron 47, 529-39 (2005).
19. Bingol, B. & Schuman, E. M. Synaptic protein degradation by the ubiquitin
proteasome system. Curr Opin Neurobiol 15, 536-41 (2005).
20. Yi, J. J. & Ehlers, M. D. Ubiquitin and protein turnover in synapse function.
Neuron 47, 629-32 (2005).
21. Jenuwein, T. & Allis, C. D. Translating the histone code. Science 293, 1074-80
(2001).
22. Apweiler, R., Hermjakob, H. & Sharon, N. On the frequency of protein
glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim
Biophys Acta 1473, 4-8 (1999).
23. Helenius, A. & Aebi, M. Intracellular functions of N-linked glycans. Science 291,
2364-9 (2001).
24. Hang, H. C. & Bertozzi, C. R. The chemistry and biology of mucin-type O-linked
glycosylation. Bioorg Med Chem 13, 5021-34 (2005).
25. Sugahara, K., Mikami, T.,  Uyama, T., Mizuguchi, S., Nomura, K. & Kitagawa,
H. Recent advances in the structural biology of chondroitin sulfate and dermatan
sulfate. Curr Opin Struct Biol 13, 612-20 (2003).
26. Coutinho, P. M., Deleury, E., Davies, G. J. & Henrissat, B. An evolving
hierarchical family classification for glycosyltransferases. J Mol Biol 328, 307-17
(2003).
27. Pellegrini, L. Role of heparan sulfate in fibroblast growth factor signalling: a
structural view. Curr Opin Struct Biol 11, 629-34 (2001).
28. Selleck, S. B. Shedding light on the distinct functions of proteoglycans. Sci STKE
2006, pe17 (2006).
29. Rudd, P. M., Elliott, T., Cresswell, P., Wilson, I. A. & Dwek, R. A. Glycosylation
and the immune system. Science 291, 2370-6 (2001).
30. Hu, H. Cell-surface heparan sulfate is involved in the repulsive guidance activities
of Slit2 protein. Nat Neurosci 4, 695-701 (2001).
31. Silver, J. & Miller, J. H. Regeneration beyond the glial scar. Nat Rev Neurosci 5,
146-56 (2004).
32. Massey, J. M., Hubscher, C. H., Wagoner, M.R., Decker, J.A., Amps, J., Silver, J.
& Onifer, S. M. Chondroitinase ABC digestion of the perineuronal net promotes
functional collateral sprouting in the cuneate nucleus after cervical spinal cord
injury. J Neurosci 26, 4406-14 (2006).
33. Love, D. C. & Hanover, J. A. The hexosamine signaling pathway: deciphering the
"O-GlcNAc code". Sci STKE 2005, re13 (2005).
34. Wells, L., Vosseller, K. & Hart, G. W. Glycosylation of nucleocytoplasmic
proteins: signal transduction and O-GlcNAc. Science 291, 2376-8 (2001).
35. Zachara, N. E. & Hart, G. W. Cell signaling, the essential role of O-GlcNAc!
Biochim Biophys Acta (2006).
36. Torres, C. R. & Hart, G. W. Topography and polypeptide distribution of terminal
N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for
O-linked GlcNAc. J Biol Chem 259, 3308-17 (1984).
25
25
37. Holt, G. D. & Hart, G. W. The subcellular distribution of terminal N-
acetylglucosamine moieties. Localization of a novel protein-saccharide linkage,
O-linked GlcNAc. J Biol Chem 261, 8049-57 (1986).
38. Roquemore, E. P., Chevrier, M. R., Cotter, R. J. & Hart, G. W. Dynamic O-
GlcNAcylation of the small heat shock protein alpha B-crystallin. Biochemistry
35, 3578-86 (1996).
39. Zachara, N. E. & Hart, G. W. O-GlcNAc a sensor of cellular state: the role of
nucleocytoplasmic glycosylation in modulating cellular function in response to
nutrition and stress. Biochim Biophys Acta 1673, 13-28 (2004).
40. Kneass, Z. T. & Marchase, R. B. Neutrophils exhibit rapid agonist-induced
increases in protein-associated O-GlcNAc. J Biol Chem 279, 45759-65 (2004).
41. Iyer, S. P. N. & Hart, G. W. Dynamic nuclear and cytoplasmic glycosylation:
Enzymes of O- GlcNAc cycling. Biochemistry 42, 2493-2499 (2003).
42. O'Donnell, N., Zachara, N. E., Hart, G. W. & Marth, J. D. Ogt-dependent X-
chromosome-linked protein glycosylation is a requisite modification in somatic
cell function and embryo viability. Mol Cell Biol 24, 1680-90 (2004).
43. Shafi, R., Iyer, S. P., Ellies, L. G., O'Donnell, N.,  Marek, K. W.,  Chui, D.,
Hart, G. W., & Marth J. D. The O-GlcNAc transferase gene resides on the X
chromosome and is essential for embryonic stem cell viability and mouse
ontogeny. Proc Natl Acad Sci USA 97, 5735-9 (2000).
44. Iyer, S. P. & Hart, G. W. Roles of the tetratricopeptide repeat domain in O-
GlcNAc transferase targeting and protein substrate specificity. J Biol Chem 278,
24608-16 (2003).
45. Jinek, M., Rehwinkel, J., Lazarus, B. D., Izaurralde, E., Hanover, J.A. & Conti, E.
The superhelical TPR-repeat domain of O-linked GlcNAc transferase exhibits
structural similarities to importin alpha. Nat Struct Mol Biol 11, 1001-7 (2004).
46. Iyer, S. P., Akimoto, Y. & Hart, G. W. Identification and cloning of a novel
family of coiled-coil domain proteins that interact with O-GlcNAc transferase. J
Biol Chem 278, 5399-409 (2003).
47. Andrali, S. S., Marz, P. & Ozcan, S. Ataxin-10 interacts with O-GlcNAc
transferase OGT in pancreatic beta cells. Biochem Biophys Res Commun 337,
149-53 (2005).
48. Bauman, A. L., Goehring, A. S. & Scott, J. D. Orchestration of synaptic plasticity
through AKAP signaling complexes. Neuropharmacology 46, 299-310 (2004).
49. Dong, D. L. & Hart, G. W. Purification and characterization of an O-GlcNAc
selective N-acetyl-beta-D-glucosaminidase from rat spleen cytosol. J Biol Chem
269, 19321-30 (1994).
50. Wells, L., Gao, Y., Mahoney, J. A., Vosseller, K., Chen, C., Rosen, A. & Hart G.
W. Dynamic O-glycosylation of nuclear and cytosolic proteins: further
characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-
GlcNAcase. J Biol Chem 277, 1755-61 (2002).
51. Toleman, C., Paterson, A. J., Whisenhunt, T. R. & Kudlow, J. E. Characterization
of the histone acetyltransferase (HAT) domain of a bifunctional protein with
activable O-GlcNAcase and HAT activities. J Biol Chem 279, 53665-73 (2004).
52. Slawson, C. Zachara, N. E., Vosseller, K., Cheung, W. D., Lane, M. D. & Hart,
G. W. Perturbations in O-linked beta-N-acetylglucosamine protein modification
26
26
cause severe defects in mitotic progression and cytokinesis. J Biol Chem 280,
32944-56 (2005).
53. Hart, G. W., Greis, K. D., Dong, L. Y., Blomberg, M. A., Chou, T. Y., Jiang,
M.S., Roquemore, E.P., Snow, D. M., Kreppel, L. K., Cole, R. N., et al. O-linked
N-acetylglucosamine: the "yin-yang" of Ser/Thr phosphorylation? Nuclear and
cytoplasmic glycosylation. Adv Exp Med Biol 376, 115-23 (1995).
54. Guinez, C., Losfeld, M. E., Cacan, R., Michalski, J. C. & Lefebvre, T. Modulation
of HSP70 GlcNAc-directed lectin activity by glucose availability and utilization.
Glycobiology 16, 22-8 (2006).
55. Kelly, W. G., Dahmus, M. E. & Hart, G. W. RNA polymerase II is a glycoprotein.
Modification of the COOH-terminal domain by O-GlcNAc. J Biol Chem. 268,
10416-24 (1993).
56. Comer, F. I. & Hart, G. W. Reciprocity between O-GlcNAc and O-phosphate on
the carboxyl terminal domain of RNA polymerase II. Biochemistry 40, 7845-52
(2001).
57. Kamemura, K., Hayes, B. K., Comer, F. I. & Hart, G. W. Dynamic interplay
between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins:
alternative glycosylation/phosphorylation of THR-58, a known mutational hot
spot of c-Myc in lymphomas, is regulated by mitogens. J Biol Chem 277, 19229-
35 (2002).
58. Cheng, X. & Hart, G. W. Alternative O-glycosylation/O-phosphorylation of
serine-16 in murine estrogen receptor beta: post-translational regulation of
turnover and transactivation activity. J Biol Chem 276, 10570-5 (2001).
59. Gewinner, C., Hart, G. W.,  Zachara, N., Cole, R., Beisenherz-Huss, C. & Groner,
B. The coactivator of transcription CREB-binding protein interacts preferentially
with the glycosylated form of Stat5. J Biol Chem 279, 3563-72 (2004).
60. Lamarre-Vincent, N. & Hsieh-Wilson, L. C. Dynamic glycosylation of the
transcription factor CREB: a potential role in gene regulation. J  Am  Chem  Soc
125, 6612-3 (2003).
61. Parker, G. J., Lund, K. C., Taylor, R. P. & McClain, D. A. Insulin resistance of
glycogen synthase mediated by O-linked N-acetylglucosamine. J Biol Chem 278,
10022-7 (2003).
62. Zachara, N. E. & Hart, G. W. The emerging significance of O-GlcNAc in cellular
regulation. Chem. Rev. 102, 431-8 (2002).
63. Zhang, F., Su, K., Yang, X., Bowe, D. B., Paterson, A. J. & Kudlow, J. E. O-
GlcNAc modification is an endogenous inhibitor of the proteasome. Cell 115,
715-25 (2003).
64. Khidekel, N., Arndt, S., Lamarre-Vincent, N., Lippert, A., Poulin-Kerstien, K. G.,
Ramakrishnan, B., Qasba, P. K. & Hsieh-Wilson L. C. A chemoenzymatic
approach toward the rapid and sensitive detection of O-GlcNAc posttranslational
modifications. J  Am Chem Soc 125, 16162-3 (2003).
65. Wice, B. M., Trugnan, G., Pinto, M., Rousset, M., Chevalier, G., Dussaulx, E.,
Lacroix, B. & Zweibaum, A. The intracellular accumulation of UDP-N-
acetylhexosamines is concomitant with the inability of human colon cancer cells
to differentiate. J Biol Chem 260, 139-46 (1985).
27
27
66. Kreppel, L. K. & Hart, G. W. Regulation of a cytosolic and nuclear O-GlcNAc
transferase. Role of the tetratricopeptide repeats. J Biol Chem 274, 32015-22
(1999).
67. Haltiwanger, R. S., Holt, G. D. & Hart, G. W. Enzymatic addition of O-GlcNAc
to nuclear and cytoplasmic proteins. Identification of a uridine diphospho-N-
acetylglucosamine:peptide beta-N-acetylglucosaminyltransferase. J Biol Chem
265, 2563-8 (1990).
68. Walgren, J. L., Vincent, T. S., Schey, K. L. & Buse, M. G. High glucose and
insulin promote O-GlcNAc modification of proteins, including alpha-tubulin. Am
J Physiol Endocrinol Metab 284, E424-34 (2003).
69. Ball, L. E., Berkaw, M. N. & Buse, M. G. Identification of the major site of O-
linked beta-N-acetylglucosamine modification in the C terminus of insulin
receptor substrate-1. Mol Cell Proteomics 5, 313-23 (2006).
70. Clark, R. J., McDonough, P. M., Swanson, E., Trost, S. U., Suzuki, M., Fukuda,
M. & Dillmann, W. H. Diabetes and the accompanying hyperglycemia impairs
cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J
Biol Chem 278, 44230-7 (2003).
71. Vosseller, K., Wells, L., Lane, M. D. & Hart, G. W. Elevated nucleocytoplasmic
glycosylation by O-GlcNAc results in insulin resistance associated with defects in
Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 99, 5313-8 (2002).
72. Arias, E. B., Kim, J. & Cartee, G. D. Prolonged incubation in PUGNAc results in
increased protein O-Linked glycosylation and insulin resistance in rat skeletal
muscle. Diabetes 53, 921-30 (2004).
73. McClain, D. A., Lubas, W. A., Cooksey, R. C., Hazel, M., Parker, G.J., Love, D.
C. & Hanover,  J. A. Altered glycan-dependent signaling induces insulin
resistance and hyperleptinemia. Proc Natl Acad Sci USA 99, 10695-9 (2002).
74. Hanover, J. A., Forsythe, M. E., Hennessey, P. T., Brodigan, T. M., Love, D. C.,
Ashwell, G. & Krause, M. A Caenorhabditis elegans model of insulin resistance:
altered macronutrient storage and dauer formation in an OGT-1 knockout. Proc
Natl Acad Sci USA 102, 11266-71 (2005).
75. Yang, X., Zhang, F. & Kudlow, J. E. Recruitment of O-GlcNAc transferase to
promoters by corepressor mSin3A: coupling protein O-GlcNAcylation to
transcriptional repression. Cell 110, 69-80 (2002).
76. Yao, D.,  Taguchi, T., Matsumura, T., Pestell, R., Edelstein, D., Giardino, I.,
Suske, G., Ahmed, N., Thornalley, P. J., Sarthy, V. P., Hammes, H. P. &
Brownlee, M.l. Methylglyoxal modification of mSin3A links glycolysis to
angiopoietin-2 transcription. Cell 124, 275-86 (2006).
77. Kelly, W. G. & Hart, G. W. Glycosylation of chromosomal proteins: localization
of O-linked N-acetylglucosamine in Drosophila chromatin. Cell 57, 243-51
(1989).
78. Yang, X., Su, K., Roos, M. D., Chang, Q., Paterson, A. J. & Kudlow, J. E. O-
linkage of N-acetylglucosamine to Sp1 activation domain inhibits its
transcriptional capability. Proc Natl Acad Sci USA 98, 6611-6 (2001).
79. Iyer, S. P. & Hart, G. W. Dynamic nuclear and cytoplasmic glycosylation:
enzymes of O-GlcNAc cycling. Biochemistry 42, 2493-9 (2003).
28
28
80. Wells, L., Kreppel, L. K., Comer, F. I., Wadzinski, B. E. & Hart, G. W. O-
GlcNAc transferase is in a functional complex with protein phosphatase 1
catalytic subunits. J Biol Chem 279, 38466-70 (2004).
81. Cole, R. N. & Hart, G. W. Cytosolic O-glycosylation is abundant in nerve
terminals. J. Neurochem. 79, 1080-9 (2001).
82. Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W. & Gong, C. X. O-GlcNAcylation
regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.
Proc Natl Acad Sci USA 101, 10804-9 (2004).
83. Liu, K., Paterson, A. J.,  Zhang, F., McAndrew, J., Fukuchi, K., Wyss, J.M., Peng,
L., Hu, Y. & Kudlow JE. Accumulation of protein O-GlcNAc modification
inhibits proteasomes in the brain and coincides with neuronal apoptosis in brain
areas with high O-GlcNAc metabolism. J Neurochem 89, 1044-55 (2004).
84. Akimoto, Y., Comer, F.I., Cole, R.N., Kudo, A., Kawakami, H., Hirano, H.
 & Hart GW. Localization of the O-GlcNAc transferase and O-GlcNAc-modified
proteins in rt cerebellar cortex. Brain Res 966, 194-205 (2003).
85. Griffith, L. S. & Schmitz, B. O-linked N-acetylglucosamine levels in cerebellar
neurons respond reciprocally to pertubations of phosphorylation. Eur  J  Biochem
262, 824-31 (1999).
86. Ewan C. Mcnay & Gold, P. E. Food for Thought: Fluctuations in Brain
Extracellular Glucose Provide Insight Into the Mechanisms of Memory
Modulation. Behavioral and Cognitive Neuroscience Reviews 1, 264-280 (2002).
87. Kreppel, L. K., Blomberg, M. A. & Hart, G. W. Dynamic glycosylation of nuclear
and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc
transferase with multiple tetratricopeptide repeats. J Biol Chem 272, 9308-15
(1997).
88. Zachara, N. E., O'Donnell, N., Cheung, W. D., Mercer, J. J., Marth, J. D. & Hart
G. W. Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in
response to stress. A survival response of mammalian cells. J Biol Chem 279,
30133-42 (2004).
89. Comer, F. I., Vosseller, K., Wells, L., Accavitti, M. A. & Hart, G. W.
Characterization of a mouse monoclonal antibody specific for O- linked N-
acetylglucosamine. Analytical Biochemistry 293, 169-177 (2001).
90. Holt, G. D., Snow, C. M., Senior, A., Haltiwanger, R. S., Gerace, L.
 & Hart, G. W. Nuclear pore complex glycoproteins contain cytoplasmically
disposed O-linked N-acetylglucosamine. J Cell Biol 104, 1157-64 (1987).
91. Chalkley, R. J. & Burlingame, A. L. Identification of GlcNAcylation sites of
peptides and alpha-crystallin using Q-TOF mass spectrometry. J  Am Soc Mass
Spectrom 12, 1106-13 (2001).
92. Link, A. J., Mock, M. L. & Tirrell, D. A. Non-canonical amino acids in protein
engineering. Curr Opin Biotechnol 14, 603-9 (2003).
93. Beene, D. L., Dougherty, D. A. & Lester, H. A. Unnatural amino acid
mutagenesis in mapping ion channel function. Curr Opin Neurobiol 13, 264-70
(2003).
94. Cornish, V. W., Benson, D. R., Altenbach, C. A., Hideg, K., Hubbell, W. L. &
Schultz, P. G. Site-specific incorporation of biophysical probes into proteins. Proc
Natl Acad Sci USA 91, 2910-4 (1994).
29
29
95. Nilsson, B. L., Soellner, M. B. & Raines, R. T. Chemical synthesis of proteins.
Annu Rev Biophys Biomol Struct 34, 91-118 (2005).
96. Shin, Y., Winans, K. A., Backes, B. J., Kent, S. B. H., Ellman, J. A. & Bertozzi,
C. R. Fmoc-Based Synthesis of Peptide-alphaThioesters: Application to the Total
Chemical Synthesis of a Glycoprotein by Native Chemical Ligation. J Am Chem
Soc 121, 11684-11689 (1999).
97. Prescher, J. A., Dube, D. H. & Bertozzi, C. R. Chemical remodelling of cell
surfaces in living animals. Nature 430, 873-7 (2004).
98. Prescher, J. A. & Bertozzi, C. R. Chemistry in living systems. Nat Chem Biol 1,
13-21 (2005).
99. Kho, Y., Kim, S. C., Jiang, C., Barma, D., Kwon, S. W., Cheng, J., Jaunbergs, J.,
Weinbaum, C., Tamanoi, F., Falck, J. & Zhao, Y. A tagging-via-substrate
technology for detection and proteomics of farnesylated proteins. Proc Natl Acad
Sci USA 101, 12479-84 (2004).
100. Domon, B. & Aebersold, R. Mass spectrometry and protein analysis. Science 312,
212-7 (2006).
101. Washburn, M. P., Wolters, D. & Yates, J. R., 3rd. Large-scale analysis of the
yeast proteome by multidimensional protein identification technology. Nat
Biotechnol 19, 242-7 (2001).
102. Ficarro, S. B., McCleland, M. L., Stukenberg, P. T., Burke, D. J., Ross, M. M.,
Shabanowitz, J., Hunt, D. F. & White, F. M. Phosphoproteome analysis by mass
spectrometry and its application to Saccharomyces cerevisiae. Nat Biotechnol 20,
301-5 (2002).
103. Oda, Y., Nagasu, T. & Chait, B. T. Enrichment analysis of phosphorylated
proteins as a tool for probing the phosphoproteome. Nat. Biotechnol. 19, 379-82
(2001).
104. Zhang, H., Li, X. J., Martin, D. B. & Aebersold, R. Identification and
quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope
labeling and mass spectrometry. Nat Biotechnol 21, 660-6 (2003).
105. Dieterich, D. C., Link, A. J., Graumann, J., Tirrell, D. A. & Schuman, E. M.
Selective identification of newly synthesized proteins in mammalian cells using
bioorthogonal noncanonical amino acid tagging (BONCAT). Proc Natl Acad Sci
USA 103, 9482-7 (2006).
106. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey,
A. & Mann, M. Stable isotope labeling by amino acids in cell culture, SILAC, as
a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1,
376-86 (2002).
107. Ross, P. L.,  Huang, Y. N., Marchese, J. N., Williamson, B., Parker, K., Hattan,
S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., Purkayastha, S., Juhasz, P.,
Martin, S., Bartlet-Jones, M., He, F., Jacobson, A. & Pappin, D. J. Multiplexed
protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric
tagging reagents. Mol Cell Proteomics 3, 1154-69 (2004).
108. Blagoev, B., Ong, S. E., Kratchmarova, I. & Mann, M. Temporal analysis of
phosphotyrosine-dependent signaling networks by quantitative proteomics. Nat
Biotechnol 22, 1139-45 (2004).
30
Chapter 2
Development of a New Chemoenzymatic Strategy to Study
O-GlcNAc Glycosylation*
2.1 Background
Protein glycosylation is one of the most abundant posttranslational modifications
and plays a fundamental role in the control of biological systems. For example,
carbohydrate modifications are important for host-pathogen interactions, inflammation,
development, and cancer.2-4  Unique among carbohydrates is the covalent attachment of
the monosaccharide N-acetyl-D-glucosamine to serine and threonine residues of proteins.
The O-GlcNAc modification is found in all higher eukaryotic organisms from C. elegans
to man and has been shown to be ubiquitous, inducible, and highly dynamic, suggesting a
regulatory role analogous to phosphorylation. However, the regulatory nature of the
modification (i.e., dynamic, low cellular abundance) also represents a central challenge in
its detection and study.5
The first methodology applied to detect O-GlcNAc glycosylation relied on the
exquisite specificity of the enzyme β1,4-galactosyltransferase-I (GalT).6  In vivo, the
GalT enzyme is a Golgi-resident type II membrane glycosyltransferase that specifically
transfers galactose from UDP-galactose (UDP-gal) to the C-4 hydroxyl of terminal
GlcNAc groups.7†  In the O-GlcNAc field, early work by Hart and colleagues used UDP-
                                                 
* Portions of this chapter were taken from N. Khidekel et al. A chemoenzymatic approach toward
the rapid and sensitive detection of O-GlcNAc posttranslational modifications. J Am Chem Soc
125, 16162-3 (2003).1
† The GalT-I enzyme was one of the first glycosyltransferases to be biochemically characterized
and is of particular interest in evolutionary biology.  In the presence of its allosteric effector, α-
lactalbumin (LA), expressed in mammary glands, the enzyme switches specificity from GlcNAc
to the  C-4 hydroxyl of glucose, forming lactose.  The evolutionary development of the GalT-LA
complex, also known as lactose synthase, is associated with the appearance of mammals.7
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[3H]-galactose and a commercially available, soluble form of the GalT catalytic domain,
as a means to detect O-GlcNAc modified proteins from cell lysate.8  In a typical
experiment, GlcNAc-modified proteins are labeled with the enzyme and UDP-[3H]-
galactose substrate, subjected to SDS-PAGE electrophoresis and the gel is exposed to
film for autoradiography. Because the GalT transfers galactose to all terminal GlcNAc
residues including those projecting from long N or O-linked carbohydrate chains, it can
not distinguish between these types of  glycosylation and the O-GlcNAc modification.8
Although non-O-GlcNAc-type glycosylation is very rare intracellularly several methods
exist to confirm the exact carbohydrate linkage detected by the GalT assay.9   In
particular, proteins may be treated with PNGase F (N-linked-glycopeptide-(N-acetyl-
beta-D-glucosaminyl)-L-asparagine amidohydrolase), an endoglycosidase that
specifically removes N-linked carbohydrates by cleaving the canonical GlcNAc from the
asparagine to which it is linked.  Additionally, O-linked carbohydrate linkages may be
cleaved by β elimination and analyzed by chromatography with comparison to known
carbohydrate standards.  While the GalT technique is effective, UDP-[3H]-galactose is
both very expensive and a weak β-emitter, with a significantly lower specific activity
than other typically used radioisotopes such as 32P.  Given the low abundance of many O-
GlcNAc proteins, and substoichiometric nature of the modification,  it may take weeks or
even months to detect an O-GlcNAc modified protein on film.10
Another early strategy to identify O-GlcNAc glycosylated proteins relied on the
carbohydrate-binding protein  (lectin) wheat germ agglutinin (WGA), which is specific
for terminal GlcNAc sugars.8  Although WGA has the capacity to detect O-GlcNAc, it
achieves high affinity interactions with complex carbohydrates by  several simultaneous
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interactions in its binding pocket.11   In contrast, the dissociation constant for free
GlcNAc and small GlcNAc-containing disaccharides is in the millimolar range,12,13
which helps explain  the low affinity and poor detection capabilities seen for many O-
GlcNAc proteins.1
To circumvent these difficulties, several antibodies have been developed to detect
O-GlcNAc proteins.10  The first of these, HGAC85, was raised against streptococcal
group A antigens and showed selectivity for O-GlcNAc.14   But according to some
published reports, it recognizes other carbohydrates as well.10  The second, the RL-2
antibody, was specifically raised against O-GlcNAc-modified nuclear pore proteins, and
although it has been shown to selectively detect O-GlcNAc by Western blotting, it lacks
the capability to detect many O-GlcNAc proteins, suggesting that peptide determinants
may be necessary for detection.15,16 Most recently, Hart and colleagues have developed a
third antibody, CTD110.6, raised against a synthetic, O-GlcNAc-modified peptide.
Although the CTD antibody is effective by Western blotting  and has demonstrated some
capacity to immunoprecipitate glycosylated proteins, it also fails to detect numerous O-
GlcNAc proteins, and thus lacks universal applicability.1  Moreover, the commercial
antibody exhibits batch-to-batch variability and often fails to detect O-GlcNAc proteins
in whole-cell lysates that migrate below 50 kDa by SDS- PAGE.17
In light of these challenges, we sought to design a multifaceted strategy for the
rapid and sensitive detection of O-GlcNAc proteins that would also be amenable to
identification of O-GlcNAc glycosylated sites, a prerequisite for understanding O-
GlcNAc function on protein targets.   Further, we aimed for an approach that could be
coupled to proteomic and quantitative proteomic strategies for the wide-scale discovery
33
of O-GlcNAc proteins and analysis of their regulation.
2.1 The Chemoenzymatic Approach Takes Advantage of a Mutant GalT and
Unnatural, Synthetic Analogue of UDP-galactose
Because conventional biological techniques for detecting O-GlcNAc were
limited, we aimed to apply the tools and strategies of chemical biology to advance the
study of this PTM.  In that regard, we chose to use synthetic chemistry to develop a
bioorthogonal UDP-galactose substrate analogue for the GalT enzyme described above.
The ideal substrate would capitalize on the selectivity of the GalT enzyme.  At the same
time, it would surpass the sensitivity of the [3H]-galactose assay while forgoing the cost
and safety risks of working with a radioactive substrate.
Our approach allows for chemoselective installation of unnatural ketone
functionality to O-GlcNAc modified proteins via the generation of a synthetic analogue
for UDP-galactose, analogue 1  (Figure 2.1). The ketone moiety has been well-
characterized in cellular systems as a neutral, yet versatile, chemical handle.18-20   Because
it is normally absent from protein side chains, the ketone serves as a unique marker to
“tag” O-GlcNAc glycosylated proteins once it is reacted with aminooxy or hydrazide-
containing molecules such as biotin.   Once biotinylated, the glycoconjugates can be
readily detected by chemiluminescence using streptavidin conjugated to horseradish
peroxidase (HRP).   The method takes advantage of the affinity of the biotin-streptavidin
interaction,  one of the strongest non-covalent interactions known in nature (Kd ~4 ×
1014 M).21  The commercial availability of aminooxy biotin and streptavidin-HRP as
well as other detection reagents such as aminooxy fluorescent dyes make this a
particularly advantageous system.
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Analogue 1 was designed on the basis of previous biochemical and structural
studies of GalT.  We chose to append the ketone functionality at the C-2 position of the
galactose ring because GalT has been shown to tolerate unnatural substrates containing
minor substitutions at the C-2 position, including 2-deoxy, 2-amino and 2-N-acetyl
subsitituents.22, 23 Moreover, UDP-2deoxy-Gal was transferred at rates comparable to
Gal, whereas 3-, 4-, and 6-deoxy-Gal were transferred at reduced rates.22-24
Figure 2.1. Strategy for detection of O-GlcNAc glycosylated proteins.   The approach
takes advantage of an unnatural, synthetic analogue for UDP-galactose to enzymatically
tag O-GlcNAc proteins for subsequent detection via biotin and streptavidin.
Analysis of the crystal structures of the GalT complexed with UDP-GalNAc revealed that
the C-2 N-acetyl moiety is accommodated in a shallow pocket within the active site.25
Importantly, recent efforts by Ramakrishnan and Qasba had revealed that the single
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Y289L mutant enlarged the donor binding pocket of the GalT and removed a key
hydrogen bond that was shown to interact with N-acyl oxygen of the UDP-galactosamine
(UDP-GalNAc).  The Y289L substitution afforded an  enzyme that could transfer UDP-
GalNAc with equal efficiency to  the  natural substrate.25 Because of the structural
similarity between analogue 1 and the UDP-GalNAc (Figure 2.2), we reasoned that the
mutant enzyme, which is readily expressed in milligram quantities from E .coli inclusion
bodies, could also be utilized with our unnatural analogue.
Figure 2.2. Crystal Structure of the β1,4-galactosyltransferase complexed with UDP-GalNAc
reveals a hydrogen bond between Y289 and the N-acyl oxygen of the UDP-GalNAc.  The Y289L
mutant transfers UDP-GalNAc with equal efficiency to the natural substrate and may likewise
transfer analogue 1 in view of their structural similarity.
Analogue 1 was initially synthesized by postdoctoral scholar Sabine Arndt,  as reported
in Khidekel et al.1  A scheme for the synthesis is reported in the experimental methods
section of this chapter.  The Y289L GalT was expressed in E. coli  as previously
described,26 with some modification as detailed in the methods section of this chapter.
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Typical yields ranged from 2.5 to 3.5 mg of active, soluble protein per liter of bacterial
culture.
2.2  Quantitative Labeling of an O-GlcNAc-Modified Peptide
We assayed the enzymatic conversion of the UDP-keto-galactose substrate using
the peptide TAPTS(O-GlcNAc)TIAPG, which encompasses an O-GlcNAc modification
site within the protein CREB previously identified in our group.27  Using wildtype GalT,
only partial transfer of the keto-sugar was observed by liquid-chromatography-mass
spectrometry (< 1.5 %) (Figure 2.3).
Figure 2.3.  Reverse phase LC-MS analysis of O-GlcNAc labeling reactions with wildtype GalT.
(A) Reverse phase LC-MS analysis and accompanying mass spectra of the labeling reaction 12 h
after the addition of 1 and wild-type GalT.  Both the starting material (a) and ketone labeled
peptide product peak (b) are visible in the base peak chromatogram.  The latter peak intensity has
been amplified 5-fold for clarity.  (B) The ESI mass spectra of peaks a and b confirm the
identities of the O-GlcNAc glycosylated peptide, [MGlcNAc+H]+ = 1118 m/z, and the product,
[Mketone-GlcNAc+H]+ =1320.635 m/z and [Mketone-GlcNAc+2H] 2+ = 661 m/z, respectively.
37
As anticipated, however, the Y289L mutant showed greater activity and afforded
complete conversion after 6 h at 4 °C (Figures 2.4 and 2.5).  Subsequent reaction of the
ketone-labeled peptide with the aminooxy derivative, N-(aminooxyacetyl)N 2-(D-
biotinoyl) hydrazine at pH ~ 4.5 gave complete formation of the corresponding O-alkyl
oxime (Figures 2.4 and 2.5).
Figure 2.4. Reverse phase LC-MS analysis of O-GlcNAc peptide labeling reactions with Y289L
GalT at (A) time 0, (B) 6 h after the addition of 1 and Y289L GalT, (C) 8 h after aminooxy biotin
addition.  Trace D shows aminooxy biotin in the absence of 1, Y289L GalT and O-GlcNAc
peptide.  A and B represent base peaks chromatograms, and C and D represent the extracted ion
chromatograms within the mass range 1319.0-1321.0 m/z and 1633.0-1635.5 m/z.  As shown in
Figure 2.5, peaks c1 and d represent the same biotin impurity.  The slight difference in their
retention times is due to minor differences in column equilibration time.
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Figure 2.5.  Electrospray ionization mass spectra of the LC-MS peaks in Figure 2.4. (A)
Spectrum of the peptide starting material (peak a), [MGlcNAc+H]+ =1118.4.  The fragment ion at
915.2 m/z represents the deglycosylated peptide [M+H]+, which was induced during ionization in
the mass spectrometer. (B) Spectrum of the ketone product (peak b), [Mketone-GlcNAc+H]+ =1320.5.
Ions at 1118.4, 915.2, and 661.1 m/z represent the O-GlcNAc glycosylated peptide, the
deglycosylated peptide and the doubly charged species of the ketone labeled peptide,
respectively. (C) Spectra of the biotin impurity (peak c1), peak c2, and the oxime product (peak
c3) The identity of the product was confirmed by ions 1633.6 and 817.7 m/z, which represent the
singly and doubly charged species of the O-alkyl oxime product, respectively.  The additional
fragment ions at 1118.4 and 915.2 m/z  correspond to the O-GlcNAc glycosylated and
deglycosylated peptide, respectively.  (D) Spectrum of the biotin impurity (peak d), obtained by
incubating biotin in the absence of 1, Y289L GalT and O-GlcNAc peptide.  Note that the
spectrum matches that of c1, indicating that these peaks arise from aminooxy biotin.
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Temp 
(°C) Final pH
 Conversion at 
11 h (%)
 Conversion at 
24.5 h (%)
4 4.5 77 100
4 4.75 42 73
4 5 31 66
4 5.25 18 43
25 5 47 79
Several technical aspects of the methodology merit attention.  First,  we found the
Y289L GalT to be highly tolerant of a variety of buffer and pH conditions, including
MOPS and HEPES at pHs ranging from 6.7 to 7.9 (data not shown).   Second, we found
the oxime-forming reaction to be highly pH dependent as monitored by LC-ESI-MS
(Table 2.1).
Table 2.1.  Characterizing oxime formation using the O-GlcNAc-keto-galactose peptide
TAPTS(O-GlcNAc)TIAPG and 6 mM aminooxy biotin as a function of reaction pH
The optimal pH, near pH 4.5, is consistent with literature reports that the acidic pH
maxima of oxime formation (near pH 5 for the reaction of hydroxylamine and acetone)
results from the rate-limiting attack of free nitrogen base on the carbonyl compound and
its rapid acid-catalyzed dehydration.28  Finally, we also found that oxime formation was
dependent on aminooxy biotin concentration at room temperature, pH 4.5 as monitored
by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-
MS). (Table 2.2), which suggests an optimum concentration at or above 3 mM.
Table 2.2. Characterizing biotin-oxime formation of the O-GlcNAc-keto-galactose peptide
TAPTS(O-GlcNAc)TIAPG and aminooxy biotin as a function of aminooxy biotin concentration
Aminooxy Biotin(mM)  Conversion at 25 h (%)
0.75 50-60
1.875 82-85
3 92-95
3.75 93
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2.3 Rapid and Sensitive Detection of O-GlcNAc-Modified Proteins
Having demonstrated the quantitative labeling of a peptide, we applied our
strategy to the O-GlcNAc glycosylated protein CREB.  Previous work in the laboratory,
using the traditional galactosyltransferase [3H]-labeling methodology had shown that both
endogenous CREB from brain and a recombinant form expressed in Sf9 (Spodoptera
frugiperda) cells were O-GlcNAc-modified.27  Here, the recombinant form was incubated
with 1 and Y289L GalT for 12 h at 4 °C. Following reaction with aminooxy biotin, the
mixture was resolved by SDS-PAGE, transferred to nitrocellulose, and probed with
streptavidin-HRP.  Strong labeling of CREB was observed by chemiluminescence within
seconds of exposure to film (Figure 2.3).  In contrast, no signal was observed over the
same time period for unglycosylated CREB (from E. coli) or when reactions were
performed in the absence of either 1 or enzyme, demonstrating the selectivity of transfer.
Figure 2.6.  The chemoenzymatic strategy affords selective labeling of glycosylated CREB.
Streptavidin-HRP signal was only observed in the presence of analogue 1, Y289L GalT and
aminooxy biotin on O-GlcNAc-modified CREB from Sf9 cells (lanes 1-3).  Unglycosylated
CREB from  E. coli  showed no signal (lane 4).
We next explored the sensitivity of the approach suing the challenging O-
GlcNAc-modified target αA-cyrstallin.29  The α  and  β crystallins are members of a
family of small heat shock proteins, which function as molecular chaperones in the eye
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lens.30   There, the crystallins are responsible for maintaining eye lens integrity, and
defects in these proteins are associated with diseases such as childhood blindness and
cataracts.30  Detection of the O-GlcNAc moiety on αA-crystallin has been reported to be
particularly difficult due to its low stoichiometry of glycosylation (<10%) and the
presence of only one major modification site.31  Indeed, we found that existing methods
such as WGA lectin and the O-GlcNAc-specific antibodies RL-2 and CTD110.65 failed
to detect any O-GlcNAc modification on αA-crystallin, even when 5 to 10 µg was used
(Figure 2.7).
Figure 2.7. Traditional methodology for O-GlcNAc detection fails to detect α-crystallin by
Western Blotting. (A) Western blot of α-crystallin  by WGA lectin.  While WGA detected the N-
linked terminal GlcNAc groups of the ovalbumin positive control, it could not detect the O-
GlcNAc moiety on α-crystallin. (B) Western blot of α-crystallin using the RL-2 antibody and (C)
CTD110.6 antibody.  Both antibodies effectively detected the O-GlcNAc present on the CREB
positive control and HeLa nuclear lysates.  No nonspecific binding to the unglycosylated CREB
from E. coli was detected.  However, the antibodies failed to appreciably detect the O-GlcNAc
present on α-crystallin, even when 10 µg of protein was used.  The arrows mark the expected
position of α-crystallin in the gel.
In contrast, our approach enabled detection of the O-GlcNAc modification within
minutes using 750 ng of αA-crystallin and subsequent work demonstrated that far less
protein (<50 ng) was necessary for strong detection via streptavidin-HRP.  For
42
comparison, tritium labeling, with wildtype GalT required 8 days of exposure to film for
comparable signal, demonstrating a significant increase in sensitivity.
Figure 2.8.  The chemoenzymatic strategy permits rapid and sensitive detection of αA-crystallin.
In comparison, [3H]-labeling required 8 days of exposure to film via autoradiography for
comparable signal on the same amount of protein, 0.75 µg.
2.4 Implications of the Chemoenzymatic Strategy
The greatly enhanced speed and sensitivity of our chemoenzymatic method
suggested that it would be an exciting new platform for studying O-GlcNAc in cellular
systems.  We envisioned that the biotin tag would be useful not only for detection but
also for isolation of O-GlcNAc-modified proteins and peptides.  Moreover, because of
the unique tolerance of the Y289L GalT enzyme, we thought that it might accept other
unnatural bioorthogonal UDP-galactose analogues, including those modified with azides,
alkynes, etc.,  for chemoselective ligation to O-GlcNAc.32  The strategy described in this
chapter has since been patented and the Hsieh-Wilson Laboratory is investigating the
utility of a new synthetic analogue of UDP-Gal with azide functionality at the C2-
hydroxyl position (Figure 2.9), to tag O-GlcNAc proteins with biotin and fluorescent
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alkynes.
Figure 2.9. The Y289L enzyme may be able to utilize other unnatural analogues for
chemoselective ligation, such as azide-functionalized UDP-gal to detect and isolate O-GlcNAc
glycosylated proteins with alkyne or phosphine-conjugated biotin and fluorescent tags.
One of the advantages of the ketone handle is its chemical reactivity in the absence of any
catalyst or cofactor, such as Cu(I) in the case of the copper-catalyzed [3+2] azide-alkyne
cycloaddition ‘click’ chemistry.33-35  Such cofactors, which can interact nonspecifically
with proteins, may present challenges in protein detection by SDS-PAGE or during mass
spectrometry analysis.  However, the poor reactivity of the ketone at physiological pH
makes it less ideal in certain contexts, thus making the UDP-galactose an attractive
synthetic target for the installation of other functionalities. Finally,  although the Y289L
GalT enzyme selectivity attaches the synthetic analogue 1 to GlcNAc-containing
proteins, as with the wildtype GalT, it can not distinguish between O-GlcNAc and
terminal GlcNAc sugars emerging from long carbohydrate chains.  This is on one hand
advantageous, because it allows this system to be used for the detection of membrane-
bound or secreted N-linked and O-linked-terminating GlcNAc glycosylated proteins as
well.  On the other, it prevents the selective identification of only O-GlcNAc modified
proteins when membrane-bound proteins are assayed.  This issue can be addressed by
elimination of N-linked sugars by treatment with the endoglycosidase PNGase F
(discussed in detail in Chapter 3). However, it also presents an interesting enzyme
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engineering problem – GalT appears to have acceptor site preferences toward specific
complex carbohydrates terminating in GlcNAc,36 but could the GalT enzyme acceptor
binding site be likewise manipulated to prefer GlcNAc directly linked to peptides versus
that attached to a sugar manifold?
While our work was in preparation, Vocadlo and colleagues reported the
extension of their carbohydrate tagging methodology to O-GlcNAc glycosylated proteins.
In their approach, an azido-GlcNAc analogue is incubated with cell culture and converted
intracellularly to a UDP-azido-GlcNAc, which can then be utilized by OGT in cells.37
After lysis, proteins are reacted with a phosphine derivative of biotin for tagging via the
Staudinger ligation, and, as in our work, are detected by Western blotting with
streptavidin.  Our chemoenzymatic strategy complements the metabolic labeling
approach and is distinct in several key respects. First, the use of an engineered GalT and
analogue 1 enables near stoichiometric labeling, resulting in higher sensitivity than
possible with the native OGT.37   Enhanced sensitivity is crucial in studying O-GlcNAc as
the regulatory nature of the modification means that it is often present in low cellular
abundance.  Second, the use of an engineered GalT rather than the native OGT allows
one to capture glycosylated species directly and avoid perturbation of metabolic
pathways.  This is important when studying physiological O-GlcNAc glycosylation levels
as OGT’s activity and substrate preference is directly effected by UDP-GlcNAc
concentration.38  In contrast, we envisioned that our approach would permit the
observation of O-GlcNAc signaling pathways after cellular stimulation, an important
frontier in the field.
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2.5 Conclusion
We have described the development of a new chemoenzymatic strategy that
detects O-GlcNAc modifications with an efficiency and sensitivity that is unrivaled by
existing methods.  Our approach capitalizes on an engineered galactosyltransferase, and a
synthetic unnatural substrate containing a bioorthogonal ketone handle.  Using this
strategy, we were able to demonstrate quantitative reaction with an O-GlcNAc peptide
substrate.  Subsequent biotinylation of the ketone to form the biotin-oxime was also
quantitative.  The approach was then applied to the rapid chemiluminescent detection of
the  O-GlcNAc protein CREB by Western blotting via streptavidin.  The new strategy
was then applied to a challenging target, the low stoichiometry O-GlcNAc protein αA-
crystallin, where it far surpassed the capabilities of traditional methodologies while at the
same time forgoing the need for costly and dangerous radioactivity.
Given the chemical versatility of the ketone handle, we can envision a variety of
applications, including affinity enrichment, and isotopic labeling for comparative
proteomics. Moreover, the study of other enzymes (e.g., farnesyltransferases and other
glycosyltransferases) may also benefit from this approach. The following chapters will
highlight our efforts to extend the approach to the discovery of new O-GlcNAc proteins,
as well as to the first proteomic and quantitative proteomic studies of O-GlcNAc in
neuronal tissue.
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2.6 Experimental Methods
General Methods
The peptide TAPTS(O-GlcNAc)TIAPG was synthesized at the Beckman Institute
Biopolymer Synthesis Center using standard Fmoc chemistry. The Fmoc-protected,
peracetylated O-GlcNAc serine amino acid was kindly synthesized by S. Tully as
reported by Seitz et al., and Comer et al.39,40,10  Baculovirus preparation and protein
expression of CREB in Spodoptera frugiperda (Sf9) cells were performed by Dr. P.
Snow at the Beckman Institute Protein Expression Facility at the California Institute of
Technology.27 HeLa cell nuclear extracts were kindly prepared by H.-C. Tai according to
published procedures.41  Wildtype GalT and Y289L were initially kindly provided by B.
Ramakrishnan with subsequent expression and purification as described below.  All
protein concentrations were measured using the Bradford assay (Bio-Rad Laboratories,
Hercules, CA).
General Reagents
Unless otherwise noted, reagents were purchased from the commercial suppliers Fisher
(Fairlawn, NJ) and Sigma-Aldrich (St. Louis, MO) and were used without further
purification. Protease inhibitors were purchased from Sigma-Aldrich or Alexis
Biochemicals (San Diego, CA).  Bovine GalT, ovalbumin, and α-crystallin were obtained
from Sigma-Aldrich.  Uridine diphospho-D-[6-3H]galactose, Hyperfilm ECL and Amplify
reagent were purchased from Amersham Biosciences (Piscataway, NJ). WGA lectin was
purchased from E-Y Laboratories (San Mateo, CA). RL-2 antibody was purchased from
Affinity Bioreagents (Golden, CO). Alkaline Phosphatase was purchased from New
England Biolabs (Beverly, MA), and BSA was obtained from Fisher (Fairlawn, NJ).
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SuperSignal West Pico chemiluminescence reagents and secondary antibodies were from
Pierce (Rockford, IL), and CTD110.6 antibody was from Covance Research Products
(Berkeley, CA). Nitrocellulose was from Schleicher and Schuell (Keene, NH), and PVDF
was from Millipore (Bedford, MA). Complete protease inhibitor cocktail tablets were
from Roche (Indianapolis, IN).  N-(aminooxyacetyl)-N’-(D-biotinoyl) hydrazine
(Aminooxy biotin) was obtained from two sources, Molecular Probes (Eugene, OR) and
Dojindo (Gaithersburg, MD).  The former material was in the form of a TFA salt and had
an effect on final buffer pH in those reactions in which it was used.  The latter had no
effect on reaction pH.
Uridine 5’-diphosphO-2-acetonyl-2-deoxy-α-D-galactopyranose Diammonium Salt
(1)
Analogue 1 was synthesized by Dr. Sabine Arndt essentially as described in Khidekel et
al (Scheme 2.1). 1
Scheme 2.1. Synthesis of analogue 1 with modifications 5/2006.
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Expression, Purification and Activity Assay of Y289L GalT
Y289L cDNA, cloned into the prokaryotic expression vector pET23a,  (Novagen,
Madison, WI),25 was kindly provided by B. Ramakrishnan and amplified in
electrocompetent DH5α cells using the Qiagen Plasmid Maxi Kit (Qiagen, Valencia, CA)
to a final DNA concentration of 5.25 µg/mL.  To generate the bacterial protein,
electrocompetent BL21(DE3) cells were electroporated and grown in Luria-Bertani (LB)
media supplemented with 100 mg/L ampicillin.  Typically, a 100 mL culture containing
100 µg/mL ampicillin was grown overnight and diluted to 1 liter using LB media.
Growth was allowed to continue until an O.D. of 0.7 at A600 was attained.  At this point,
isopropyl-beta-D-thiogalactopyranoside (IPTG) was added to a final concentration of 1
mM to induce protein production.  The culture was grown for another 4 h, and the cells
were harvested by centrifugation at 600 × g for 10 min.  The bacterial pellet from the 1
liter culture  was resuspended in 10 mL PBS (10.1 mM Na2HPO4, 1.76 mM KH2HPO4,,
137 mM NaCl, 2.7 mM KCl, pH 7.4) with Complete protease inhibitor tablets.    The
pellet was sonicated on ice, 5 × 30 sec, to lyse the cells and release inclusion bodies.   In
some cases, the bacterial pellet was frozen at –20 °C prior to lysis.  Subsequently, the
suspension was diluted to 80 mL using PBS and centrifuged at 14,000 × g for 30 min.
The inclusion body pellet was thoroughly washed four times with PBS containing 25%
(w/v) sucrose.  The protein pellet was washed one final time with 10 mM sodium
phosphate buffer, pH 7.4 and resuspended in this buffer.   Subsequently, inclusion bodies
were precipitated out of suspension (characterized by a white, fluffy precipitant) with
80% EtOH, and lyophilized overnight.  Inclusion bodies were dissolved in 10 mL of 5 M
guanidine hydrochloride (Gu-HCl) and 0.3 M Na2SO3 at room temperature, with
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Complete protease inhibitor tablets. In some cases, not all material was soluble in Gu-
Hcl, in which cases resuspended inclusion bodies were briefly centrifuged to remove
particulate.
To sulfonate all the free  thiols in the protein molecule, 1 mL of 50 mM S-
sulfonating agent, 2-nitrO-5-(sulfothio)-benzoate (NTSB), was added to this solution and
stirred vigorously. Completion of sulfonation was judged by the color change of the
solution from red to pale yellow (~1-1.5 h).  (NTSB was prepared essentially as described
in Thannhauser et al.,42 by bubbling a mixture of 95% O2/5% CO2 through a solution of
5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) dissolved in 0.3 M Na2SO3.  The reaction
was incubated in a 38 °C water bath and reaction was judged complete by a color change
from deep orange to pale yellow, ~1 h.  Maintaining this temperature during reaction was
particularly critical for NTSB formation).
After sulfonation, the protein solution was diluted 10-fold with water in order to
precipitate the sulfonated protein.  The protein precipitate was collected by centrifugation
at 10,000 × g for 5 min, and washed three times in water, followed by centrifugation to
remove any remaining sulfonating agent. The sulfonated  protein was re-dissolved in 5 M
Gu-HCl to a protein concentration of 1 mg/mL, (which has an absorption of 1.9 to 2.0
OD at 275 nm).
For refolding, the protein solution was diluted 10-fold, in 9 portions over the
course of 15 min in a folding solution (5 M D,L–Arginine, 50 mM Tris-HCl, 5 mM
EDTA, 4 mM cysteamine and 2 mM cystamine, pH 8.0) at 4 °C, to give a final
concentration of 0.5 M Gu-HCl, 0.5 M D,L–Arginine, 50 mM Tris-HCl, 5 mM EDTA, 4
mM cysteamine and 2 mM cystamine, pH 8.0.  The solution was gently stirred during the
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refolding process.  In some cases, the protein solution was slowly refolded, over the
course of 48 h at 4 °C, via addition of refolding solution by peristaltic pump. After
refolding, the protein solution was dialyzed against 3 × 4 liters of 50 mM Tris-HCl, pH
8.0, 5 mM EDTA, 4 mM cysteamine and 2 mM cystamine at 4 °C to remove Gu-HCl and
arginine.  The protein that precipitated during dialysis (white fluffy residue) was removed
by centrifugation and the supernatant was concentrated using the Amicon concentrator
(Millipore, Bedford, MA) to a final concentration of ~ 1 mg/mL and subsequently used
for peptide and protein labeling experiments.
After protein concentration, enzyme activity toward analogue 1 was assayed via
reaction with the peptide TAPTS(O-GlcNAc)TIAPG as follows: the peptide TAPTS(O-
GlcNAc)TIAPG (10 µM) was dissolved in 10 mM HEPES buffer, pH 7.9 containing 5
mM MnCl2. Ketone analogue 1 and mutant Y289L GalT were added to final
concentrations of 500 µM and 20-100 ng/µL, respectively.  Reactions were incubated at 4
°C for 6-12 h and stopped by acidification to a final concentration of 0.1% TFA.  Extent
of TAPTS(O-GlcNAc-keto-galactose)TIAPG formation was judged via MALDI-TOF
analysis. For the analysis, peptide samples were concentrated on C18 zip tips (Millipore,
Bedford, MA) and combined with the MALDI matrix (2,5-dihydroxybenzoic acid in 20%
CH3CN, 0.1% TFA in water).  Spectra were acquired on a PerSeptive Biosystems
Voyager-DE Pro at 20,000 kV in the reflector mode.  Typically, 100% conversion was
observed at 12 h at 4 ºC using 20 ng/µL of enzyme.
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Labeling of the O-GlcNAc Peptide
The peptide TAPTS(O-GlcNAc)TIAPG (10 µM) was dissolved in 25 mM MOPS buffer,
pH 6.7 containing 5 mM MnCl2.  Ketone analogue 1 and mutant Y289L GalT were added
to final concentrations of 1 mM and 100 ng/µL, respectively.  Prior to enzyme addition,
an aliquot of the reaction was removed as an initial time point for LC-MS analysis.
Reactions were incubated at 4 °C for 6 h, after which an aliquot of the reaction mixture
was removed for product analysis by LC-MS.  The remainder of the reaction was diluted
5-fold into PBS.  N-(aminooxyacetyl)-N’-(D-biotinoyl) hydrazine (Molecular Probes,
Eugene, OR) was added to a final concentration of 12 mM.  (Final pH of this reaction
was ~pH 4.5).  After 8 h at 25 °C, the extent of biotin-oxime product was measured by
LC-MS. Labeling reactions with wildtype GalT were performed identically, with the
exception that reactions were incubated at 37 °C for 12 h.
Labeling of the O-GlcNAc Peptide to Monitor pH and Concentration Dependence of
Oxime Formation
 The  peptide TAPTS(O-GlcNAc)TIAPG (10 µM) was dissolved in 10 mM HEPES
buffer, pH 7.9 containing 5 mM MnCl2 . Ketone analogue 1 and mutant Y289L GalT
were added to final concentrations of 500 µM and 20-100 ng/µL, respectively.  Reactions
were incubated at 4 °C for 24 h and then diluted, 3- to  5-fold, into 50 mM NaOAc,
buffered with AcOH, at the pHs described in Table 2.1 and Table 2.2 in the text. N-
(aminooxyacetyl)-N'-(D-biotinoyl) hydrazine from Dojindo (Gaithersburg, MD) was
added to a final concentrations as described in the tables.  The extent of biotin-oxime
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product was monitored by LC-MS for reactions measuring pH dependence and MALDI-
TOF for those measuring concentration dependence.
LC-MS Monitoring of O-GlcNAc Peptide Labeling Reactions
Liquid chromatography and mass spectrometry (LC-MS) were performed on an LCQ
Classic ion trap mass spectrometer (ThermoFinnigan, San Jose, CA) interfaced with a
Surveyor HPLC system (ThermoFinnigan, San Jose, CA) at the California Institute of
Technology Chemistry Mass Spectrometry facility.  Approximately 10 pmol of peptide
from each labeling reaction was loaded onto a Luna column (2mm i.d. X 50mm)
prepacked with 3 µm  100Å C18 RP particles.  Flow rate was maintained at 190 µL/min
with a gradient optimized for separation of the O-GlcNAc peptide from labeled products.
LC buffer A consisted of 2% CH3CN in 0.1M aqueous AcOH and buffer B consisted of
90% CH3CN in 0.1M aqueous AcOH.  The gradient consisted of 0-3 min, 2% B; 3-11
min, 2%-11%B; 11-14.5 min, 11%-27.5% B; 14.5-18min, 27.5%-100% B; 18-22min,
100% B, where the initial 5 minutes of flow were diverted to waste in order to avoid
contamination of the mass spectrometer with salts.  The LCQ was operated in automated
mode using Xcalibur software.  The electrospray voltage was 4.5 kV and the heated
capillary was 200 °C.  Ion injection time was set at 200 ms for full MS scan mode of
operation (3 microscans per scan).  The ion selection window was set at 500-1700 m/z for
all experiments.
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Labeling of CREB Protein
Recombinant O-GlcNAc glycosylated CREB was generated by coexpression of CREB
with OGT in Sf9 cells as described previously.27 500 ng of CREB, in 20 mM HEPES pH
7.9, 100 mM KCl, 0.2 mM EDTA, 15% glycerol was added to 50 mM MOPS pH 6.45.
MnCl2 (50 mM) was added to a final concentration of 5 mM and alkaline phosphatase
(2.5 mU/ µL) was added to a final concentration of 0.25 mU/µL  to hydrolyze UDP
produced by the GalT  reaction in order to prevent product inhibition.43  Analogue 1 and
Y289L GalT were then added to final concentrations of 1 mM and 40 ng/µL,
respectively.  Control reactions without enzyme or analogue 1 were treated identically.
Following incubation at 12 h at 4 °C, the reactions were diluted 5-fold into PBS
containing protease inhibitors (5 µg/mL pepstatin, 5 µg/mL chymostatin, 20 µg/mL
leupeptin, 20 µg/mL aprotinin, 20 µg/mL antipain, 0.2 mM PMSF).   Aminooxy biotin
(Molecular Probes, Eugene, OR ) was added to a final concentration of 2 mM, and the
biotinylation reactions were incubated with gentle shaking for 12 h at 37 °C.  Reactions
were aliquoted for analysis and stopped by boiling in SDS-PAGE loading dye.  Proteins
were resolved by 10% SDS-PAGE, electrophoretically transferred to nitrocellulose, and
probed with streptavidin-HRP.
Nitrocellulose blots were blocked for 1 h at RT using 3% periodated-BSA44 in
PBS, rinsed once with TBS (50 mM Tris•HCl, 150 mM NaCl, pH 7.4) containing 0.05%
(v/v) tween-20, and probed with streptavidin-HRP (1:2500 to 1:5000) in TBS-0.05%
tween for 1 h at RT.  Note that we found some variability among different batches of
streptavidin.  In some cases, blots were probed for 1 h with streptavidin-HRP, rinsed
several times with TBS-0.05% tween, and reprobed with another aliquot of streptavidin-
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HRP.  After probing with streptavidin, membranes were rinsed and washed 5 × 10 min
with TBS-0.1% tween containing 0.05% BSA.  Streptavidin-HRP signal was visualized
by chemiluminescence upon exposure to film.  After streptavidin visualization,
membranes were stripped in 5 mM Na2HPO4 pH 7.5, 2% SDS, and 2 mM (β -
mercaptoethanol) βME, for 45 min at 60 °C, rinsed several times with dH20, and re-
probed with anti-CREB antibody as previously described27 with the modification that the
antibody was used at a concentration of 1:400.
Labeling reactions with CREB expressed in E. coli were performed identically.
To generate the bacterial protein, rat CREB cDNA was cloned into the prokaryotic
expression vector pET23b(+) (Novagen, Madison, WI) using HindIII and NdeI restriction
endonucleases.  Electrocompetent BL21(DE3) cells were electroporated and grown in LB
media supplemented with 100 mg/L ampicillin.  Protein expression was induced with 0.3
mM IPTG.  Recombinant CREB was purified using Ni-NTA agarose (Qiagen, Valencia,
CA) as described previously.27
Labeling of α-Crystallin
Bovine lens αA-crystallin (a mixture of A and B chains) was resolved by SDS-PAGE
electrophoresis and Coomassie-stained with standards in order to quantify the amount of
A chain in the mixture.  For reactions, 8.7 µg of α-crystallin (6.5 µg of A chain) in 20
mM HEPES pH 7.9 was added to 50 mM MOPS pH 6.45 containing 5 mM MnCl2 and
0.25 mU/µL alkaline phosphatase. Analogue 1 and Y289L GalT were added to final
concentrations of 1 mM and 100 ng/µL, respectively.  Reactions were incubated at 4 °C
for 18 h and then diluted 5-fold with PBS pH 6.7, protease inhibitors, and aminooxy
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biotin (Molecular Probes, Eugene, OR) (6.5 mM final concentration).  Biotinylation
reactions were incubated with gentle shaking at 25 °C for 12 h. After biotinylation,
reactions were aliquoted for analysis and subsequently boiled in SDS-PAGE loading dye.
Proteins were resolved on 15% SDS-PAGE gels, transferred to nitrocellulose, and probed
with streptavidin-HRP or stained with Coomassie Brilliant Blue.  Blotting with
streptavidin-HRP was performed as described above.  Importantly, with larger quantities
of protein, in the absence of Y89L and 1, a background signal was observed.  This
background was dependent upon incubation with aminooxy biotin, as it was not observed
with streptavidin-HRP blotting of keto-galactose labeled proteins.  Stringent dialysis after
biotinylation failed to remove the background signal, which was readily distinguished
from true labeling due to its weaker intensity compared to labeled proteins.
UDP-[3H]galactose Labeling of α-Crystallin
3H-labeling was performed essentially as described.8 Briefly, 12.5 µg of α-crystallin (6.5
µg of A chain) in 20 mM HEPES pH 7.9 was added to 10 mM HEPES pH 7.9 containing
5 mM MnCl2 and protease inhibitors.  UDP-[3H]-galactose was added to a final
concentration of 0.03 µCi/µL, and the reaction was initiated with the addition of 25 mU
bovine β1,4-galactosyltransferase, autogalacosylated as described by Roquemore et al.8
Reactions were incubated at 37 °C for 1 h 15 min.  Reactions were subsequently
aliquoted for analysis and stopped by boiling with SDS-PAGE loading dye. Proteins were
resolved on 15% SDS-PAGE gels, stained with Coomassie Brilliant Blue, incubated with
Amplify reagent, and dried for subsequent exposure to Hyperfilm MP at –80 °C.
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Western Blotting of α-crystallin using Antibodies RL-2 and CTD110.6
  α-Crystallin, and appropriate positive and negative controls were resolved by 15% SDS-
PAGE.  All Western blotting steps were performed at RT unless otherwise noted.
Western blotting with the RL-2 antibody was performed according to reported methods 46
with some changes suggested by the manufacturer to reduce background noise.  α -
Crystallin and controls were electrophoretically transferred to nitrocellulose blots, and the
blots were blocked for 1 h in 5% BSA in high salt (250 mM NaCl) TBS-1% tween-20
(hsTBS-T).  RL-2 antibody, at a concentration of 1:2000, was subsequently added in
blocking buffer and blots were incubated for 1.5-2 h.  Blots were then rinsed with
hsTBST and washed 6X5 min.  Secondary goat anti-mouse IgG antibody was applied at a
concentration of 1:10,000 in hsTBS-T containing 1% BSA.  After 1 h, blots were rinsed
and washed as described before chemiluminescence detection on film (Figure 2.9).
Western blotting with the CTD110.6 antibody was performed according to
manufacturer’s recommendations.  Briefly, α-crystallin and controls were transferred to
PVDF and washed 2 × 15 min with TBS-0.1% tween-20 (TBST). Blots were blocked in
TBST containing 3% BSA for 1 h, rinsed 2× with TBST, and probed with CTD110.6
(1:2500) in blocking buffer for 1 h.  Blots were then rinsed 2× with TBST and washed
2X5 min with the same buffer.  Secondary goat anti-mouse IgM antibody was applied at
a concentration of 1:10,000 in blocking buffer for 1 h, and blots were subsequently rinsed
with TBST and washed 5 × 5 min before chemiluminescence detection on film.
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WGA Lectin Blotting of α-crystallin
WGA western blotting was performed essentially as described.46,8  Briefly, α-crystallin
and controls were resolved by 15% SDS-PAGE and electrophoretically transferred to
nitrocellulose.  Blots were blocked for 1 h in 3% periodate-treated BSA in PBS, rinsed 2
× 15 min with PBS-0.05% tween-20 (PBST), and probed for 2 h with WGA-HRP
(1:8000) in PBST.  Subsequently, blots were rinsed with PBST, washed 3 × 10 min, then
3 × 20 min before chemiluminescence detection on film.
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Chapter 3
Discovery of O-GlcNAc-Modified Proteins from Cell Lysates
and Identification of O-GlcNAc Glycosylated Sites via Mass
Spectrometry*
3.1 Background and Introduction
Dynamic glycosylation of proteins by O-linked b-N-acetylglucosamine (O-
GlcNAc) has been increasingly implicated in the regulation of cellular physiology and
function.3 Although discovered more than 20 years ago, the elucidation of O-GlcNAc as
a posttranslational modification has been slow, a feature attributed to the lack of effective
tools for its detection and study.4  Despite recent advances,5-7 few methods exist to
rapidly assess the presence or absence of the O-GlcNAc modification on proteins isolated
directly from cells.  Many approaches involve protein purification or overexpression,
procedures that are time-consuming and specific to each protein.8,9  In addition, no
methodology exists for the rapid identification of O-GlcNAc glycosylated sites, an
important prerequisite for understanding O-GlcNAc function.  Here, we discuss the
development of a parallel strategy for the detection of the O-GlcNAc modification in
cells.1  As an illustration of the method, we show that the transcription factors c-Fos, c-
Jun and ATF-1 are O-GlcNAc modified, and we identify O-GlcNAc on an entirely new
class of proteins, transcriptional coactivators.  We also discover that the methyl-CpG-
binding protein (MeCP2), a critical regulator of neuronal development and gene
                                                 
*Parts of this chapter taken from H.-C. Tai, N. Khidekel, S. B. Ficarro, E. C. Peters & L. C.
Hsieh-Wilson. Parallel identification of O-GlcNAc-modified proteins from cell lysates. J Am
Chem Soc 126, 10500-1 (2004).1 and N. Khidekel, S. B. Ficarro, E. C. Peters & L. C. Hsieh-
Wilson.  Exploring the O-GlcNAc proteome: direct identification of O-GlcNAc-modified
proteins from the brain. Proc Natl Acad Sci USA 101, 13132-7 (2004).2
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expression, is O-GlcNAc-modified.  Finally, we illustrate the ability of the
chemoenzymatic strategy  to readily isolate  O-GlcNAc-modified peptides from CREB
and αA-crystallin, as well as identify glycosylation sites on the O-GlcNAc transferase
(OGT) and the transcription factor ΔFosB, implicated in the physiology of addiction.
In the previous chapter, we described a chemoenzymatic method to tag purified
O-GlcNAc proteins with a biotin moiety.4 We envisioned exploiting this tagging
chemistry toward the development of a new parallel strategy to identify O-GlcNAc
glycosylated proteins and the identification of O-GlcNAc glycosylated sites.
Specifically, O-GlcNAc modified proteins from cell lysates would be biotinylated and
then selectively captured by affinity chromatography To establish whether a given
protein was O-GlcNAc glycosylated, one would simply examine whether the protein of
interest was captured.  Using this approach, multiple proteins could be readily
interrogated in parallel by Western blotting using antibodies selective for the proteins of
interest (Figure 3.1).
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Figure 3.1.   Strategy for identifying O-GlcNAc proteins from cells. (A) Traditional methods for
isolating and identifying O-GlcNAc proteins typically rely on the GalT UDP-[3H]-galactose
labeling methodology described in Chapters 1 and 2, in which a single O-GlcNAc protein is
immunoprecipitated and detected via autoradiography.  Detection often requires weeks to months
of exposure to film for endogenous proteins.  (B) The parallel approach takes advantage of the
chemoenzymatic strategy to biotinylate O-GlcNAc proteins for capture via streptavidin.  Western
blotting of captured material can be conducted for multiple proteins simultaneously and the high
affinity biotin-streptavidin interaction enhances sensitivity of detection.
This approach would have several notable advantages over traditional strategies for O-
GlcNAc detection. It would accelerate the discovery of O-GlcNAc proteins by
circumventing the time-consuming step of overexpressing or immunoprecipitating
individual proteins of interest.  Virtually any protein of interest could be examined for the
modification as a wide variety of antibodies are available for Western blotting.  The
significantly enhanced sensitivity of our tagging chemistry relative to existing methods
would enable identification of even low-abundance regulatory proteins.4
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Because selective biotinylation and isolation of O-GlcNAc species can also be
applied to peptides,  we sought to extend the chemoenzymatic strategy to the mapping of
glycosylation sites.  Over 100 O-GlcNAc proteins have been identified,10 but the
modification sites for many remain unknown.  Notably, cases in which sites have been
identified resulted in the discovery of important functional details regarding O-GlcNAc,
including its role  in transcriptional repression.11,12,13  Thus, identification of glycosylated
sites is an important goal in the field.  Unfortunately, the O-GlcNAc transferase lacks a
consensus sequence for glycosylation,14 precluding facile site prediction, and as with
other PTMs, analytical detection of O-GlcNAc-modified sites has proven challenging.
The traditional strategy to map sites involves [3H] labeling of O -GlcNAc proteins
followed by protease digestion and HPLC purification/edman sequencing of radiolabeled
peptides.15    This approach lacks sensitivity and often necessitates purification of large
quantities of protein and peptide.  In some cases, O-GlcNAc glycosylated peptide have
also been directly observed by mass spectrometry during collision-associated dissociation
(CAD).16,17  During CAD, protonated peptides undergo collisions with an inert gas in
which the translational energy of collision is converted into vibrational energy,
distributed along all covalent bonds.  This mode of excitation results primarily in amide
bond cleavage and is routinely used for peptide sequence identification.18  However,
CAD-induced bond cleavage proceeds along lowest energy pathways, and  for O-GlcNAc
peptides, this results primarily in loss of the labile PTM. This both precludes site
identification and prevents substantial peptide bond cleavage, often yielding poor-quality
peptide sequences.19  Finally, because O-GlcNAc peptides and O-phosphate peptides are
often substoichiometric, they may be difficult to detect and identify in a mixture of other
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peptides, even with reverse-phase chromatographic separation prior to mass
spectrometry.
In the phosphorylation field, several techniques have evolved to address these
difficulties.  These have included selective enrichment of phosphorylated peptides
through metal affinity chromatography20 and antibodies.21  In addition, chemical
strategies have been used that remove the phosphate linkage through β-elimination,
replacing it with a stable species that includes an affinity tag such as biotin, for peptide
isolation.22  Recently, Wells and co-workers applied a similar strategy to O-GlcNAc.  In
their ‘mild ß-elimination followed by Michael addition of dithiothreitol’ (BEMAD)7
approach, O-GlcNAc is eliminated and the resulting α,β unsaturated carbonyl is attacked
with the nucleophile DTT. The resulting peptide can then be specifically enriched
through thiol affinity chromatography.  Importantly, BEMAD was shown to successfully
enrich O-GlcNAc peptides from several purified proteins. However, the technique is
inherently destructive and does not retain information as to whether the isolated peptide
was originally modified by O-GlcNAc, O-phosphate or another O-linked carbohydrate.
Although O-GlcNAc is more susceptible to ß-elimination than O-phosphate, extensive
controls are required to determine whether a modified peptide originally contained a
phosphate or a carbohydrate.  Moreover, O-GlcNAc-Thr followed by Pro, was found to
be difficult to eliminate, requiring conditions harsh enough to cleave phosphates and even
peptide bonds.7
In light of these issues, we reasoned that the chemoenzymatic strategy would nicely
complement existing strategies and provide unique advantages.  Specifically, the ketone
handle serves as a unique identifier of O-GlcNAc peptides and allows for their selective
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isolation and enrichment in the presence of other unmodified, or differentially modified
peptides (Figure 3.2).  Because the chemoenzymatic labeling is non-destructive it also
allows for detection of multiple PTMs on O-GlcNAc peptides.  Finally, we envisioned
that the approach would be amenable to the broader study of proteomics as well as
quantitative analysis of site-specific changes in O-GlcNAc in response to cell stimuli.
Figure 3.2. Strategy for identifying O-GlcNAc glycosylation sites.  The approach utilizes
the chemoenzymatic strategy to tag O-GlcNAc proteins.  Subsequent protease digestion and
enrichment via avidin chromatography separates O-GlcNAc peptides from the total peptide
mixture, which improves detection sensitivity during mass spectrometry.
3.2 The Parallel Approach for Discovery of O-GlcNAc Proteins from Complex
Mixtures
Implementation of the parallel approach required the extension of the
chemoenzymatic strategy, described in Chapter 2, from purified proteins to complex
mixtures. H.-C. Tai first applied the approach to cells.1  HeLa cells were rapidly lysed
under denaturing conditions to preserve the physiological glycosylation state of the
proteins.  The cell extract was then labeled with the UDP-ketone analogue 1 and mutant
GalT for 12 h at 4 °C.  We found that N-linked glycans could be removed simultaneously
during this incubation period by treatment with PNGase F.  Following reaction with
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aminooxy biotin, the biotinylated O-GlcNAc proteins were captured with streptavidin-
agarose beads, resolved by SDS-PAGE, and transferred to nitrocellulose membrane. To
determine whether the captured proteins had been biotinylated, the membrane was blotted
with streptavidin conjugated to horseradish peroxidase (HRP).  A strong
chemiluminescence signal was observed, indicating successful labeling of proteins from
extracts (Figure 3.3A).  Little signal was detected in the absence of either enzyme or 1,
strongly suggesting that O-GlcNAc modified proteins had been specifically labeled and
captured.
To confirm the results, we examined whether the transcription factor CREB
(cAMP-responsive element binding protein) was among the captured proteins.  CREB is
present in low cellular abundance and contains only two major O-GlcNAc glycosylation
sites.12  As such, it represents a challenging cellular target. We readily detected CREB in
the captured fraction by Western blotting using an anti-CREB antibody (Figure 3.3B).  In
contrast, the catalytic domain of  PKA (cAMP-dependent protein kinase), which has been
shown to lack any detectable O-GlcNAc,23 was not detected.  These results demonstrate
that low-abundance O-GlcNAc glycoproteins from cells can be selectively captured and
identified.
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Figure 3.3.  Selective isolation of chemoenzymatically tagged O-GlcNAc glycosylated proteins
via streptavidin. (A) Captured HeLa cell lysate is only detected by streptavidin blotting in the
presence of both Y289L GalT and analogue 1. (B) Western blotting for individual proteins prior
to (Input) and following (Capture) affinity capture. (C) Traditional tritium labeling and
immunoprecipitation of c-Fos with the anti-c-Fos antibody required nearly 1000 hours of
autoradiography exposure for detection.
H. -C. Tai next applied the approach toward the parallel identification of novel protein
targets.  Although the AP-1 transcription factor complex has been shown to be GlcNAc
glycosylated, the specific proteins and nature of the glycosidic linkage (i.e., N-linked
glycosylation, O-linked glycosylation, or direct O-GlcNAc) have remained unresolved.24
Figure 3.3B shows that the two AP-1 family members c-Fos and c-Jun were captured,
indicating that both proteins are O-GlcNAc glycosylated. As independent confirmation,
we used the traditional approach of UDP-[3H]galactose and GalT, followed by
immunoprecipitation of c-Fos.  Notably, tritium labeling required 1000 h of exposure to
film for strong detection (Figure 3.3C).  In contrast, our strategy permitted the detection
of c-Fos within minutes.
Importantly, the approach enables study of the O-GlcNAc modification across
structurally or functionally related protein families.  ATF-1, a structural homolog and
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dimerization partner of CREB,25 shares only partial sequence identity within the region of
CREB glycosylation. Nonetheless, ATF-1 was present in the captured fraction, indicating
that both family members are subject to O-GlcNAc glycosylation in HeLa cells.
Our strategy also permitted the identification of an entirely new class of O-
GlcNAc glycosylated proteins, histone acetyltransferases (HAT).  CREB-Binding Protein
(CBP) is a HAT involved in chromatin remodeling and activation of numerous
transcription factors.26 As shown in Figure 3.3B, we found that CBP is O-GlcNAc
glycosylated. This finding is  interesting in light of recent observations that O-GlcNAc
transferase (OGT), the enzyme that catalyzes the modification, interacts with a histone
deacetylase complex to promote gene silencing.  Our results demonstrate that a broader
set of transcriptional components are O-GlcNAc modified, and they support the notion
that O-GlcNAc may serve as a general mechanism for transcriptional control.
Having demonstrated that the parallel approach could be used to identify new O-
GlcNAc glycosylated proteins in HeLa cells, we applied the strategy to primary cultured
neurons.  In particular, given its role in transcriptional regulation, we investigated
whether O-GlcNAc glycosylation affected neuron-specific proteins important for gene
expression.  In collaboration with Yi Sun’s laboratory at UCLA, we used the parallel
strategy to probe for O-GlcNAc glycosylation on the transcriptional repressor MeCP2.
MeCP2 specifically binds methylated DNA where it helps to silence transcription by
recruiting chromatin remodeling complexes such as histone deacetylases (HDACs).27
Interestingly, MeCP2 plays a critical role in the developmental X-linked mental
retardation disorder, Rett Syndrome, (RTT).27  Mutations in both the DNA-binding and
protein interaction domain of the MeCP2 gene appear to be the primary causes of RTT
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and evidence suggests that changes in expression of one of the targets of MeCP2
repression, the brain derived neurotrophic factor, BDNF, may be involved in the RTT
phenotype.28,29
As shown in Figure 3.4, we isolated O -GlcNAc glycosylated proteins from
cultured neurons using the parallel approach, and showed that MeCP2 appears to be O-
GlcNAc-modified in glucosamine-treated neurons.  Additional studies in the lab showed
that MeCP2 is likewise O -GlcNAc-modified in the basal state (data not shown).
Interestingly, depolarization appears to induce MeCP2 phosphorylation and DNA
dissociation,30 so it will be important to understand the effect of neuronal activity on
glycosylation as well.  Current efforts  in the lab, (Appendix II), are aimed at identifying
the site(s) of MeCP2 glycosylation in order to understand the significance of O-GlcNAc
glycosylation for MeCP2 function.
Figure 3.4. The transcriptional repressor MeCP2 is O-GlcNAc glycosylated in neurons.  MeCP2
is detected in the input lysate of glucosamine-treated as well as glucosamine-treated, depolarized
cortical neurons. It is specifically captured by streptavidin after chemoenzymatic labeling with
Y289L GalT, analogue 1, and the aminooxy biotin, demonstrating that it is O-GlcNAc modified
(anti-MeCP2 Western blotting was conducted by Jessica Zellhoefer, in the laboratory of Yi Sun).
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3.3 Identification of O-GlcNAc Glycosylated Peptides via the Chemoenzymatic
Strategy
In order to apply the chemoenzymatic strategy to O-GlcNAc-modified peptides,
we used an approach similar to the streptavidin protein capture approach described
above.  In the case of peptide capture, however, we employed monomeric avidin, which
has previously been applied to biotinylated cysteine-containing peptides in the isotope-
code affinity tag (ICAT) quantitative proteomic strategy.31  Specifically, because
tetrameric streptavidin  binds biotin with such high affinity, eluting biotinylated material
requires harsh conditions, usually in the presence of excess biotin.  These conditions are
generally not compatible with mass spectrometry.  In contrast, monomeric avidin, with a
significantly-reduced Kd readily releases biotinylated peptides in acidic/organic
commixtures, which allows for direct mass spectrometry, and reuse of the avidin resin.32
To demonstrate the efficacy of the approach, CREB from Sf9 cells was incubated
with 1 and mutant GalT, reacted with aminooxy biotin, and digested with trypsin.
Following avidin affinity chromatography, enrichment of the expected CREB
glycopeptide, 256TAPTSTIAPGVVMASSPALPTQPAEEAAR284 was observed by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)
(Figure 3.5).
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Figure 3.5. Enrichment of CREB O-GlcNAc peptides via the chemoenzymatic strategy. (A)
MALDI-TOF spectrum of CREB tryptic peptides prior to avidin chromatography. The peak at
m/z 3539.55 corresponds to the mass of the O-GlcNAc glycosylated peptide labeled with the
ketone-biotin moiety. (B) MALDI-TOF spectrum of the eluent following avidin affinity capture
of CREB peptides. The spectrum reveals enrichment of the labeled CREB peptide at m/z 3539.82
as well as two peaks at m/z 3555.80 and 3571.68 that correspond to oxidized forms of this
peptide. The peptide at m/z 2988.52 displays some nonspecific interaction with the avidin column
and can be readily discerned as unlabeled by LC-MS/MS.
 Importantly, during liquid chromatography-tandem mass spectrometry (LC-
MS/MS) of the enriched glycopeptide, the biotin-ketone moiety facilitated the
identification of the O-GlcNAc peptide by providing a unique mass signature in the
various stages of MS (Figure 3.6).  Specifically, the primary fragmentation at the MS/MS
stage of CAD was loss of the biotin-ketogalactose moiety, at the labile glycosidic
linkage.  This resulted in detection of the GlcNAc-modified peptide and unmodified
peptide.  In the MS3 stage (not shown), the GlcNAc-modified peptide was specifically
isolated and fragmented to generate the unmodified peptide, which could then be
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sequenced in the MS4 stage for peptide identification.  Notably, the charge loss of the
biotin-ketogalactose moiety and the neutral loss of the GlcNAc group are characterized
by  mass  differences that could readily and unambiguously be used to diagnose GlcNAc-
containing peptides.
Figure 3.6. Identification of the O-GlcNAc modified peptide on CREB by LC-MS/MS. The O-
GlcNAc-modified CREB peptide, 256TAPTSTIAPGVVMASSPALPTQPAEEAAR284 (m/z
1181.37).  is observed  during the MS stage.  CAD revealed signature losses of the biotin-ketone
moiety (m/z 1512.97) and the GlcNAc moiety (m/z 1411.49) during MS/MS.  Higher-order MS
analysis verified the identification of this peptide from the resultant y and b ions.
Having demonstrated the strategy with CREB, we applied it to the identification
of the low-stoichiometry site on αA-crystallin.4,17  Previous studies had demonstrated that
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αA-crystallin was no more than 10% glycosylated at its major site.  Thus, it had served as
a challenging target to test the sensitivity of several methods applied toward O-GlcNAc
peptide detection.4,17  Here we found that the O-GlcNAc-modified peptide of  αA-
crystallin was readily observed by LC-MS after chemoenzymatic labeling and
enrichment.  In this case, the unique characteristics of the glycosylated peptide afforded
direct detection of an O-GlcNAc-modified fragment in the MS3 stage of MS, allowing the
characterization of the exact modification site (Figure 3.7A, B).
Figure 3.7.  Application of the chemoenzymatic strategy toward the identification of the αA-
crystallin peptide. (A) MS analysis revealed the tagged O - GlcNAc peptide
158AIPVSREEKPSSAPSS173 (m/z 787.86).  The tag provided a diagnostic signature by tandem
MS.  The MS/MS spectrum of the triply charged parent ion revealed the signature loss of the
ketone-biotin moiety to yield the doubly charged GlcNAc-modified peptide (m/z 922.85) as the
predominant species.  The MS3 revealed the loss of the GlcNAc moiety to yield the unmodified
peptide (m/z 821.64) as well as several y and b fragment ions containing the GlcNAc moiety that
were used to establish the glycosylation site as Ser162.  Glycosylated y and b ions are indicated
with the subscript G.  MS4 analysis generated additional y and b ions as well as several internal
fragment ions that were used to sequence the peptide. (B) Summary of the y and b fragment ions.
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Importantly, although αA-crystallin demonstrates that O-GlcNAc site mapping is
possible, CAD-type-fragmentation generally prevents detection of modified amino acids,
because loss of the PTM dominates the fragmentation. Therefore, we envisioned that
combining our chemoenzymatic strategy with chemical labeling approaches such as β-
elimination (discussed in Chapter 4) or new modes of mass spectrometry fragmentation
such as electron transfer dissociation (ETD),33 (Chapter 5), would allow us to both
selectively isolate O-GlcNAc peptides and map sites of modification.
Having established that we could identify known O-GlcNAc glycosylated
peptides and sites via the chemoenzymatic strategy, we aimed to identify new
glycosylation sites on interesting targets.  We first examined O-GlcNAc transferase, of
which both the endogenous34 and recombinant23,35 forms have been shown to be
glycosylated.   In order to identify the specific sites, we treated the short splice form of
human OGT36 from Sf9 insect cells via the chemoenzymatic approach and analyzed the
captured peptides by MALDI-TOF MS.  Prior to avidin enrichment, O-GlcNAc-modified
peptides from OGT showed low signal intensity and were difficult to detect among the
mixture of other OGT peptides.  Enrichment revealed several prominent peptides that
corresponded to chemoenzymatically-tagged O-GlcNAc peptides from OGT (Figure
3.8A, B).
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Figure 3.8.  Enrichment of OGT O-GlcNAc peptides via the chemoenzymatic labeling
strategy. (A) MALDI-TOF spectrum of OGT tryptic peptides prior to avidin  chromatography
reveals a number of OGT peptides while no labeled O-GlcNAc modified peptides are visible. The
arrow with m/z 2548.16 the location within the spectrum that enrichment subsequently shows
contains O-GlcNAc-modified peptides. (B) Affinity chromatography reveals enrichment of a
peak at m/z 2548.16 and two oxidized forms of the same peptide. This mass corresponds to the
labeled O-GlcNAc peptide 390ISPTFADAYSNMGNTLK406, whose sequence was confirmed by
LC-MS/MS. The mass at m/z 2836.77 corresponds to the labeled O-GlcNAc form of the OGT
tryptic peptide 421AIQINPAFADAHSNLASIHK440. The mass at m/z 2251.08 does not
correspond to theoretical OGT tryptic modified or unmodified peptides and may be a
contaminant.
Subsequent LC-MS analysis identified a number of regions of glycosylation
within OGT.   Specifically, we found three in the tetratricopeptide repeat N-terminal
d o m a i n  w i t h i n  t h e  p e p t i d e s :  390ISPTFADAYSNMGNTLK406
407EMQDVQGALQCYTR420 and 421AIQINPAFADHSNLASIHK440. Additionally, we
identified two in the C-terminal domain, 826TIIVTTR832 and 1037IKPVEVTESA1046.
Sequencing confirmed the identity of two of these peptides (Figure 3.9A,B).  LC-MS/MS
experiments described in Chapter 5 and Appendix II confirmed the other sequences as
well.
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Figure 3.9. Identification of O-GlcNAc modified peptides on OGT by LC-MS/MS. (A)
Tandem mass spectra of  the labeled O - G l c N A c  p e p t i d e
390ISPTFADAYSNMoxGNTLK
406 (m/z 856.02). CID revealed signature losses of the
ketone-biotin moiety (m/z 1025.00) and the GlcNAc moiety (m/z 923.56). Higher-order
MS analysis provided conclusive identification of this peptide from the resultant y and b
ions.  (B) Tandem mass spectra of the labeled O-GlcNAc peptide 1037IKPVVEVTESA1046
(m/z 895.96). CID revealed signature losses of the ketone biotin moiety (m/z 1275.43)
and the GlcNAc moiety (m/z 1072.43). Higher-order MS analysis provided conclusive
identification of this peptide from the resultant y and b ions as well as internal fragment
ions.
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As a final application of our chemoenzymatic  strategy toward O-GlcNAc
glycosylated peptides, we investigated the glycosylation on the transcription factor
ΔFosB.  Like other Fos family transcription factors, this c-terminal truncation variant of
the FosB gene functions as a transcriptional regulator.  Uniquely, however, ΔFosB
protein expression is induced only upon chronic stimulus, and persists in response to
chronic drug treatments.  In fact, a number of studies suggest that  it may mediate the
molecular foundations of drug abuse, reward and addiction.37,38  In collaboration with
Eric Nestler’s laboratory, Dr. H.-Y. Cheng in the lab discovered that ΔFosB was
glycosylated.  To gain insight into the funtional role of O-GlcNAc on ΔFosB, we tagged
the recombinant protein from Sf9 cells with the keto-galactose probe and searched for
modified peptides in the LC-MS/MS of digested ΔFosB.  We identified two distinct sites
of glycosylation on ΔFosB, one of which is in the N-terminal transactivation domain.39
Importantly, as with the biotin-keto-galactose moiety, the loss of the keto-galactose group
and keto-galactose-GlcNAc group, provides a unique signature with which to identify
tagged peptides by mass spectrometry.  Although the glycosylated peptides were not
specifically captured in this case, we were able to identify them by searching spectra for
the distinct mass signatures (Figure 3.10).
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Figure 3.10. Discovery of O-GlcNAc glycosylated sites on ΔFosB. (A) LC-MS/MS signature
of the ketogalactose labeled O-GlcNAc peptide  69AITTSQDLQW78 from ΔFosB including
summary of the b and y fragment ions identified by MS3 (B) LC-MS/MS signature of the
ketogalactose labeled O-GlcNAc peptide 122STGGASGSGGPSTSTTTSGPVSAR145 from ΔFosB
including b and y fragment ions identified by MS4.
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3.4 Discussion
We have developed a parallel chemoenzymatic strategy that allows isolation and
identification of O-GlcNAc glycosylated proteins from cell lysate.  Our strategy detects
low-abundance proteins containing only a few modification sites, and circumvents the
need to purify individual proteins.  Using this approach, H.-C. Tai in the lab, identified
O-GlcNAc modified transcription factors such as the members of the AP-1 transcription
factor complex, as well as the transcriptional coactivator/histone acetyltransferase CBP.
We extended the approach to other cell types including neurons, by demonstrating
glycosylation on the transcriptional repressor MeCP2.
In addition, we applied the technique to the analysis of O-GlcNAc peptides in
order to facilitate mapping of glycosylation sites.  Here, we were able to selectively
isolate O-GlcNAc glycosylated peptides from CREB and αA-crystallin, as well as
identify new sites on OGT and the transcription factor ΔFosB.
At least three splice variants of human OGT are known and detected in HeLa
cells40: the nucleo-cytoplasmic 110kDa form, the 103kDa protein, which appears to be
targeted to the mitochondria, and a short 75kDa form.  Here, we examined O-GlcNAc
glycosylation of the short recombinant form, where we identified sites of modification
within the N-terminal tetratricopeptide repeat domain (TPR) and within the extreme C-
terminus.  The TPR motif is known to mediate protein-protein interactions.41  In the case
of OGT, the domain is necessary for OGT dimerization35 as well as for interaction with
the transcriptional repressor mSin3A, where the mSin3A-OGT complex mediates gene
silencing in concert with HDACs.42  Moreover, although the OGT catalytic domain is in
its C-terminus, the TPR repeats are required for glycosylation of certain protein
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substrates, including the p62 nucleoporin protein.23,43  Thus, in lieu of a primary
consensus sequence for glycosylation, OGT may select substrates partially through larger
protein-recognition motifs.  The localization of O-GlcNAc sites within the TPR repeats
suggests that glycosylation of OGT may serve to modulate OGT-protein interactions,
possibly regulating OGT substrate interaction.   We also found two sites of glycosylation
in the C-terminal domain of OGT.  Removal of the extreme C-terminus of OGT,
including the peptide IKPVEVTESA on which we find glycosylation, ablates catalytic
activity.23  Interestingly, Lubas and Hanover found that removal of all but the last three
TPR repeat of OGT, as in this short transcript, reduced glycosylation of protein substrates
and enhanced autocatalytic activity of the enzyme in vitro.23  Therefore, it will be
important to analyze the nucleo-cytoplasmic, long-form of OGT for O-GlcNAc
glycosylation as distinctions in glycosylation sites and levels of glycosylation may help
define the functional differences between these two isoforms.
After we identified O-GlcNAc-modified sites on ΔFosB, Dr. H.-Y. Cheng in the
lab created  Thr->Ala or Ser-> Ala mutations for the dominant site of glycosylation and
found that as with the transcription factors CREB and Sp1, O-GlcNAc glycosylation
appeared to have a repressive affect on ΔFosB transactivation potential.  Future work in
the laboratory may explore the mechanisms by which O-GlcNAc affects ΔFosB
transcriptional activity, perhaps by modulating protein-protein interactions with as yet
undetermined N-terminal domain interacting partners.  In addition, it will be important to
determine if glycosylation on ΔFosB and FosB is differentially regulated in a manner that
influences their strikingly different half-lives in the brain.  Although the peptides on
which we find glycosylation are conserved between and ΔFosB  and FosB, OGT-
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substrate interactions may result in differences between ΔFosB and FosB recognition and
glycosylation.  Alternatively, these glycosylation sites may be conserved, but FosB may
also be glycosylated in its extreme c-terminus in a manner that affects its degradation,
while the c-terminal truncation variant, ΔFosB, is protected from degradation. Finally, it
will be important to discover if endogenous ΔFosB in the brain is likewise glycosylated,
and how this glycosylation is regulated in response to activity and drugs of abuse.
One of the key advantages of the peptide tagging approach is the ability to
selectively enrich glycosylated peptides from the mixture of  significantly more abundant
unmodified peptides, which may prevent O-GlcNAc peptide detection.  Moreover, in
contrast to other strategies,  the unique signature produced during LC-MSn allows us to
unambiguously assign O-GlcNAc peptides, sometimes in the absence of enrichment, as
seen with ΔFosB.  Overall, we anticipate that the strategy will accelerate both the
discovery of O-GlcNAc modified-proteins and our understanding of this  modification in
a physiological context.
3.5 Experimental Methods
General Reagents
Unless otherwise noted, reagents were purchased from the commercial suppliers Fisher
(Fairlawn, NJ) and Sigma-Aldrich (St. Louis, MO), and were used without further
purification.  Protease inhibitors were purchased from Sigma-Aldrich or Alexis
Biochemicals (San Diego, CA).  Peptide N-glycosidase F (PNGase F) was purchased
from New England Biolabs (Beverly, MA).  Sequencing grade trypsin was from Promega
(Madison, WI).  Sequencing-grade chymotrypsin was from Roche (Indianapolis, IN).
Agarose-conjugated protein A, agarose-conjugated streptavidin, SuperSignal West Pico
chemiluminescence reagents, horseradish peroxidase (HRP)-conjugated streptavidin and
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anti-rabbit IgG antibody were from Pierce (Rockford, IL).  Nitrocellulose membrane was
from Schleicher and Schuell (Keene, NH). N-(aminooxyacetyl)-N'-(D-biotinoyl)
hydrazine was purchased from Dojindo (Gaithersburg, MD). CTD 110.6 anti-O-GlcNAc
antibody was from Covance (Princeton, NJ). Mutant GalT (Y289L) was expressed and
purified as described in Chapter 1. His-tagged ∆FosB from Sf9 cells was kindly provided
by E. Nestler.  All protein concentrations were measured using the Bradford assay (Bio-
Rad Laboratories, Hercules, CA) or BCA assay, (Pierce, Rockford, IL).  Preparation of
HeLa Cell Extracts, Labeling and Capture of O-GlcNAc Modified Proteins from HeLa
Cells, and Radiolabeling and Immunoprecipitation of c-Fos were all performed exactly as
described in Tai et al.1
Preparation of Neuronal Extracts and Chemoenzymatic Labeling and Capture of O-
GlcNAc Modified Proteins for MeCP2 analysis
Embryonic (E17) rat cortical neurons, cultured in 37 oC humidified air with 5% CO2 in
basal eagle medium (Sigma) with 5% fetal bovine serum, 1 X B27 supplement (GIBCO),
2 mM L-glutamine (GIBCO), and penicillin (100 U/mL)/streptomycin (100 U/mL)
(GIBCO) were provided by J. Zellhoefer from Yi Sun’s laboratory at UCLA.  Prior to
lysis, neurons were treated with 10mM glucosamine (in 100mM HEPES pH 7.4) for 8.5 h
and, in some cases, 50mM KCl for 1 h 50 min for depolarization experiments.  After
induction, cells from a 100 mm dish were trypsinized and pelleted.  After removing
media by aspiration, the pellet was resuspended in boiling lysis buffer (1% SDS and
protease inhibitors, 15 µg/mL antipain, 15 µg/mL leupeptin, 7.5 µg/mL chymostatin, 7.5
µg/mL pepstatin, 1 mM phenylmethylsulfonyl fluoride, sonicated for 10 sec, and boiled
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for 8 min.  After centrifugation at 21,500 × g for 15 min, the supernatant was collected as
denatured neuronal extract.
A small fraction of neuronal extract was saved and used for CTD110.6 anti-O-
GlcNAc Western blotting to ensure successful glucosamine uptake (data not shown).
The remainder of the neuronal extract (typically 600 µg of total protein in 80 µL) was
diluted 5-fold into 10 mM HEPES pH 7.9, 2.5 mM DTT, 1.25 mM adenosine 5’-
diphosphate, 1.8% NP-40, 5 mM MnCl2 containing protease inhibitors (15 µg/mL
antipain, 15 µg/mL leupeptin, 7.5 µg/mL chymostatin, 7.5 µg/mL pepstatin, 0.75 mM
phenylmethylsulfonyl fluoride).  Diluted extract was then supplemented with and 0.5 mM
analogue 1 and 20 µg/mL Y289L GalT.  The reaction mixture was incubated at 4 oC for
12 h, and dialyzed into buffer A (10 mM HEPES pH 7.9, 5 M urea) 3 × 3 h at 4 oC. The
sample was then acidified to pH 4.8 by adding 3 M NaOAc pH 3.9 to a final
concentration of 50 mM and mixed for 10 min. Aminooxy biotin derivative was added to
a final concentration of 3 mM.  After incubation at room temperature for 20 h, the sample
was neutralized by adding 0.5 M HEPES pH 7.9 to a final concentration of 33 mM,
followed by dialysis into buffer B (10 mM HEPES pH 7.9, 6 M urea, 100 mM NaCl) 2 ×
15 h and 1 × 3 h at RT, and into buffer C (10 mM HEPES 7.9, 100 mM NaCl, 0.2%
triton-X100) 2 × 3 h, 1 × 15 h at 4º C. Dialyzed sample was collected as labeled neuronal
extract.
      Labeled neuronal extract was supplemented with 1 mM DTT and protease inhibitors
(10 µg/mL antipain, 10 µg/mL leupeptin, 5 µg/mL chymostatin, 5 µg/mL pepstatin, 0.5
mM phenylmethylsulfonyl fluoride), and 25 µg of material was saved as input to the
streptavidin capture. The remainder of the material was precleared with sepharose 6B
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beads (30 µL/100 µg of proteins) for 1 h at 4 oC.  After centrifugation at 5,000 × g for 3
min, the supernatant was collected and incubated with agarose-conjugated streptavidin
(30 µL/100 µg of proteins) for 2 h at 4 oC.  Following centrifugation at 5,000 × g for 3
min, the supernatant was removed, and the beads were washed 3× with 8 volumes of low
salt wash buffer (0.1 M Na2HPO4 pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS) and 3× with high salt wash buffer (0.1 M Na2HPO4 pH 7.5, 0.5
M NaCl, 0.2% Triton X-100).  After washing, the beads were boiled for 10 min in 2.5
volumes of elution buffer (50 mM Tris-HCl 6.8, 2.5% SDS, 100 mM DTT, 10% glycerol,
2 mM biotin).  After centrifugation at 2,000 × g for 1 min, the supernatant was collected
as the captured material.
Control reactions without analogue 1 or Y289L GalT were treated identically.
After capture, Streptavidin-HRP Western blots were conducted to ensure successful
labeling and capture of O-GlcNAc-modified proteins (data not shown). Anti-MeCP2
Western blots were conducted by J. Zellhoefer.
Labeling of CREB and O-GlcNAc Transferase (OGT) for Mass Spectrometry
Baculovirus preparation and protein expression were performed as described
previously.12 CREB (2 µg) or OGT (10 µg) in 20 mM HEPES pH 7.9, 100 mM KCl, 0.2
mM EDTA, and 15% glycerol were supplemented with 5 mM MnCl2.  Analogue 1 and
Y289L GalT were added to final concentrations of 750 µM and 40 ng/µL, respectively.
Control reactions without enzyme or analogue 1 were treated identically except water
was added in place of one of the components.  Following incubation at 12 h at 4 °C, the
reactions were diluted 2-fold with saturated urea. NaOAc (2.7 M) pH 3.9 was added to a
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final concentration of 50 mM and a final pH of 4.8.  Aminooxy biotin derivative was
added to a final concentration of 5 mM, and the biotinylation reactions were incubated
with gentle shaking for 20-24 h at 23 °C.  Reactions were aliquoted for analysis by
Western blotting or mass spectrometry and stopped by boiling in SDS-PAGE loading
dye.  Proteins were resolved by 10% SDS-PAGE and either electrophoretically
transferred to nitrocellulose or stained with Coomassie Brilliant Blue. Western blotting
with streptavidin-HRP was performed as described above to confirm successful labeling
(data not shown).
In-Gel Trypsin Digestion, Avidin Enrichment and MALDI-TOF Analysis of
Labeled CREB and OGT
CREB and OGT bands were excised from Coomassie-stained gels and treated essentially
as described by Shevchenko et al.44 Briefly, excised bands were destained overnight in
50% MeOH, 5% AcOH. Destained bands were dehydrated in CH3CN, dried by vacuum,
and rehydrated in 10 mM DTT in 50 mM NH4HCO3 pH 8.0. After 30 min reduction at
room temperature, excess DTT was removed, and proteins were alkylated in 50 mM
iodoacetamide in 50 mM NH4HCO3 pH 8.0 for 30 min at room temperature in the dark.
After alkylation, excess iodoacetamide was removed and protein bands were washed in
100 mM NH4HCO3 pH 8.0 for 10 min, followed by two successive dehydrations in
CH3CN. Wash and dehydration steps were repeated once more, and excess CH3CN was
removed under vacuum. Protein bands were rehydrated in 15 ng/µL trypsin dissolved in
50 mM NH4HCO3 pH 8.0.  Excess trypsin solution was removed after rehydration, and
20-30 µL of 50 mM NH4HCO3 pH 8.0 was then added to cover the gel slices.  Proteins
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were digested overnight at 37 °C. Following digestion, peptides were extracted with two
successive washes of water (50 µL each) followed by 50% acetonitrile/5% formic acid in
water (100 µL), and dried by vacuum centrifugation.
      A small portion of each sample was saved prior to affinity chromatography for
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-
TOF MS). The remainder was subjected to avidin affinity chromatography (Applied
Biosystems, Foster City, CA).  Chromatography was performed essentially as described
by the manufacturer except that the volume of washes was doubled. Eluted peptides were
partially dried by vacuum centrifugation, and a small portion of the eluted peptides was
analyzed by MALDI-TOF MS.  For the analysis, peptide samples were concentrated on
C18 zip tips (Millipore, Bedford, MA) and combined with the MALDI matrix (2,5-
dihydroxybenzoic acid in 20% CH3CN, 0.1% TFA in water).  Spectra were acquired on a
PerSeptive Biosystems Voyager-DE Pro at 20,000 kV in the reflector mode.
 LC-MS/MS Analysis of Avidin-Enriched CREB and OGT Peptides
 Automated nanoscale liquid chromatography and tandem mass spectrometry (LC-
MS/MS) were conducted using a ThermoFinnigan Surveyor HPLC and  LTQ ion trap
mass spectrometer along with a variation of the “vented column” approach described by
Licklider et al.45 Avidin-enriched peptides were loaded onto a 5 cm-long X 75 µm i.d.
precolumn packed with 5 µm C-18 silica (Monitor 100 Å) retained by a Kaisel frit.  After
thorough washing, the vent was closed and the sample was transferred to a 12 cm long X
75 µm i.d. column with a pulled 5 µm tip packed with the same material.  The
chromatographic profile was from 100% solvent A (0.1% aqueous AcOH) to 50%
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solvent B (0.1% AcOH in CH3CN) in 30 min at approximately 200 nL/min (manual split
from 300 µL/min).  Additional time was allotted for column washing and reequilibration.
The LTQ was operated in automated mode using Xcalibur software.  The acquisition
method during MS/MS analysis involved one MS precursor ion scan followed by five
data-dependent MS/MS scans. Higher-order MS analyses involved an MS precursor scan
followed by targeted MS4 scans of those masses that specifically demonstrated loss of the
ketone-biotin moiety and ketone-biotin-GlcNAc moiety in the MS/MS analysis. In the
case of the OGT sample peptides, MS4 data was used to search against an OGT sequence
database using SEQUEST.46  All potential peptide identifications were manually verified.
In the case of the CREB sample, the acquisition method involved targeted MS/MS
analysis of the presumptive ketone-biotin-GlcNAc modified peptide at m/z 1181.2, with
simultaneous targeted MS3 analysis of the GlcNAc modified peptide at m/z 1513.6 and
MS4 analysis of the unmodified peptide at m/z 1412.1.
      The electrospray voltage was set at 1.6 kV and the heated capillary was set at 250 °C.
The ion selection window was set at 500-2000 m/z for all experiments.  For MS/MS and
higher-order MS analyses, the relative collision energy for collision-induced dissociation
(CID) was preset to 35% and a default charge state of +2 was selected to calculate the
scan range for acquiring tandem MS spectra. The precursor ion isolation window was set
at 3.5 for maximum sensitivity.
Chemoenzymatic Labeling, Biotinylation and Avidin Enrichment of α-Crystallin
Bovine lens α-crystallin (8.7 µg, Sigma-Aldrich) was incubated with analogue 1 (750
µM), and Y289L GalT in 20 mM HEPES pH 7.9 containing 5 mM MnCl2 and 100 mM
89
89
NaCl for 12 h at 4 °C.  The reactions were then diluted 2-fold with saturated urea, 2.7 M
NaOAc pH 3.9 (50 mM final concentration, pH 4.8) and N-(aminoxyacetyl)-N’-(D-
biotinoyl) hydrazine (5 mM final concentration, Dojindo), and incubated with gentle
shaking for 20-24 h at 23 °C.  The tagged α-A-crystallin was excised from a Coomassie-
stained gel and digested with trypsin (Promega) essentially as described by Shevchenko
et al.44   Avidin affinity chromatography and LC-MS/MS were performed as described
above.
Chemoenzymatic Labeling and LC-MS/MS Analysis of ΔFosB
Recombinant ΔFosB from Sf9 cells (12.5 µg) was incubated with the unnatural analogue
1 (500 µM), and Y289L GalT in 20 mM HEPES pH 7.9 containing 5 mM MnCl2 and 100
mM NaCl for 12 h at 4 °C.  The reactions were then diluted 3-fold with 9M urea, 2.7 M
NaOAc pH 3.9, 100% THF and 2-Aminooxy-N-(3-perfluorolhexyl)propyl-acetamide
(Fluorous Technologies, Pittsburgh PA) in 100% THF (final concentration 3.8 M urea, 50
mM NaOAc, 20% THF, 3mM 2-Aminooxy-N-(3-perfluorolhexyl)propyl-acetamide, final
pH 4.8) and incubated with gentle shaking for 20-24 h at 23 °C.  Excess reagents were
removed via  microcon (Millipore, Billerica, MA) by repeated dialfiltration into 5 M
urea, 50 mM NH4HCO3, pH 8.1.  The protein solution was then reduced in 10 mM DTT
for 1 h at RT, alkylated in 40 mM iodoacetamide for 1 h at RT, and  reacted with 40 mM
DTT for 1 h at RT to remove excess iodoacetamide.  The protein solution was then
diluted to a final urea concentration of 2M, and trypsin (Promega) was added to a final
concentration of  0.015 µg/µL.  Trypsin digestion was carried out at 37º C for 6.5 h, and
chymotrypsin (Roche, Indianapolis IN)  was subsequently added to a final concentration
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of  0.015 µg/µL, with 10 mM CaCl2.  Digestion was allowed to proceed for 6 h at 37º C,
and then stopped by acidification.  Fluorous solid phase extraction  chromatography (as
described in appendix II) failed to  detect modified ΔFosB peptides, so we inspected
sample input via LC-MS/MS for presence of O -GlcNAc keto-galactose modified
peptides.  (Later experiments suggested that  the presence of ketone and aldehyde by-
products in THF  may have interfered with aminooxy labeling).
Automated nanoscale liquid chromatography and tandem mass spectrometry (LC-
MS/MS) were conducted using a ThermoElectron Surveyor HPLC and  LCQ Deca  ion
trap mass spectrometer along with a variation of the “vented column” approach as
described for CREB and OGT above. The LCQ Deca XP was operated in automated
mode using Xcalibur software.  The acquisition method during MS/MS analysis involved
one MS precursor ion scan followed by three data-dependent MS/MS scans. Higher-order
MS analyses involved an MS precursor scan followed by targeted MS3 scans of those
masses that specifically demonstrated loss of the keto-galactose moiety and ketone-
galactose-GlcNAc moiety in the MS/MS analysis. MS3 data were used to search against
an FosB sequence database using SEQUEST. All potential peptide identifications were
manually verified.
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Chapter 4
Exploring the O-GlcNAc Proteome:
Direct Identification of O-GlcNAc-Modified Proteins from the Brain*
4.1 Background and Introduction
Protein PTMs represent an important mechanism for the regulation of cellular
physiology and function.  The covalent addition of chemical groups (e.g., phosphate,
acetate, carbohydrate) extends the capabilities of proteins and provides a selective and
temporal means of controlling protein function.2,3 Despite the importance of PTMs, their
extent and significance are only beginning to be understood.  We have been investigating
O-GlcNAc glycosylation, the covalent attachment of β-N-acetylglucosamine to serine or
threonine residues of protein.4 Unlike most carbohydrate modifications, O-GlcNAc is
dynamic and intracellular and, as such, shares common features with protein
phosphorylation.5 Over 100 proteins bearing the O-GlcNAc group have been identified to
date, including transcription factors, cytoskeletal proteins, protein kinases, and nuclear
pore proteins.6 Recent studies have elucidated diverse roles for the O-GlcNAc
modification, ranging from nutrient sensing to the regulation of proteasomal degradation
and gene silencing.4 Moreover, perturbations in O-GlcNAc levels have been associated
with disease states such as cancer, Alzheimer’s, and diabetes.7,6
Several lines of evidence suggest an important role for O-GlcNAc in the brain.
First, activation of protein kinase A or C pathways leads to reduced levels of O-GlcNAc
in certain protein fractions from cerebellar neurons,8 suggesting an intriguing, dynamic
                                                 
* Parts of this chapter taken from N. Khidekel, S. B. Ficarro, E. C. Peters & L. C. Hsieh-
Wilson.  Exploring the O-GlcNAc proteome: direct identification of O-GlcNAc-modified
proteins from the brain. Proc Natl Acad Sci USA 101, 13132-7 (2004).
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interplay between the two modifications.  Second, O-GlcNAc transferase (OGT), the
enzyme that catalyzes the modification, is most abundant in the brain and pancreas.9
Interestingly, the activity of OGT appears to be modulated by complex mechanisms,
including differential splicing, interaction with regulatory partners, and regulation via
PTMs.9 In the brain OGT forms a stable complex with protein phosphatase 1 (β and γ)10
highlighting the apparent interrelationship between O-GlcNAc and phosphorylation, one
of the best characterized PTM’s regulating brain function.  Third, OGT and the
corresponding beta-N-acetylglucosaminidase (O-GlcNAcase) are particularly abundant in
the nerve terminal,11 or synaptosome, where they are enriched in the presynaptic cytosol11
and around synaptic vesicles,12 suggesting neuron-specific functions for the modification.
Finally, a critical role for O-GlcNAc in the brain is suggested by its presence on proteins
important for neuronal function and pathogenesis such as cAMP-responsive binding
protein (CREB)13 and β-amyloid precursor protein (APP).14
Despite tantalizing evidence of its significance, the O-GlcNAc modification has
been definitively linked to only a handful of proteins from the brain.11 Efforts to identify
proteins have been challenged by the difficulty of detecting the modification in vivo.
Like many PTMs, O-GlcNAc is often dynamic, substoichiometric, and prevalent on low-
abundance regulatory proteins.  The sugar is both enzymatically and chemically labile,
being subject to reversal by cellular glycosidases and cleavage on the mass spectrometer.
As with many protein kinases, the lack of a well-defined consensus sequence for OGT
has precluded the determination of in vivo modification sites based on primary sequence
alone.
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Several powerful methods have been reported for the identification of O-GlcNAc
modified proteins.  Proteins have been tritium labeled,15 enriched using lectins or
antibodies,16,17 or chemically tagged by metabolic labeling or BEMAD (β-Elimination
followed by Michael Addition with Dithiothreitol).17,18 However, none of the existing
methods is ideally suited to the direct, high-throughput identification of O-GlcNAc
proteins from tissues or cell lysates.  For instance, the tritium methodology is labor
intensive and lacks sensitivity, necessitating purification of relatively large amounts of
protein.  Enrichment of O-GlcNAc proteins using antibodies has not afforded direct
observation of O-GlcNAc glycosylated peptides and thus cannot rule out false positives.17
Initially, metabolic labeling was shown to identify only the highly glycosylated protein
p62.18 Moreover, the method has not yet been applied to map glycosylation sites, and it
may not be broadly applicable to tissues due to cellular uptake requirements.  Although
the BEMAD approach can be used to map sites on purified proteins and protein
complexes, it is an inherently destructive technique that requires extensive controls to
establish whether a peptide contains a phosphate, O-GlcNAc or complex O-linked
carbohydrate group.17
A robust strategy for exploring the O-GlcNAc proteome would permit
investigations into the breadth of the modification and its potential functions across
various tissues and species.  Direct detection of the O-GlcNAc moiety would enable
conclusive identification of the glycoproteins and localize the modification to specific
functional domains, a prerequisite for understanding the physiological role of the
modification.  Moreover, such an approach might also allow for quantitative comparisons
of glycosylation levels in cellular or disease states.
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In Chapter 2 we described a chemoenzymatic strategy for the rapid and sensitive
detection of purified O-GlcNAc proteins.19 In Chapter 3, the approach was applied to the
discovery of individual O-GlcNAc proteins from cells, as well as to the isolation and
identification of O-GlcNAc peptides and sites of modification.20 Here, we describe
extension of the approach to the first, direct, high-throughput identification of O-GlcNAc
proteins from the mammalian brain.  Using this strategy, 23 new O-GlcNAc modified
proteins have been identified, including regulatory proteins associated with gene
expression, neuronal signaling, and synaptic plasticity.1 In addition, we have utilized the
chemoenzymatic strategy to discover O-GlcNAc proteins specific to the synaptosome, an
area enriched in the enzymes that regulate O-GlcNAc cycling.  The synaptosomal O-
GlcNAc proteins identified here strongly implicate O-GlcNAc in a role in synaptic
vesicle cycling and neurotransmitter release.  Overall, the diversity represented by this set
of proteins provides new insight into the role of O-GlcNAc in neuronal function and
should yield exciting targets for future study.
4.2 Proteome-Wide Identification of O-GlcNAc Proteins in the Brain
Previously, we described a chemoenzymatic strategy for the detection of purified O-
GlcNAc glycosylated proteins.  Our approach took advantage of an engineered β-1,4-
galactosyltransferase (GalT) enzyme to transfer a ketone-containing galactose analogue
selectively to the 4-position of GlcNAc on glycosylated proteins.  Once transferred, the
ketone functionality was reacted with an aminooxy biotin nucleophile, permitting rapid,
sensitive detection of O-GlcNAc modified proteins by chemiluminescence.  We applied
this methodology to the parallel discovery of O-GlcNAc proteins from cell lysate via
streptavidin capture and western blotting for proteins of interest.  We likewise
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demonstrated that this approach could be used to isolate O-GlcNAc modified peptides
and identify sites of glycosylation from single proteins such as CREB and OGT (Chapter
3). We reasoned that this biotin tagging approach could be extended to complex mixtures,
in order to enrich O-GlcNAc glycosylated peptides and discover O-GlcNAc proteins
(Figure 4.1).  Numerous studies have demonstrated the importance of enrichment
strategies for the detection of PTMs.21 In our case, proteins from cellular lysates would be
selectively labeled with the ketone-biotin handle, digested, and glycopeptides captured
using avidin affinity chromatography.  Mass spectrometric analysis of the enriched
glycopeptides would afford the proteome-wide identification of novel glycosylated
proteins.  Importantly, the approach would also permit the direct detection of modified
peptides, enabling simultaneous mapping of O-GlcNAc to specific functional domains
within a protein.
Figure 4.1. Chemoenzymatic strategy for identifying O-GlcNAc glycosylated peptides from
complex mixtures.
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Having demonstrated the selective tagging and capture of O-GlcNAc glycosylated
peptides from purified proteins (Chapter 3), we extended the approach to the O-GlcNAc
proteome of the mammalian brain.  Rat brain lysates were separated into nuclear and
S100 cytoplasmic fractions, labeled with the tag, and digested with trypsin.  We also
subjected a portion of the samples to proteolytic digestion with GluC to broaden the
scope of analysis and generate confirmatory peptide sequences.  Due to the overall
complexity of the sample, the digested peptides were fractionated via strong cation
exchange chromatography prior to avidin affinity chromatography.
Nearly 100 peptides containing the characteristic signature loss of the ketone-
biotin tag were observed by LC-MS/MS.  Figure 4.2A shows an averaged ESI spectrum
of ions eluting from the LC column with retention time 17.0 to 18.1 minutes.  Peaks
corresponding to peptides with the diagnostic signature were subsequently selected for
targeted MS4 analysis.  Notably, the vast majority of peaks in this region contained the
GlcNAc-ketone-biotin moiety, demonstrating significant enrichment of this low-
abundance modification.  Figure 4.2B shows the MS/MS spectrum of a representative
peptide (m/z = 789.2), indicating the characteristic loss of a ketone-biotin moiety (m/z =
925.5) and GlcNAc-ketone-biotin moiety (m/z 823.9).  Higher-order MS analysis
generated a definitive series of b and y ions (Fig. 4.2C), and database searching identified
the peptide as belonging to the protein synaptopodin.  Notably, alternative MS
instrumentation and techniques such as Q-TOF22 can be utilized to obtain sequencing
information of species exhibiting the characteristic loss signature.
101
Figure 4.2.  Analysis of tagged O -GlcNAc peptides from brain lysates.  (A) Summed m/z
spectrum of ions eluting from the LC column with retention time 17.0 to 18.1 minutes.  Peaks
indicated with an asterisk represent peptides that yielded the diagnostic ketone-biotin and
GlcNAc-ketone-biotin loss signature upon MS/MS.  (B) MS/MS spectrum of a representative
peak (m/z = 789.23), showing loss of a ketone-biotin moiety (m/z = 925.50) and GlcNAc-ketone-
biotin moiety (m/z 823.92). Fragmentation during MS4 analysis yielded numerous b and y ions,
which permitted sequencing of the peptide. (C) Prominent fragment ions used to identify the
peptide as 203VSGHAAVTTPTKVYSE218 from synaptopodin.
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Using this approach, we successfully sequenced 34 unique peptides corresponding to 25
proteins from rat brain (Table 4.1).  Importantly, two of the proteins, microtubule-
associated protein 2B  (MAP2B) and host cell factor (HCF) have previously been
reported to be O-GlcNAc glycosylated,23,24 providing strong validation of our
methodology.  In addition, our results extend earlier reports by establishing distinct
amino acid stretches within each protein that bear the modification.  Two sites of
glycosylation were identified in the N-terminal region of MAP2B.  In accordance with a
demonstrated interaction between the N-terminal region of HCF and both wheat germ
agglutinin lectin and an anti-O-GlcNAc antibody,24 we observed four distinct sites within
three peptides in the N-terminal region of HCF.  We also identified O-GlcNAc on
erythrocyte protein band 4.1-like 3 within a region that shares significant sequence
identity to a reported glycopeptide from human erythrocyte membrane protein band 4.1
(1026TITSETTSTTTTTHITK1042 a n d  772(TAQ)TITSETPSSTTTTQITK791,
respectively).25
In addition to known proteins, our approach enabled the identification of 23 novel
O-GlcNAc glycosylated proteins from the mammalian brain (Table 4.1).  The proteins
fall into a broad range of functional classes, including those involved in transcriptional
regulation, neuronal signaling, and synaptic plasticity.  Consistent with studies
demonstrating that O-GlcNAc modifies transcription factors and RNA polymerase II, we
identified a large number of proteins involved in transcription.  In addition to low-
abundance transcription factors, we found O-GlcNAc on novel transcriptional proteins
such as coactivators,  corepressors, and chromatin remodeling enzymes, which suggests
expanded roles for O-GlcNAc in transcriptional control.
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Table 4.1. O-GlcNAc glycosylated proteins identified from the mammalian brain
Notably, our methodology also afforded the simultaneous detection of multiple PTMs.
For instance, we observed an O-GlcNAc modified peptide with a characteristic loss of 98
Da upon CID, consistent with phosphorylation within the same peptide (data not shown).
Moreover, two O-GlcNAc modifications were identified within the same peptide of HCF
(data not shown).
Although we readily isolated O-GlcNAc-modified peptides, the mapping of
specific O-GlcNAc glycosylation sites is inherently difficult due to the lability of the
glycosidic linkage upon CAD and the preference of OGT for sequences rich in serine,
threonine, and proline residues.  To address this issue, we combined precedented β-
elimination strategies with our methodology to localize specific modification sites.
Previous studies have shown that glycosylated and phosphorylated serine/threonine
NCBI 
Protein Entry Function Peptide Sequence Residues
Transcriptional Regulation
SOX2 (sex-determining region Y-box 2) 31543759‡ transcription factor SEASSSPPVVTSSSHSR 248-264
ATF-2 (activating transcription factor 2) 13591926 transcription factor, histone acetyltransferase AALTQQHPPVTDGDTVK 262-278
HCF (host cell factor) 34881756 transcriptional regulator, chromatin associated factor TAAAQVGTSVSSAANTSTRPIITVHK** 620-645
HCF (host cell factor) 34881756 transcriptional regulator, chromatin associated factor SPITIITTK 802-810
HCF (host cell factor) 34881756 transcriptional regulator, chromatin associated factor VMSVVQTK 691-698 
SRC-1 (steroid receptor coactivator-1) 34863079 transcriptional coactivator for nuclear receptors INPSVNPGISPAHGVTR 188-204
CCR4-NOT4 34855140 global transcriptional regulator, mRNA metabolism SNPVIPISSSNHSAR 329-343
CCR4-NOT subunit 2 34864872 global transcriptional regulator, mRNA metabolism SLSQGTQLPSHVTPTTGVPTMSLHTPPSPSR 79-109
TLE-4 (transducin-like enhancer protein 4) 9507191 transcriptional corepressor TDAPTPGSNSTPGLRPVPGKPPGVDPLASSLR 298-329
RNA binding motif protein 14 16307494‡ transcriptional coregulator for steroid receptors AQPSVSLGAAYR 239-250
Nucleic Acid Binding Proteins
NFRKB (nuclear factor related kappaB) 34862978 DNA binding protein VPVTATQTK 896-904
zinc finger RNA binding protein 34854400 RNA binding protein AGYSQGATQYTQAQQAR 58-74
Intracellular Transport
Hrb (HIV-1 Rev binding protein) 34859394 RNA trafficking APVGSVVSVPSHSSASSDK* 360-378
GRASP55 (Golgi reassembly stacking protein 2) 20301956 membrane protein transport, Golgi cisternae stacking VPTTVEDR 423-430
Cellular Organization / Dynamics
erythrocyte protein band 4.1-like 3 16758808 cytoskeletal protein TITSETTSTTTTTHITK 1026-1042
erythrocyte protein band 4.1-like 4 16758808 cytoskeletal protein TTSTTTTTHITKTVKGGISE 1031-1050
erythrocyte protein band 4.1-like 1, isoform L 11067407 cytoskeletal protein DVLTSTYGATAETLSTSTTTHVTK 1460-1483
erythrocyte protein band 4.1-like 1, isoform L 11067407 cytoskeletal protein TLSTSTTTHVTKTVKGGFSE 1472-1491
spectrin beta chain, (fodrin beta chain) 34879632 axonal/pre-synaptic cytoskeletal protein HDTSASTQSTPASSR 2354-2368
MAP1B (microtuble-associated protein 1B) 19856246 axonogenesis TTTKTTRSPDTSAYCYE 2018-2034
MAP2B (microtubule-associated protein 2B) 111965 dynamic assembly of microtubules at dendrites SSKDEEPQKDKADKVADVPVSE 366-387
MAP2B (microtubule-associated protein 2B) 111965 dynamic assembly of microtubules at dendrites KADKVADVPVSE 376-387
MAP2B (microtubule-associated protein 2B) 111965 dynamic assembly of microtubules at dendrites TSSESPFPAKE 788-798
Cellular Communication / Signal 
Transduction
WNK-1 (lysine deficient protein kinase) 16758634 signal transduction, ion homeostasis DGTEVHVTASSSGAGVVK 1584-1601 
WNK-1 (lysine deficient protein kinase) 16758634 signal transduction, ion homeostasis MGGSTPISAASATSLGHFTK 2043-2062
PDZ-GEF 34857578 guaninine nucleotide exchange factor for RAP1/2 ISSRSSIVSNSSFDSVPVSLHDE 1211-1233
PDZ-GEF 34857578 guaninine nucleotide exchange factor for RAP1/2 SSFDSVPVSLHDER 1221-1234
PDZ-GEF 34857578 guaninine nucleotide exchange factor for RAP1/3 SVPVSLHDE  1225-1233
synaptopodin 11067429 dendritic spine formation VSGHAAVTTPTKVYSE 203-218
bassoon 9506427 synaptic vesicle cycling VTQHFAK*** 1338-1444
Uncharacterized Proteins
hypothetical protein FLJ31657 34855501 unknown IGGDLTAAVTK 196-206
1300019H17Rik protein 34880180 unknown EAALPSTK 286-293
KIAA1007 protein 34851212 unknown TVTVTKPTGVSFK 1051-1063
DACA-1 homolog 34861007 unknown IGDVTTSAVK 271-280
*The site of modification was localized to Ser372 or Ser373 using a combination of chemoenzymatic tagging and β-elimination. ** We identified two distinct sites of O -GlcNAc 
 glycosylation on this peptide.  ***Confirmed by peptide synthesis and MS sequencing analysis (see Supporting Information).  ‡Mouse proteins identified in the NCBI database. 
  Corresponding rat orthologs were identified in the Celera database.
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residues as well as carboxyamido-modified cysteine residues undergo β-elimination to
form dehydroalanine/β-methyldehydroalanine under strong alkaline conditions.17,26
Subsequent Michael addition of a thiol nucleophile generates a stable sulfide adduct.  We
first labeled S100 cytoplasmic lysates with our ketone-biotin tag and enriched the O-
GlcNAc glycopeptides using avidin chromatography as described.  One of the enriched
fractions was then selected for β-elimination, followed by butanethiol addition (Figure
4.3).  Tandem MS analysis of the resultant peptides permitted localization of the
glycosylation site on HIV-1 Rev binding protein from seven possible residues on the
peptide 360APVGSVVSVPSHSSASSDK378 to Ser372 or Ser373.  Notably, tandem MS
analysis prior to β-elimination conclusively demonstrated that the original peptide was O-
GlcNAc glycosylated, rather than phosphorylated or modified with a complex
carbohydrate.  With further refinement of the β-elimination methodology toward
complex mixtures, we anticipate that the combined ketone labeling and β-elimination
approaches will be a powerful tool for identifying specific O-GlcNAc modification sites.
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Figure 4.3.  Combining the chemoenzymatic and β-elimination approaches to map specific
glycosylation sites.  (A) Strategy for the formation of a stable sulfide adduct from tagged O-
GlcNAc peptides.  (B) MS/MS analysis of the sulfide adduct of peptide
360APVGSVVSVPSHSSASSDK378 from HIV-1 Rev binding protein.  Several y and b fragment
ions containing the sulfide moiety (indicated with the subscript S) were observed, permitting
peptide sequencing and identification of Ser372 or Ser373 as the glycosylation site.  (C) MS/MS
spectrum of the corresponding peptide prior to β-elimination shows the characteristic ketone-
biotin signature, indicating that the original peptide was O-GlcNAc glycosylated.  MS4 analysis of
the peptide confirmed its amino acid sequence.  (D) Summary of the prominent b and y-ions from
MS/MS analysis of the β-eliminated peptide.  Fragment ions y7, y10, and b15 localized the site of
modification to one of two serines within the peptide.  An additional ion, consistent with b13,
strongly suggested Ser372 as the specific site of glycosylation.
Having demonstrated the effectiveness of the chemoenzymatic strategy for protein
mixtures from the brain, we sought to identify O-GlcNAc proteins at the synaptosome, a
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region critical for neuronal communication, which is enriched in the enzymes of O-
GlcNAc cycling.11   Rat brain synaptosomal lysate was prepared, labeled and trypsin
digested as described in the experimental methods.  Overall, we identified 34 peptides
from 15 unique proteins, including several that we had identified via the initial screen
above (Table 4.2).  As expected, proteins involved in vesicle cycling and
neurotransmitter release, such as the scaffolding protein bassoon were enriched in the
synaptosome, allowing us to identify a host of O-GlcNAc glycosylated peptides within it
and the related scaffolding protein piccolo.  Previous studies O-GlcNAc antibody
precipitation had suggested that Piccolo was a putative O-GlcNAc-modified protein;17
here we found at least seven unique sites of modification.  Consistent with the presence
of OGT at synaptic vesicles,12 many of the identified proteins are  involved in synaptic or
intracellular vesicle recycling.  Moreover, we identified O-GlcNAc on the protein
ankyrin-B, a closely-related protein to ankyrin-G, which localizes to nodes of ranvier of
myelinated axons and was previously shown to be O-GlcNAc modified.27
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NCBI 
Protein Entry Function Peptide Sequence Residues
NAD+ ADP-ribosyltransferase 3* 4808552
DNA binding enzyme/cell 
cycle control in mitotic 
cells
APVRTVTK 171-179
Hrb (HIV-1 Rev binding protein) 34859394 RNA trafficking APVGSVVSVPSHSSASSDK 360-378
GRASP55 (Golgi reassembly 
stacking protein 2) 20301956
membrane protein 
transport, Golgi cisternae 
stacking
VPTTVEDR 423-430
ankyrin b, brain isoform 2 77681962 intracellular vesicle cycling/protein sorting VGLQAQPMHSELVK 323-336
cappuccino* 45767878 vesicle tethering in organelle biogenesis RAAAGYAACLLPGAGAR 63-79
erythrocyte protein band 4.1-like 1, 
isoform L 11067407 cytoskeletal protein DVLTSTYGATAETLSTSTTTHVTK 1460-1483
AAK1 (AP2 associated kinase 1 
isoform 1) 91992157
regulates clathrin-
mediated endocytosis LTDPIPTTETSIAPR 353-367
ProSAP1/Shank 2 (proline-rich 
synaptic-associated protein 1) 32491882
pdz-domain 
scaffolding/adaptor 
protein
SPEVMSTVSGTR 1651-1662
Neuron Navigator 1 109498680
microtubule-
associated/neurite 
outgrowth
TPPVAVTSPITHTAQSALK 537-555
SCAMP1 (secretory carrier-
associated membrane protein) 3914958
cell surface vesicle 
recycling MPNVPNTQPAIMKPTEEHPAYTQITK 53-78
ankyrin repeat domain 40 109488798
contains ankyrin protein-
protein interaction 
domain
TPESTKPGPVCQPPVSQNR 295-313
AP180 (assembly protein 180) 55725
clathrin-mediated 
synaptic vesicle 
endocytosis
SSPATTVTSPNSTPAK 305-320
NF-kB essential modulator 37576796 regulatory subunit of IkappaB complex MQNQSVEAALR 204-214
bassoon 9506427 synaptic vesicle cycling STAPAASHPAGKPQPGPTTAPGPQPAGLPR 3823-3852
bassoon 9506427 synaptic vesicle cycling HEASASSSAAAAAAR 2639-2653
bassoon 9506427 synaptic vesicle cycling LYSSMSDTNLAEAGLNYHAQR 1973-1993
bassoon 9506427 synaptic vesicle cycling HSYSLGFADGR 2014-2024
bassoon 9506427 synaptic vesicle cycling ASGAGGPPRPELPAGGAR 2283-2300
bassoon 9506427 synaptic vesicle cycling SSVSQSPAPTYPSDSHYTSLEQNVPR 3198-3223
bassoon 9506427 synaptic vesicle cycling HPTDLLSHPLPMR 2040-2052
bassoon 9506427 synaptic vesicle cycling GLAGPTTVPATK 2920-2931
bassoon 9506427 synaptic vesicle cycling QLLPSTATVR 2172-2181
bassoon 9506427 synaptic vesicle cycling VTQHFAK 1338-1344
bassoon 9506427 synaptic vesicle cycling FPFGSSCTGTFHPAPSAPDK 1900-1919
bassoon 9506427 synaptic vesicle cycling VSPAIHITAATDPK 2678-2691
bassoon 9506427 synaptic vesicle cycling LLDTSFASSER 2800-2810
bassoon 9506427 synaptic vesicle cycling ISSVPGTSR 1636-1644
piccolo 7493836 neurotransmitter release NQPLMIAPVSTDNTYAVSHLGSK 3929-3951
piccolo 7493836 neurotransmitter release PAVPQIPVTTQKPTDTCPK 2463-2481
piccolo 7493836 neurotransmitter release TVVTMDESTSNVVTK 2852-2866
piccolo 7493836 neurotransmitter release VSTGEVMDYSSK 2975-2986
piccolo 7493836 neurotransmitter release QVISGVGISTPQYSTAR 2996-3012
piccolo 7493836 neurotransmitter release SCTAQQPATTLPEDR 2897-2911
piccolo 7493836 neurotransmitter release ITSNYEVIR 3920-3928
*Human protein; residues marked in red are potential glycosylation sites as narrowed down by beta-elimination
Table 4.2. O-GlcNAc proteins identified from the synaptosome
4.3. Discussion
Here we have described the first direct, high-throughput analysis of O-GlcNAc
glycosylated proteins from the mammalian brain.  The proteins were identified using a
chemoenzymatic approach that exploits an engineered galactosyltransferase enzyme to
108
selectively label O-GlcNAc proteins with a ketone-biotin tag.  The tag provides both a
straightforward means to enrich low-abundance O-GlcNAc peptides from complex
mixtures and a unique signature upon tandem MS for unambiguous identification of the
O-GlcNAc glycosylated species.  In contrast to reported antibody and metabolic labeling
methods,17,18 the strategy provides direct evidence of O -GlcNAc glycosylation and
permits mapping of modification sites to short amino acid sequences.  The ability to
localize O-GlcNAc is essential for surveying its distribution across the proteome as well
as understanding its functional significance on a given protein or family of proteins.
An exciting feature of our approach is its potential to explore the interplay among
PTMs.3,28,29  In this study, we identified two peptides that contained more than one PTM.
For instance, the N-terminal domain of HCF showed two O-GlcNAc moieties within the
same peptide, and a second peptide exhibited evidence of both phosphorylation and
glycosylation.  Notably, all O-GlcNAc proteins known to date are phosphoproteins, and
evidence suggests that glycosylation functionally antagonizes phosphorylation in many
cases.30,31  The approach reported herein involves a non-destructive technique that does
not require the removal  of other PTMs in order to study O-GlcNAc.  As such, this
strategy should permit a direct examination of whether specific glycosylation and
phosphorylation events are mutually exclusive in vivo, as suggested for the C-terminal
domain of RNA polymerase II,30,32 or whether the two modifications coexist, as recently
reported for the transcription factor signal transducer and activator of transcription 5
(Stat5).33  Thus, this strategy is complementary to top-down MS approaches that can be
used to simultaneously interrogate multiple PTMs from intact proteins.34
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The chemoenzymatic approach can also be combined with existing β-elimination
strategies, providing a powerful tool to identify precise sites of glycosylation. Notably,
emerging MS techniques such as electron transfer dissociation (ETD), which has been
successfully used to map phosphopeptide sites, could also be combined with our
methodology to directly map glycosylation sites and abrogate the need for β-
elimination.35 Notably, following publication of our work, Vosseller and colleagues
reported the discovery of O-GlcNAc post-synaptic density (PSD) proteins via WGA
lectin chromatography.36  The authors identified 18 O-GlcNAc-modified proteins in their
extract preparation.  Interestingly, many of the modified peptides detected in the study
overlap directly with those we identified in the synaptosomal study described in this
chapter, as well those we describe in a quantitative study in Chapter 5.  While the lectin
study was effective, the weak affinity of WGA for O-GlcNAc necessitated the generation
of a 40 ft affinity column to separate O-GlcNAc and unmodified peptides.  Such a
method is probably not feasible for most laboratories and is not obviously amenable to
the detection of intact O-GlcNAc proteins.
In this work, we demonstrated the power of the chemoenzymatic approach by
identifying 25 O-GlcNAc glycosylated proteins from the mammalian brain, as well as
another 11 proteins from synaptosomal preparations.  Over the last 20 years, the O-
GlcNAc modification has been established on approximately 100 proteins.37  Thus, our
results represent a significant expansion in the number of known O-GlcNAc proteins, and
they provide new insights into the breadth of the modification and its potential functions
in the brain.
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Consistent with previous studies demonstrating an important role for O-GlcNAc
in transcriptional regulation, we identified two novel transcription factors, sex
determining factor Y box (SOX2) and activating transcription factor-2 (ATF-2).  SOX2 is
a member of the high mobility group (HMG) box superfamily of minor groove DNA-
binding proteins,38  which are implicated in guiding cell fate during diverse
developmental processes.  Although primarily known for its role in embryogenesis,
SOX2 has also been detected in the adult central nervous system.39  ATF-2 is a DNA-
binding transcription factor that is ubiquitous but enriched in the brain.40  It also appears
to possess an intrinsic histone acetyltransferase (HAT) activity that is required for
activating transcription.41  As O-GlcNAc has been implicated in nutrient sensing and the
development of insulin-resistant diabetes,4,5 it is interesting that ATF-2 appears to play
multiple roles in glucose homeostasis.  For instance, ATF-2 has been shown to up-
regulate transcription from the insulin promoter in human pancreatic β-cells in a
Ca2+/calmodulin-dependent protein kinase IV (CaMKIV)-dependent manner.42  In
addition, recent studies indicate that ATF-2 activates the gluconeogenic gene
phosphoenolpyruvate carboxykinase (PEPCK) in HepG2 hepatic cells upon retinoic acid
induction.43
While transcription factors and RNA polymerase II have been shown to be
glycosylated, other important elements of the transcriptional machinery have not been
well documented.  In this study, we demonstrated O-GlcNAc on novel transcriptional
proteins, including coactivators and corepressors.  This finding suggests broader roles for
O-GlcNAc in regulating transcription than previously recognized.  For instance, we
found the modification on two proteins (including a ubiquitin ligase) in the carbon
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catabolite repression 4-negative on TATA-less (CCR4-NOT), a large protein complex
involved in mRNA metabolism and the global control of gene expression.44  In addition,
O-GlcNAc was identified on the steroid receptor coactivator-1 (SRC-1), a chromatin
remodeling protein that functions as a transcriptional coactivator for estrogen, thyroid,
and other nuclear receptors.45  Finally, O-GlcNAc was found on HCF, a chromatin-
associated factor that interacts with both OGT and the Sin3A histone deacetylase
(HDAC) complex in vivo.24  Mammalian Sin3A interacts with OGT and thereby
synergistically represses transcription from both basal and Sp-1 driven promoters.46  We
identified four distinct sites of glycosylation within the N-terminal domain of HCF, a
region required for interaction with both OGT and Sin3A.24  It will be interesting to
examine the functional impact of HCF glycosylation on its binding to Sin3A and OGT,
and on gene silencing.
Importantly, our results demonstrate that a number of proteins involved in
neuronal signaling and synaptic function are the targets of O-GlcNAc glycosylation.  For
instance, we identified the modification on PDZ-GEF, a guanine nucleotide exchange
factor that activates the Ras-related GTPases Rap1 and Rap2.47  PDZ-GEF contains a
PDZ domain, a protein-interacting module often involved in the assembly of signal
transduction complexes at the synapse.48  Another O-GlcNAc protein is WNK-1 (With
No Lysine K), a serine/threonine protein kinase whose activation has been linked to ion
transport and hypertension.49  Moreover, we identified two brain-enriched proteins
important for synaptic function, synaptopodin and bassoon.  The actin-associated protein
synaptopodin is essential for dendritic spine formation, with synaptopodin-deficient mice
exhibiting a lack of spine apparatuses as well as impaired long-term potentiation and
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spatial learning.50  Bassoon, a scaffolding protein of the cytomatrix assembled at the
active zone (CAZ) plays a critical role in synaptic vesicle cycling.51
Given the enrichment of the O-GlcNAc cycling enzymes to neuronal
synaptosomes, and to synaptic vesicles, we sought to identify synaptosomal-specific
proteins that might be O-GlcNAc modified.  Indeed, we found 15 such proteins and 34
O-GlcNAc peptides.  Here, we recapitulated a result from whole brain lysate, by
identifying the  1338VTQHFAK1344  peptide from bassoon as O-GlcNAc modified.  In
addition, we identified another 13 regions of O-GlcNAc modification within bassoon.
Along with bassoon, we also found O-GlcNAc modification on the protein piccolo,
which likewise localizes to the CAZ and appears to serve both a scaffolding and Ca(2+)-
sensing role important in synaptic plasticity.52   Given the extensive glycosylation of
these two proteins, what might be the significance of glycosylation for proteins involved
in vesicle cycling and release?
Interestingly, piccolo is also found in pancreatic β-cells, where it appears to
mediate cAMP-dependent exocytosis and insulin secretion.53  The O-GlcNAc transferase
is most abundant in pancreas and brain, and as discussed in Chapter 1, evidence suggests
that it may function as a glucose sensor.54  OGT is uniquely poised to respond to shifts in
extracellular glucose as its substrate, UDP-GlcNAc, is the major product of the
hexosamine biosynthesis pathway, and varying the UDP-GlcNAc concentration changes
OGT’s Km and peptide substrate preference.
5  As with synaptic vesicles in the brain,
OGT is found to localize with secretory granules of endocrine islet cells in the pancreas.55
Thus, one possibility is that O-GlcNAc may function to regulate vesicle trafficking in
both tissues in a glucose-dependent manner.  In the brain, this may serve to  modulate
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neurotransmitter release or protein trafficking in a manner that corresponds to changes in
cellular glucose uptake.  Studies suggest that vesicle cycling and neurotransmitter release
are altered in response to extracellular glucose concentration, well before detectable
changes in ATP levels.56  O -GlcNAc cycling is an attractive potential mediator of this
process.  In addition, it may function in a protective manner to prevent excitotoxic injury
by inhibiting excess neurotransmitter release.  Indeed, O-GlcNAc has been shown to
mediate survival in response to various cell stresses in cultured cells.57
Our studies support a robust role for O-GlcNAc in vesicle recycling, as many of
the other identified proteins are likewise involved in this process, such as SCAMP 37,
which has been implicated in vesicle budding during clathrin-mediated endocytosis,58 and
AAK1, a serine/threonine kinase whose phosphorylation of the adaptor protein AP2
negatively regulates endocytosis in vitro.59  In addition, we also find O-GlcNAc on
proteins associated with the post-synaptic density, such as Shank2, a scaffolding protein
important in mediating glutamate receptor function.60,61  Taken together, these findings
strongly suggest that O-GlcNAc glycosylation likely plays critical roles in neuronal
communication and synaptic function.
4.3 Conclusion
In summary, we demonstrate a chemoenzymatic strategy for the high-throughput
identification of O-GlcNAc glycosylated proteins from the mammalian brain.  The
approach permits the enrichment and direct identification of O-GlcNAc glycosylated
peptides from complex mixtures and can be combined with existing technologies to map
specific glycosylation sites.  The generality of the method should enable explorations of
the O-GlcNAc proteome in any cell type or tissue.  Moreover, studies of the dynamic
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interplay among PTMs and future extension of the methodology to quantitative
proteomics should be possible. Using the approach, we discovered 23 new O-GlcNAc
glycosylated proteins from the brain, as well as ten synaptosomal-specific proteins,
including regulatory proteins associated with gene expression, neuronal signaling, and
synaptic plasticity.  The functional diversity represented by this set of proteins suggests
an expanded role for O-GlcNAc in regulating neuronal function.  Moreover, the
identification of O-GlcNAc on proteins specifically involved in vesicle cycling suggests a
unique role for O-GlcNAc in regulating cellular trafficking and neurotransmitter release.
We anticipate that further investigations of the proteins identified in this study, coupled
with the continued development of chemical tools, will provide new insights into the
physiological importance of this posttranslational modification.
4.4 Experimental Methods and Supporting Figures
Preparation of Rat Forebrain Extracts
The forebrains of Sprague Dawley rats (Charles River Laboratories) were dissected on
ice, lysed into 10 volumes of homogenization buffer, and fractionated into nuclear and
S100 cytoplasmic components as described by Dignam et al.,62 except that protease
inhibitors, phosphatase inhibitors, and a hexosaminidase inhibitor (50 mM GlcNAc)63
were added to the buffers.  Prior to labeling, the extracts were dialyzed into 20 mM
HEPES pH 7.3, 0.1 M KCl, 0.2 mM EDTA, 0.2% Triton X-100, 10% glycerol.
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Preparation of Synaptosomal Rat Forebrain Extracts
The forebrains of 8-10 week-old Sprague Dawley rats (Charles River Laboratories) were
dissected on ice and sliced by razor into 3 pieces per hemisphere.  Forebrains were
fractionated as described by Kiebler  et al.,64 with some modification.  Importantly, all
steps were conducted at 4 ºC unless otherwise stated.  Briefly, two forebrains at a time
were lysed into 7 ml of ice-cold homogenization buffer (0.32 M sucrose, 10 mM TRIS-
HCl pH 7.4, containing protease inhibitors) via manual homogenization (5 strokes) with a
glass dounce homogenizer. Homogenized  extract was combined with extract from
another two forebrains, diluted to 30 ml with homogenization buffer, and mechanically
homogenized (700 rpm) for eight strokes.  Homogenate was spun at 1000 × g  for 10 min
(SS34 rotor) to pellet nuclei.  Supernatant was recovered and spun at 14,000 × g for 20
min (SS34 rotor) to pellet the P2 fraction.  The P2 pellet was washed by resuspension in
fresh homogenization buffer and spun again at 14,000 ×  g for 20 min (SS34).
Supernatant was decanted and the P2 pellet was resuspended in 4 ml of homogenization
buffer and diluted two-fold with 50% optiprep solution.  (50% optiprep solution was
prepared by mixing 5 volumes of Optiprep (Accurate Chemicals, Westbury NY) with 1
volume of diluent, 0.32 M sucrose, 60 mM Tris-HCl pH 7.4).   An optiprep gradient  was
layered into tubes for use in the HB-6 rotor as follows: 9mL of  15% optiprep (a mixture
of 3 volumes of 50% optiprep and 7 volumes of homogenization buffer) was loaded on
the bottom via serological pipet.  Then, 9 ml of 12.5% optiprep (a mixture of 2.5 volumes
of 50% optiprep and 7.5 volumes of homogenization buffer) was gently layered above the
15% layer, via 18-gauge needle and syringe, while slightly tipping the rotor tube.
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Finally, 9 ml of 9% optiprep (a mixture of 1.8 volumes of 50% optiprep and 8.2 volumes
of homogenization buffer) was layered above the 12.5% layer as described above.  The
resuspended P2 pellet was gently loaded, (via syringe and 18 gauge 6-inch blunt end
stainless steel needle (Popper, New Hyde Park NY)), from the bottom of the prepared
gradient.  The sample was centrifuged at 18,000 × g for 20 min (HB-6 rotor).
Synaptoneurosomes were collected as the first white voluminous band (below the top
yellow band of myelin), resuspended in 5/2 volume of preincubation buffer  (10 mM
HEPES pH 7.4, 10 mM Glucose, 4.8 mM KCl, 1.2 mM Na2HPO4, 2.4 mM MgSO4, 132
mM NaCl,  1.2 mM EGTA) and spun at 2000 × g, 15 min (SS34 rotor).  Supernatant was
discarded and synaptosomes were lysed directly in boiling 1% SDS with  Complete
Protease Inhibitors (Roche, Indianapolis, IN).
Chemoenzymatic Labeling of Rat Forebrain Extracts
Extract (1-10 mg; 1-3 mg/mL) was incubated with 5 mM MnCl2, 1.25 mM ADP, 0.5 mM
unnatural UDP substrate, and Y289L GalT (25 ng/µL) for 12-14 h at 4 °C.  Following
enzymatic labeling, extracts were dialyzed into denaturing buffer (5 M urea, 50 mM
NH4HCO3 pH 7.8, 100 mM NaCl; 3 × 2 h). The pH was adjusted with 2.7 M NaOAc pH
3.9 (final concentration 50 mM, pH 4.8).  Aminooxy biotin (2.75 mM) was added, and
the reactions were incubated for 20-24 h at RT.  Extracts were diluted with 3 M
NH4HCO3 pH 9.6 (50 mM final concentration, pH 8) and dialyzed (1× 2 h, 1 × 10 h) into
6 M urea, 50 mM NH4HCO3 pH 7.8, 100 mM NaCl, followed by either denaturing (4 M
urea, 50 mM NH4HCO3 pH 7.8, 10 mM NaCl) or non-denaturing buffer (50 mM
NH4HCO3 pH 7.8, 10 mM NaCl).
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Chemoenzymatic Labeling of Synaptosomal Extracts
Extracts (10-15 mg/mL) were diluted 5-fold with 100mM HEPES pH 7.9, 25mM
adenosine 5’-diphosphate, 20% Triton X-100, 100mM MnCl2 into labeling buffer (10mM
HEPES pH 7.9, 1.25mM adenosine 5’-diphosphate, 1.8% Triton X-100, 5mM MnCl2
containing Complete Protease Inhibitors, and 0.75 mM phenylmethylsulfonyl fluoride).
Diluted extract was then supplemented with 0.5 mM analogue 1, 40 µg/mL Y289L GalT.
The reaction mixture was incubated at 4 o C for 12 h, and dialyzed into buffer A (10 mM
HEPES pH 7.9, 5 M urea) 3 × 3 h at 4 o C. The sample was then acidified to pH 4.8 by
adding 2.7 M NaOAc pH 3.9 to a final concentration of 50mM. Aminooxy biotin
derivative (30 mM) was added to a final concentration of 2.75 mM.  After incubation at
room temperature for 20-24 h, the sample was neutralized by adding 0.5 M HEPES pH
7.9 to a final concentration of 33 mM, followed by dialysis into buffer B (10 mM HEPES
pH 7.9, 7 M urea, 100mM NaCl) 1× 12 h and 2 × 3 h at RT, and into buffer C (50mM
NH4HCO3 pH 8, 2M urea)  3 × 4 h at 4 ºC.
Proteolytic Digestion and Cation Exchange/Avidin Affinity Chromatography
Non-denatured extracts from the previous step were concentrated and denatured/reduced
as described in the ICAT protocol from Applied Biosystems.  Proteins were then
alkylated with 15 mM iodoacetamide for 45 min in the dark, diluted to 0.04% SDS with
50 mM NH4HCO3 pH 7.8, and digested with trypsin or GluC (20-30 ng/µL) for 12-14 h
at 37 °C.  Urea-denatured extracts were diluted with 50mM NH4HCO3 pH 8 to a final
concentration of less than 1 M urea following the reduction (10 min) and alkylation steps,
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and subjected to protease digestion as described above.  Synaptosomal extracts were
reduced in 10mM DTT (from a stock of 500 mM in 50mM NH4HCO3 pH 8) for 1h at
RT, alkylated in 20mM iodoacetamide (from a stock of 500 mM in 50mM NH4HCO3 pH
8) for 1 hr at RT, and  incubated with 20mM DTT for 1 h at RT to  react with excess
iodoacetamide.  The extract solution was then centrifuged at 15,000 rpm for 5 min to
remove any insoluble material.  Protein concentration was measured via Biorad assay,
and then extracts were diluted to a final urea concentration of 1M. Sequencing-Grade
Trypsin (Promega) was added to a final concentration of 0.015µg/µL for proteolytic
digestion at 37 ºC.   In all cases, proteolytic enzymes were added at a ratio of 1:20-1:30 to
protein extracts.
Proteolytic digests conducted in the presence of urea were desalted with peptide
macrotrap cartridges (Michrom Bioresources).  Digests conducted without urea were
acidified with 1% aqueous TFA and diluted into cation exchange load buffer (Applied
Biosystems).  In some cases, synaptosomal samples were dimethyl labeled for
quantitative proteomics as described in Chapter 5. Cation exchange chromatography was
performed on 0.5-3 mg of lysate as described by the manufacturer Applied Biosystems,
except that peptides were eluted with a step gradient of 100 mM, 250 mM, and 350 mM
KCl in 5 mM KH2PO4 containing 25% CH3CN.  Fractionated peptides were enriched via
avidin chromatography (Applied Biosystems) as described by the manufacturer except
that the washes were tripled in volume.
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β-Elimination of Avidin-Purified Peptides
Following avidin chromatography, a portion of the S100 lysate fraction (40 mM KCl
elution) was subjected to β-elimination exactly as described by wells et al.,17 using 25
mM butanethiol, and reactions were stopped with AcOH.
LC-MS Analysis of Avidin-Enriched Biotinylated Peptides
Automated nanoscale reversed-phase HPLC/ESI/MS was performed using an HPLC
pump, autosampler (Agilent Technologies), and linear ion trap mass spectrometer
(ThermoElectron) with a variation of the “vented column” approach described by
Licklider et al.65  For data-dependent experiments, the mass spectrometer was
programmed to record a full-scan ESI mass spectrum (m/z 500-2000) followed by five
data-dependent MS/MS scans (relative collision energy = 35%; 3.5 Da isolation
window).  Precursor ion masses for candidate glycosylated peptides were identified by a
computer algorithm (Charge Loss Scanner; developed in-house with Visual Basic 6.0)
that inspected product ion spectra for peaks corresponding to losses of the ketone-biotin
and ketone-biotin-GlcNAc moieties. Up to eight candidate peptides at a time were
analyzed in subsequent targeted MS4 experiments to derive sequence information.
Approximately 20% of the avidin-enriched peptides from each cation exchange
fraction were loaded onto a 360 µm O.D. X 75 µm i.d. precolumn packed with 4 cm of 5
µm Monitor C18 particles (Column Engineering) at a flow rate of 4 µL/min.  After
desalting, the vent was closed and peptides eluted to a 360 µm O.D. X 75 µm i.d.
analytical column with integrated emitter tip (10 cm of 5 µm C18, ca. 5 µm tip, see
Martin et al. for more details.66  The chromatographic profile was from 100% solvent A
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(0.1% aqueous AcOH) to 50% solvent B (0.1% AcOH in CH3CN) in 30 min.  The flow
rate through the analytical column was approximately 100 nL/min.  The mass
spectrometer was programmed to record a full-scan ESI mass spectrum (m/z 500-2000),
followed by MS4 scans of each peptide (relative collision energy = 35%; 3.5 Da isolation
window for each fragmentation).  In the first stage of tandem MS, precursor ions were
isolated and fragmented to yield O-GlcNAc modified peptide ions.  In the second stage,
these ions were isolated and fragmented to yield ions corresponding to the unmodified
peptide.  In the third stage, unmodified peptide ions were isolated and fragmented, and
the fragment ions were detected in the final stage. For all MS experiments, the
electrospray voltage was set at 1.6 kV and the heated capillary was maintained at 250 °C.
For database analysis to identify O-GlcNAc proteins, Bioworks Browser 3.1SR1
(Thermoelectron)software was used to create files from MS4 data. These files were then
directly queried, using the SEQUEST algorithm,67 against amino acid sequences in the
NCBI rat/mouse protein database.
In the course of manual analysis, it was discovered that SEQUEST assignment of
an MS4 targeted peptide at precursor ion mass m/z 899.6 incorrectly identified the peptide
as AALTQQHPPVTNGDTVK from the protein ATF-2.  Manual analysis demonstrated
that peptide was AALTQQHPPVTDGDTVK, which failed to generate sequence identity
to any peptide in either the NCBI or Celera non-redundant databases.  Therefore, we
concluded that the peptide represents the chemically deamidated product of ATF-2.
Notably, chemical deamidation is substantiated by recent data for deamidation rates of
specific amino acid sequences.68  We confirmed the identity of the singly charged peptide
VTQHFAK of bassoon by chemically synthesizing the corresponding peptide and
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comparing its MS/MS  spectrum to the MS4 spectrum of the tagged peptide isolated from
the brain.  The spectra were nearly identical, verifying the assignment.
Annotated MS4 spectra for nuclear and cytoplasmic S100 fractions are presented
in the supporting information of Khidekel et al., 2004.1
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Chapter 5
Probing the Dynamics of O-GlcNAc Glycosylation Using the
Chemoenzymatic Strategy and Quantitative Proteomics
5.1 Background and Introduction
The addition of post-translational modifications (PTMs) to proteins represents a
fundamental mechanism by which protein function is elaborated.1,2 In the brain, finely-
tuned regulation of PTMs such as phosphorylation govern mechanisms of neuronal
plasticity, the proposed basis for learning and memory.3,4 Roles are also emerging for
other PTMs, such as polyubiquitination, which modulates protein degradation in response
to neuronal activity.5 Even more remarkably, recent studies highlight the dynamic
equilibrium of PTMs whose switch-like behavior alters protein function and has dramatic
consequences for cells.6 For example, the dynamic shuttling of sumoylation and
acetylation on the transcription factor MEF2A appears to regulate its transactivation
potential and, ultimately, neuronal morphology.7
Our work has focused on O-GlcNAc glycosylation, the covalent attachment of β-
N-acetylglucosamine to serine or threonine residues of proteins.8 O-GlcNAc is
intracellular and dynamic, sharing more in common with phosphorylation than with ER
or Golgi-mediated glycosylation.  The modification is mediated by a unique nucleo-
cytoplasmic O-GlcNAc transferase (OGT) necessary for life at the single cell level.9 A
diverse group of over 100 proteins has been has been identified as O-GlcNAc-modified,
including transcription factors, proto-oncogenes, cytoskeletal-associated proteins, and
protein kinases.10,11 Recent studies highlight a role for O-GlcNAc in many cellular
processes, such as nutrient sensing, cell division, the stress response and gene
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silencing.8,12 Moreover, perturbations in O-GlcNAc levels have been associated with
disease states such as cancer, Alzheimer’s, and diabetes.11,13
Evidence suggests that O-GlcNAc may play a particularly important role in the
brain.  OGT is most abundant in the brain and pancreas,14 and neuron-specific knockout
of the OGT gene induces early postnatal lethality.15 The activity of OGT appears to be
modulated by complex mechanisms, including differential splicing, interaction with
regulatory partners, and changes in UDP-GlcNAc concentration.14 In the brain, OGT
forms a stable complex with protein phosphatase-1 (β and γ),16 highlighting the potential
interrelationship between O-GlcNAc and phosphorylation, one of the best characterized
PTMs regulating neuronal function.  Finally, OGT and the corresponding β-N-
acetylglucosaminidase (O-GlcNAcase) are particularly abundant in the nerve terminal,17
or synaptosome, where they are enriched in the presynaptic cytosol and around synaptic
vesicles,18 suggesting neuron-specific functions for the modification.
Despite tantalizing evidence for its significance, the regulation of O-GlcNAc
glycosylation, particularly in the brain, is poorly understood.  Early studies suggested that
O-GlcNAc is a highly dynamic modification, with a turnover rate that exceeds that of the
protein backbone.19 Moreover, O-GlcNAc levels in lymphocyte cells were shown to
respond dynamically to mitogens.20 Recent evidence suggests that O-GlcNAc levels can
rapidly respond (within minutes) to ligand-binding on neutrophils.21 Finally, O-GlcNAc
levels showed marked upregulation in response to numerous cell stresses, and
perturbation of the O-GlcNAc enzymes decreased cell survival in response to stress.22   In
the brain, O-GlcNAc regulation has received only limited attention thus far.  In cultured
cerebellar neurons, O-GlcNAc levels of cytoskeletal-associated proteins were shown to
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respond reciprocally to PKA and PKC activators and inhibitors, highlighting the apparent
antagonism between the two modifications, in certain contexts.23 Most of the studies
assaying O-GlcNAc regulation took advantage of the traditional [3H]-labeling
methodology24 or antibodies with varying degrees of O-GlcNAc specificity25 to detect O-
GlcNAc. These approaches are generally insensitive,24 and not applicable to the direct
identification of specific proteins, and sites of modification on which O-GlcNAc
glycosylation might be dynamically regulated.26
Recently, several new, significantly advanced approaches for the identification of
O-GlcNAc glycosylated proteins have been described. O-GlcNAc proteins have been
chemically tagged by metabolic labeling27,28  or BEMAD (β-Elimination followed by
Michael Addition with Dithiothreitol)26 and O-GlcNAc peptides have been directly
identified via weak lectin affinity chromatography.29 However, no method currently
exists for unbiased, quantitative proteomics analyses of O-GlcNAc glycosylation.  While
metabolic labeling has been used to identify new O-GlcNAc proteins, it is not ideally
suited for the study of O-GlcNAc dynamics as it requires the use of high concentrations
of an unnatural GlcNAc analogue, which may perturb both physiological O-GlcNAc
levels and substrate targets of the OGT.30 Moreover, it may not useful for the study of O-
GlcNAc dynamics in tissue due to cellular and organismal uptake requirements. Although
the BEMAD approach can be used to map sites on purified proteins and protein
complexes, it is a destructive technique that requires extensive controls to establish
whether a peptide contains a phosphate, O-GlcNAc or complex O-linked carbohydrate
group.26 Finally, the latest lectin-based strategy effectively identified over 60 O-GlcNAc
glycosylated peptides from the brain, but required the use of a 40 ft affinity column to
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separate O-GlcNAc and unmodified peptides.29 Such a strategy may not be technically
feasible for many laboratories, and is not directly applicable to the detection and
identification of intact O-GlcNAc proteins.
In the previous chapters, we described the development of a new chemoenzymatic
strategy to rapidly and sensitively detect O-GlcNAc modified proteins.  We applied this
strategy to the discovery of single proteins from cell lysate as well as the identification of
O-GlcNAc-modification sites.  Finally, we combined the approach with high-throughput
mass spectrometry for the first explorations of the O-GlcNAc proteome of the brain.  We
simultaneously discovered 23 O-GlcNAc proteins, as well as another 12 specific to the
synaptosomal compartment, which is enriched in the enzymes of O-GlcNAc cycling, and
is critical for neuronal communication.
As our approach enables sensitive detection and specific isolation of O-GlcNAc
proteins and peptides from both cells and tissue, we felt that it would be an ideal platform
on which to study O-GlcNAc dynamics and regulation.  In this chapter, we first
demonstrate the effectiveness of the approach to identify changes in O-GlcNAc
glycosylation on single protein targets.  We find that O-GlcNAc levels on cyclic AMP
response element (CRE)-binding protein (CREB), a transcription factor implicated in
pancreatic cell survival and diabetes,31 can be modulated in cultured pancreatic cells.
Second, we combine the chemoenzymatic strategy with quantitative mass spectrometry
approaches for the first proteomic studies of O-GlcNAc dynamics, both from cultured
primary neurons and brain tissue.
Several elegant strategies have been described for quantitative mass-
spectrometry-based proteomics such as stable isotope labeling with amino acids in cell
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culture (SILAC),32 and isobaric tags for relative and absolute quantification (iTRAQ).33
Moreover, these approaches have been successfully coupled with phosphoprotein34 and
phosphopeptide35 enrichment to monitor changes in phosphorylation in response to
extracellular stimuli.  Nonetheless, these quantification strategies have some limitations.
SILAC requires multiple cell divisions for highest incorporation of amino acid isotopes
and therefore is not suited to post-mitotic cells, such as neurons, or tissue.  ITRAQ
requires the use of mass spectrometry instruments that can detect very low mass ions
(e.g., Q-TOF) that do not allow multiple stages of mass spectrometry and thus may not be
conducive to the sequencing of chemoenzymatically-tagged O-GlcNAc-modified
peptides.  Therefore, in order to study O-GlcNAc in the brain, we chose to combine the
chemoenzymatic approach with a modified dimethyl labeling strategy,36 which
incorporates stable isotopes onto peptide N-terminal amines and ε-amino groups of lysine
residues by reductive amination.  This approach is extremely rapid, proceeds
quantitatively, and in contrast to other strategies, is very inexpensive.
In order to facilitate the sequencing of quantified peptides, we also investigated
the utility of electron-transfer dissociation (ETD) for the mapping of O-GlcNAc
glycosylation sites.  ETD relies on a mode of fragmentation (e.g., the transfer of electrons
from an anion donor source and subsequent intermolecular rearrangement and cleavage)
that is independent of peptide sequence or the presence of PTMs.37 In contrast to
collision-associated dissociation (CAD), ETD has the capacity to preserve PTMs on the
peptide backbone for exact site identification.  In addition, unlike the similar strategy of
electron capture dissociation (ECD), ETD is conducted on a modified ion trap mass
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spectrometer, a comparatively inexpensive instrument that will be accessible to many
laboratories.
In this chapter, we demonstrate the quantitative proteomics strategy on neurons
treated with the O -GlcNAcase inhibitor O- (2-acetamidO -2-deoxy-D-
glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc), where we find site-specific
changes in O-GlcNAc glycosylation on several proteins.  Moreover, we show that O-
GlcNAc levels respond rapidly, in the cortex, to kainic-acid induced seizures.  We also
highlight the power of ETD to identify exact sites of O-GlcNAc modification, which
forgoes the need for destructive chemical approaches for site mapping.  Overall, the
strategy permits concomitant discovery of new O-GlcNAc proteins and detection of O-
GlcNAc glycosylation changes in response to stimuli.  These discoveries show that O-
GlcNAc is indeed reversible and dynamic in the brain and provide new molecular targets
for understanding O-GlcNAc regulatory pathways in neuronal tissue.
5.2  O-GlcNAc Dynamics on Individual Proteins
The transcription factor CREB is implicated in  a host of cellular processes, including
glucose homeostasis, cell survival, and synaptic plasticity.38  Multiple signal transduction
cascades converge on CREB, and N. Lamarre-Vincent, in our group, discovered that
CREB was O-GlcNAc-modified in a region necessary for interaction with the TFIID
complex of the basal transcriptional machinery.39  The interaction with TFIID is
effectively blocked by O-GlcNAc glycosylation in vitro.  Moreover, cell stimulation with
agents that increase levels of O-GlcNAc (such as the UDP-GlcNAc precursor
glucosamine and PUGNAc) repress endogenous CREB-mediated transcription in cells.
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In pancreatic cells, this repression is associated with decreases in transcription of pro-
survival factors and increased levels of cellular apoptosis.40
Global upregulation of O-GlcNAc levels can be monitored using the anti-O-
GlcNAc antibody CTD110.6.  However, traditional methods to identify O-GlcNAc
changes directly on CREB were ineffective. [3H]-labeling with β -1,4-
galactosyltransferase required hundreds or thousands of hours of exposure for detection,
while the O-GlcNAc antibodies, CTD110.6 and RL-2 could not detect endogenous
CREB.41
Previously, we had developed a chemoenzymatic strategy to efficiently
biotinylate and thereby detect endogenous O-GlcNAc-modified CREB from cell
lysates.42  Here, we sought to apply this approach to measure changes in CREB
glycosylation in response to cellular simulation.  In this approach (Figure 5.1),  O-
GlcNAc-modified proteins from two (or more) different cell populations are labeled, and
the protein of interest, in this case CREB, is immunoprecipitated from each cell state.
Streptavidin labeling of the immunoprecipitated protein detects the O-GlcNAc
modification, which can be compared across cell states, while Western blotting for the
protein controls for variation in immunoprecipitation between samples.
Figure 5.1. Strategy for detection of dynamic changes in O-GlcNAc glycosylation on individual
proteins where “B” represents the chemoenzymatically transferred biotin tag).
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We applied this strategy to pancreatic HIT-T15 cell lysate treated with glucosamine, a
precursor to UDP-GlcNAc, the substrate for OGT.  Glucosamine, which bypasses the
rate-limiting enzyme of hexosamine synthesis, generally increases global O-GlcNAc
levels.  HIT-T15 cells were treated with forskolin, an adenylate cyclase activator known
to activate cAMP pathways and increase CREB transactivation potential, and
glucosamine or control vehicle.  After treatment, control and experimental cells were
lysed and chemoenzymatically labeled. Western blotting with streptavidin-HRP of
immunoprecipitated CREB showed a statistically significant increase in O-GlcNAc
glycosylation on CREB in response to glucosamine treatment (Figure 5.2A).  This was
consistent with a glucosamine-induced decrease in CREB-mediated transcription as
measured by a CRE-promoter luciferase reporter assay in HIT-T15 cells (Figure 5.2B,
courtesy of N. Lamarre-Vincent).
Figure 5.2. The chemoenzymatic strategy allows direct detection of changes in O-GlcNAc
glycosylation on the transcription factor CREB. (A) CREB glycosylation increases 33% ± 12%
with glucosamine treatment, *P<0.006; n=4 (B) CREB-mediated transcription of a CRE-
luciferase reporter is repressed in response to glucosamine treatment, *P<0.0001; n=4.
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PUGNAc treatment of cells likewise resulted in an increase in CREB O-GlcNAc
modification, although a more modest one, and a concomitant decrease in CREB-
mediated transcription (Figure 5.3A, B courtesy of N. Lamarre-Vincent).
Figure 5.3. The chemoenzymatic strategy allows direct detection of changes in O-GlcNAc
glycosylation on the transcription factor CREB in response to PUGNAc. (A) CREB glycosylation
increases 21%± 5% with PUGNAc treatment,*P<0.0005; n=5 (B) CREB-mediated transcription
of a CRE-luciferase reporter is repressed in response to glucosamine treatment, * P< 0.03; n = 3.
Because the chemoenzymatic approach is also amenable to tissues, current efforts
in the laboratory are focused at understanding O-GlcNAc dynamics on CREB in vivo, in
animal models of diabetes.  Overall, the approach is readily amenable to other proteins
and should provide a sensitive way to monitor and understand O-GlcNAc regulation on
individual protein targets.
5.3  Quantitative Proteomics of O-GlcNAc Glycosylation in Neurons
Having demonstrated that the chemoenzymatic strategy could be used to quantify
changes in glycosylation on individual endogenous proteins, we applied the approach
toward the O-GlcNAc proteome of cultured primary neurons and the brain. In the
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approach, proteins are chemoenzymatically labeled and proteolytically digested.
Peptides from two different cell states are differentiated by the incorporation of stable
isotopes via reductive amination of lysine ε-amino groups and peptide N-terminal
amines.  The use of either formaldehyde and NaCNBH3 or deuterated formaldehyde and
NaCNBD3  creates mass differences of 6 or 12 Da, depending on the presence of a lysine
residue, which readily permits differentiation of peptides at even higher charge state.
Subsequent mass spectrometry analysis of avidin enriched, dimethylated O-GlcNAc
peptides allows for quantification of changes in glycosylation state (Figure 5.4).
Figure 5.4. Chemoenzymatic strategy for proteome-wide quantification of O-GlcNAc dynamics.
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In order to evaluate the effectiveness of the dimethyl labeling strategy, we first labeled a
single protein digest of α -casein and evaluated the extent of labeling by liquid-
chromatography mass spectrometry (LC-MS).  We found that reductive amination
proceeded quantitatively for both lysine and N-terminal primary amines in less than 10
min at pH 7.5 (data not shown).  Unlike other strategies, which incorporate stable
isotopes by acylation of N-terminal primary amines or ε-amino groups of lysines with
groups such as succinic anhydride,43 this approach does not change the overall charge of
the peptide, thus preserving high ionization efficiency.
Having established the best conditions for dimethyl labeling, we investigated our
ability to capture and quantify known O-GlcNAc peptides from complex mixtures.10,42
α-crystallin (ca. 300 pmol) and OGT (ca. 10 pmol) proteins  were mixed with two
separate samples of rat brain or primary neuronal culture lysate in ratios of 1:1 for each
protein. The samples were chemoenzymatically labeled and proteolytically digested with
trypsin.  After digestion, peptides were dimethyl labeled, mixed and fractionated by
strong-cation exchange to reduce sample complexity.  O-GlcNAc peptides were captured
by avidin affinity chromatography, and the sample was analyzed by (LC-MS) on the
hybrid LTQ/orbitrap mass spectrometer.  Accurate quantification of peptide ratios was
achieved in MS mode via the orbitrap mass analyzer, which takes advantage of new ion
trapping principles44 to generate mass accuracy upwards of 20 ppm.45  In order to identify
quantified ions, peptides that specifically showed the biotin-ketone and biotin-ketone-
GlcNAc loss during MS/MS analysis (described in Chapters 3 and 4) were targeted for
sequencing by MS4 analysis.
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Figure 5.5.  Application of the chemoenzymatic quantitative proteomics strategy toward
α-crystallin and O-GlcNAc transferase peptides isolated from a complex mixture. (A)
Chromatogram and corresponding orbitrap MS spectrum of avidin affinity captured αA-crystallin
O-GlcNAc glycosylated peptide 158AIPVSREEKPSSAPSS173 in light form (m/z 806.4159) and
heavy form (m/z 810.06134).  αA-crystallin protein was mixed with two samples of lysate in a
heavy:light ratio of 1:1 and the mixture was chemoenzymatically labeled.  The O-GlcNAc
glycosylated peptide was captured and observed at a ratio of 0.97 - 0.09, 0.97 + 0.10 (g.s.d. of
1.10), n = 7. (B) Chromatogram and corresponding orbitrap MS spectrum of the avidin affinity
captured OGT O-GlcNAc glycosylated peptide 390ISPTFADAYSNMGNTLK406 in light form
(m/z 1302.5691) and heavy form (m/z 1308.60461).  OGT protein was mixed and labeled as
above and this O-GlcNAc glycosylated peptide was observed at a ratio of 0.93 - 0.12, 0.93 + 0.14
(g.s.d. of 1.15), n = 7.
As shown in Figure 5.5, we were successfully able to isolate and quantify O-GlcNAc-
modified peptides 158AIPVSREEKPSSAPSS173 f r o m  α -crystallin and
390ISPTFADAYSNMGNTLK406 from OGT, from the complex lysate mixture (peptide
identity was confirmed by MS4 sequencing analysis).  The ratio of signal intensities from
the heavy to light peptide forms, across the entire chromatographic profile of each form,
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allowed direct, peptide-specific quantification. This α-crystallin peptide was observed at
a mean ratio of 0.97 - 0.09, 0.97 + 0.10 (geometric standard deviation, g.s.d. 1.10), while
the OGT peptide was observed at a mean ratio of 0.93 - 0.12, 0.93 + 0.14 (g.s.d. of 1.15).
Importantly, hydrogen-based isotopic tags are known to be subject to isotope
resolution effects during reverse-phase chromatography such that deuterium-labeled
peptides can elute in advance of non-deuterated counterparts, which can interfere with
quantification.46  In general, we found that deuterated and non-deuterated dimethylated
peptides (Figure 5.5) coeluted in the LC.  This is consistent with reports that deuterium
incorporated into a dimethyl label does not produce an isotope effect.36,46
In addition to the two peptides shown in Figure 5.5, we reproducibly captured and
quantified two more peptides from α-crystallin, encompassing the major known
glycosylation sites of both the A47 and B19 forms of α-crystallin.  Additionally, we also
captured another seven glycosylated peptides from OGT that encompassed all the known
glycosylated sites within that protein.42  Table 5.1 shows all the α-crystallin and OGT
peptides and their mean and standard deviations across all experiments in which they
were accurately quantified.  The mean ratio across all peptides was 0.91 - 0.17, 0.91 +
0.21 (g.s.d. of 1.23), which compares favorably with the reported mean ratios of peptides
from standard protein mixtures used in similar iTRAQ and SILAC quantification (mean
observed ratios of 1.03 ± 0.16 and 1.03 ± 0.17 for an expected 1:1 ratio, respectively).33
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Table 5.1.  Summary of O-GlcNAc glycosylated peptides from α-crystallin and O-GlcNAc
transferase (OGT) isolated and quantified via the chemoenzymatic quantitative proteomics
strategy
Having demonstrated the selective capture and accurate quantification of O-
GlcNAc glycosylated peptides, we applied our strategy to the quantification of O-
GlcNAc peptides from neuronal lysate.  Consistent with its ability to inhibit the O-
GlcNAcase enzyme, we found that PUGNAc strongly upregulated O-GlcNAc levels on
numerous proteins in primary cortical neurons, as determined by Western blotting with
an anti-O-GlcNAc antibody (Figure 5.6).
Protein Peptide Sequence n Ratio g.s.d.
crystallin 1 AIPVSREEKPSSAPSS 7 0.97 1.10
crystallin 2 AIPVSREEKPSSAPS 7 0.90 1.15
crystallin 3 EEKPVVTAAPK 4 0.81 1.13
OGT1 IKPVEVTESA 7 0.91 1.36
OGT 2 AIQINPAFADAHSNLASIHK 7 0.77 1.20
OGT 3 ISPTFADAYSNMGNTLK 7 0.93 1.15
OGT 4 EMQDVQGALQCYTR 5 0.98 1.11
OGT 5 AIQINPAFADAHSNLASIHKDSGNIPEAIASYR 4 1.01 1.29
OGT 6 AIQINPAFADAHSNLASIHKDSGNIPEAIAS 3 0.72 1.21
OGT 7 AATGEEVPRTIIVTTR 7 0.96 1.19
OGT 8 EAIRISPTFADAYSNMGNTLK 2 1.12 1.16
a b
a Geometric mean
b Geometric standard deviation
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Figure 5.6. PUGNAc treatment of cultured primary cortical neurons significantly
elevates O-GlcNAc glycosylation levels, as monitored by the anti-O-GlcNAc antibody
CTD110.6.
In order to identify the proteins undergoing dynamic regulation, neurons treated in
the presence or absence of PUGNAc were separated into nuclear and S100 cytoplasmic
fractions, chemoenzymatically labeled and digested with trypsin.  Digested proteins were
dimethyl labeled, fractionated by strong cation-exchange chromatography, and tagged O-
GlcNAc peptides were enriched via avidin chromatography.  In order to normalize for
procedural errors, we mixed α-crystallin and OGT into lysates at a ratio of 1:1, prior to
chemoenzymatic labeling.
Quantification by orbitrap MS was conducted in tandem with MS/MS analysis,
which was used to identify peaks bearing the distinctive biotin-ketone-GlcNAc loss
signature characteristic of O-GlcNAc peptides. Twenty-two peptides from the nuclear
sample and 11 peptides from the corresponding cytoplasmic sample showed an increase
in O-GlcNAc glycosylation upon PUGNAc stimulation.  Interestingly, we found that the
presence of PUGNAc did not result in increased O-GlcNAc glycosylation on all proteins
universally, suggesting that not all O-GlcNAc sites are subject to direct reversibility.  For
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example, in the same nuclear sample, 4 O-GlcNAc peptides showed no measurable
change in glycosylation, whereas in the cytoplasmic sample 16 peptides showed no
measurable change.  We also observed decreases in glycosylation on 5 nuclear and 4
cytoplasmic O-GlcNAc peptides.
Portions of dynamically regulated peaks from cytoplasmic and nuclear lysates
were targeted for sequencing by MS4 CAD analysis.  Figure 5.7A shows a representative
MS spectrum of an upregulated O-GlcNAc peptide. The CAD MS/MS spectrum of the
deuterated, triply charged peptide (m/z = 862.3889), indicates the characteristic loss of a
biotin-ketone moiety (m/z = 1208.43) and biotin-ketone-GlcNAc moiety (m/z = 1005.34)
(Figure 5.7B).  Higher-order MS analysis generated a series of internal cleavages, as well
as b and y ions along the amide backbone, that enabled definitive sequencing of the
peptide (Figure 5.7C).  Database searching identified the peptide as belonging to the
protein elongation initiation factor 4G (EIF4G) (Figure 5.7C).
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Figure 5.7. Sequencing of quantified O-GlcNAc peptides from neuronal lysates by CAD.  (A)
Orbitrap MS spectrum of a significantly upregulated peptide in response to PUGNAc treatment.
(B) CAD MS/MS spectrum of the deuterated peak (m/z = 862.3889), showing loss of a ketone-
biotin moiety (m/z=1208.43) and GlcNAc-ketone-biotin moiety (m/z = 1005.34). (C)
Fragmentation during MS4 analysis yielded numerous internal cleavages and several prominent b
and y ions, which permitted identification of the peptide as 158AQPPSSASSR173 from elongation
initiation factor 4G.
As an alternative to MS4 CAD sequencing, we explored the utility of ETD to
sequence chemoenzymatically tagged O-GlcNAc peptides and directly identify sites of
m/z
858 859 860 861 862 863 864 865
m/z
0
50
100 MS
d0
400 800 1200 1600
m/z
0
50
100 1208.43
1005.34
MS2 CAD
[M+2H]2+
[MGlcNAc+2H]2+c
300 400 500 600 700 800 900
0
50
100 MS4 CAD
y8
PPSS
PPSSA
PPSSAA
PPSSAAS
y4 y9
859.3644
859.8681
860.3705
862.3889
862.8907
863.3888
863.8995
863.8995
d6
A
y8-H20
[M+H]+ -H20
Re
la
tiv
e 
Ab
un
da
nc
e
Re
la
tiv
e 
Ab
un
da
nc
e
Re
la
tiv
e 
Ab
un
da
nc
e
B
C
b-ions
A Q P P S S AA S R 173158
y-ionsy8 y4y9
144
modification.  Figure 5.8A shows the  MS spectrum of different upregulated O-GlcNAc
modified peptide.  In this case, ETD sequencing provided nearly complete sequence
coverage in MS/MS mode, through the generation of c and z ions produced by cleavage
between the amide nitrogen and the peptide backbone α-carbon (Figure 5.8B).  Database
searching identified this peptide as belonging to the transcriptional repressor p66.
Importantly, ETD fragmentation preserved the linkage to the tagged O-GlcNAc, which
narrowed down the possible O-GlcNAc site to serines 584 and 586.
Figure 5.8. Sequencing of quantified O-GlcNAc peptides from neuronal lysate via ETD. (A) MS
spectrum of a second upregulated O-GlcNAc peptide from neuronal lysate. (B) ETD MS/MS
analysis of the deuterated peak at 607.3885 yielded c and z ions that permitted identification of
the peptide as 584SISQSISGQK593 from the transcriptional repressor p66.  The presence of the
tagged GlcNAc moiety on the c series of ions narrowed site identification to S584 and S586.
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Using a combination of CAD and ETD, we successfully sequenced seven of the
dynamically upregulated peptides (Table 5.2).  In addition, we identified one more
peptide by ETD MS/MS, which was not observed by in the orbitrap MS analysis.
Table 5.2. Quantification of O-GlcNAc glycosylated proteins from PUGNAc-treated neuronal
culture
In our previous work, we had identified the steroid receptor coactivator 1 (SRC-1)
as O-GlcNAc modified in the brain.1  Here we showed that the same peptide can be
regulated by PUGNAc treatment in primary cortical cultures. Importantly, sequencing by
ETD permitted identification of the exact site of O-GlcNAc-modification as Thr-203.
Likewise, we had previously demonstrated that the zinc finger RNA binding protein was
O-GlcNAc modified.10 Here, we isolated the site of modification as Ser-61,  and found
that in cortical neurons, this site of glycosylation could be dramatically upregulated by
inhibiting the O-GlcNAcase enzyme.
We also find that O-GlcNAc glycosylation is reversible on the nucleic acid
binding nucleoporin 153 (NUP153).  Nucleoporins have been well characterized as O-
GlcNAc-modified proteins.48,49  Here, we specifically identified a site of glycosylation in
the C-terminal domain of NUP153, which is necessary for docking and trafficking
mRNA.50  Consistent with a role for O-GlcNAc in transcriptional repression, we also
Table 1  Identification and quantification of changes in O -GlcNAc glycosylation induced by PUGNAc
BHC80 62645406 neuronal gene repression, scaffolding FTPTTLPTSQNSIHPVR 284-300 ETD
eIF4G 62658155 translation elongation scaffolding AQPPSSAASR 63-72 MS4
Nucleoporin 153 1709215 RNA binding and transport KEELPQSSSAG 1004-1114 MS4
OGA 18777747 N -acetyl-D-glucosaminidase QVAHSGAK 401-408 MS4
p66β 67846054 transcriptional repression SISQSISGQK 584-593 ETD
SRC-1 34863079 coactivation of nuclear receptor transcription INPSVNPGISPAHGVTR 188-204 ETD
zinc finger RNA-binding protein 34854400 RNA-binding protein AGYSQGATQYTQAQQAR 58-74 ETD
RecQ protein-like 4 17313266 DNA helicase KQAAFGGSGPR 378-388 ETD
a Fold change represents the observed heavy:light ratio averaged over all experiments.  See Supplementary Methods for details on statistical analysis.
b Potential glycosylation sites determined by ETD are shown in red.
24.6
Peptide Sequenceb  Residues  MS Method FunctionaProteina  NCBI Entry Fold Changea
N/D
1.4
33
4.7
28.7
40.3
1.5
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found a site of glycosylation on  p66β, which interacts with histone tails and mediates
transcriptional repression by the methyl-CpG-binding domain protein MBD2.51
In order to confirm that the observed changes were specific to O-GlcNAc rather
than due to PUGNAc-induced changes in protein expression, we treated neurons with
PUGNAc and chemoenzymatically labeled the lysate of these and untreated control
neurons.  We then specifically captured O-GlcNAc proteins by streptavidin and probed
for changes in streptavidin-binding after PUGNAc treatment by Western blotting.
Western blot analysis for the proteins O-GlcNAcase and p66β demonstrated that
PUGNAc treatment of neurons had little impact on protein expression.  However, it
dramatically influenced streptavidin binding, in a manner consistent with changes in O-
GlcNAc observed by mass spectrometry (Figure 5.9).
Figure 5.9. Western blot analysis of chemoenzymatically labeled and streptavidin-captured O-
GlcNAc neuronal proteins following PUGNAc treatment. PUGNAc induced minimal changes in
protein expression in O-GlcNAcase and the transcriptional repressor p66β  (input), but had a
significant impact on streptavidin-binding (eluent), which signifies upregulation of O-GlcNAc
glycosylation on these two proteins. (Western Blot courtesy of P. Clark).
Having demonstrated that we could use the chemoenzymatic strategy to examine
O-GlcNAc regulation from cultured neurons, we applied the strategy to the intact brain.
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In particular, given the emerging role of O-GlcNAc in the stress response,22 and its
prevalence on many proteins involved in synaptic vesicle cycling (Chapter 4), we
examined whether O-GlcNAc was responsive to a strong neuronal stimulation.  Kainic
acid seizure induction is a well-characterized model for the study of epilepsy52 and has
also been used to activate excitatory pathways in the brain that lead to gene expression.53
We administered kainic acid to rats via intraperitoneal injection and monitored their
behavioral responses.  We isolated cerebral cortices at three time points: the peak of
seizure (~2.5 h post-injection),  when animals had resumed some normal resting behavior
(~6 h post-injection) and when animals showed nearly identical behavior to saline-
injected controls (~10 h post-injection).  Western blotting of fractionated cortical lysate
with the CTD110.6 antibody revealed that O-GlcNAc levels were elevated at ~2.5 h post-
injection and returned essentially to basal levels by ~10 h post-injection (Figure 5.10).
Figure 5.10. Representative O-GlcNAc antibody Western blots of nuclear cortical lysate from
control and kainic acid treated animals.  At ~2.5 h and ~6h post-injection O-GlcNAc levels
appear to be elevated on several protein bands (marked with arrows), but after prolonged
recovery, (10 h post-injection, ~8.5 h after onset of seizing behavior) O-GlcNAc levels return to a
basal state.
In order to characterize the proteins undergoing dynamic O -GlcNAc
glycosylation in response to neuronal hyperactivity, we chemoenzymatically-labeled
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cortical lysate from the ~6 h post-injection animals, then proteolytically digested and
dimethyl labeled the peptides. O-GlcNAc peptides were then selectively enriched by
avidin affinity chromatography. Thirteen of 83 O-GlcNAc peptides detected by MS
underwent a robust, reproducible increase in response to excitatory kainic acid
stimulation of rats.  Using CAD tandem mass spectrometry, we successfully identified 4
of these proteins  as well as two proteins that did not appear to undergo changes in
glycosylation under these conditions (Table 5.3).
Table 5.3. O-GlcNAc glycosylated peptides upregulated in the mammalian cerebral cortex in
response to kainic acid administration
We identified a peptide on elongation initiation factor 4G (EIF4G), which was
dynamically regulated in response to kainic acid administration.  Glycosylation at EIF4G,
a molecular scaffold which mediates mRNA interaction with the ribosome,54 was also
strongly upregulated by PUGNAc treatment.  Notably, previous work on O-GlcNAc had
found that other components of the translational machinery are modified by
glycosylation, such as the EIF4A binding protein p67, which controls the
phosphorylation state of eukaryotic initiation factor 2α (EIF2α) and its activity.55 Our
work suggests that as with transcription, the O-GlcNAc modification may play several
roles in the translation process and that the modification can be dynamically regulated in
response to robust neuronal activity. We also found that the transcription factor early
growth response 1 (EGR-1) was O-GlcNAc modified and that O-GlcNAc levels change
Protein NCBI Entry Fold Change P  Value n Function Peptide Sequence Residues
EGR-1 6978799 10.1 0.02 2 gene transcription, stress response ALVETSYPSQTTR 87-99
eIF4G 62658155 5.3 0.02 2 translation elongation AQPPSSAASR 63-72
GRASP55 51259254 1.8 0.06 2 membrane protein transport, golgi stacking VPTTVEDR 423-430
Hrb 90101424 1.6 0.03 4 RNA trafficking SSSADFGSFSTSQSHQTASTVSK 291-313
bassoon 9506427 1.3 0.11 4 synaptic vesicle cycling SPSTSSTIHISYGQPPTTANYGSQ- 1402-1440
TEELPHAPSGPAGSGR
bassoon 9506427 1.5 0.12 2 synaptic vesicle cycling ASGAGGPPRPELPAGGAR 2283-2300
inositol polyphosphate-4-phosphatase 13591898 1.2 0.56 4 lipid phosphatase SDQQPPVTR 177-186
a Fold change represents the observed heavy:light ratio averaged over all experiments.
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dramatically upon kainate acid treatment.  EGR-1 is a   known immediate early gene
whose expression is activated by a host of stimuli such as fear conditioning and stress.
Consistent with earlier reports that EGR-1 expression is upregulated ~2-fold in the
cerebral cortex following kainic acid administration,56 we found that its expression was
elevated  1.8 ± 0.2-fold at ~ 6 h post-injection (data not shown).  Given that O-GlcNAc
glycosylation is upregulated ~ 10-fold, our mass spectrometry  data suggest that gene
expression changes alone can not account for the dramatic effect of kainate treatment on
EGR-1 glycosylation.
Importantly, MS4 sequencing also identified 20 O-GlcNAc peptides from 6 new
and 12 previously characterized O-GlcNAc proteins.  Changes in glycosylation for these
proteins were either within experimental error, or within a low signal to noise in the
orbitrap MS spectra, preventing accurate quantification (Table 5.4).
Table 5.4. O-GlcNAc glycosylated proteins identified from kainic-acid treated animals
Not all O-GlcNAc glycosylated sites will be amenable to direct peptide-specific
quantification, due to low abundance or accessibility to protease digestion.  These
difficulties underscore the power of the chemoenzymatic strategy to specifically isolate
both O-GlcNAc modified peptides and proteins.  In a complementary approach to
Protein NCBI Entry Function Peptide Sequence Residues
bassoon 9506427 synaptic vesicle cycling VTQHFAK 1338-1444
CCR4-NOT4 34855140 global transcriptional regulation, mRNA metabolism SNPVIPISSSNHSAR 329-343
CRMP-2 599966 axonal guidance, neuronal polarity TVTPASSAK 512-520
erythrocyte protein band 4.1-like 1, isoform L 11067407 cytoskeletal protein DVLTSTYGATAETLSTSTTTHVTK 1460-1483
HCF 109511332 chromatin-associated factor QPETYHTYTTNTPTTAR 1232-1248
LMP-1 62988302 contains PDZ and LIM domain AQPAQSKPQK 28-37
MAP2b 547890 dynamic assembly of microtubles at dendrites VADVPVSEATTVLGDVHSPAVEGFVGENISGEEK 380-413
O -GlcNAcase 18777747 N -acetyl-D-glucosaminidase QVAHSGAK 401-408
PDZ-GEF 34857578 GTP/GDP exchange factor for RAP1/2 SSIVSNSSFDSVPVSLHDER 1215-1233
phosphatidylinositol-binding clathrin assembly protein 16758324 regulation of clathrin assembly SSGDVHLPISSDVSTFTTR 436-454
Rab3 GDP/GTP exchange protein 1947050 regulation of GTP/GDP exchange for Rab3 subfamily G proteins SSSSTTASSSPSTIVHGAHSEPADSTEVGDK 699-729
Rad23b 60422770 translocation ubiquitinated proteins AAAATTTATTTTTSGGHPLEFLR 176-198
SH3p8 2293466 SH3 domain binding protein, synaptic vesicle cycling ITASSSFR 283-290
SRC-1 34863079 coactivation of nuclear receptor transcription INPSVNPGISPAHGVTR 188-204
SynGAP 34098355 inhibitory regulation of Ras pathway, synaptic strength regulation QHSQTPSTLNPTMPASER 1121-1138
Ythdf3 109466336 contains YtH domain IGGDLTAAVTK 145-155
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peptide-specific quantification, current efforts in the laboratory are focused on using the
chemoenzymatic strategy to capture intact O-GlcNAc glycosylated proteins after kainic
acid induction.  Changes in protein association with streptavidin can then be detected
either directly by Western blotting with known antibodies, or my mass spectrometry
analysis of captured and proteolytically digested proteins.
5.4. Discussion
In this chapter, we have described an efficient, sensitive strategy for the
quantification of O-GlcNAc on single proteins, as demonstrated on the transcription
factor CREB.  The approach capitalizes on the biotin affinity tag for sensitive detection
and thus should be applicable for the quantitative study of other low-abundance O-
GlcNAc proteins that are not amenable to traditional techniques.42
Using the approach, we have provided direct evidence that O-GlcNAc levels on
CREB can be upregulated in response to glucosamine and PUGNAc treatment of
pancreatic cells, in agreement with the effect of these compounds on CREB-mediated
transcription.  The effect of PUGNAc is modest and may represent the fact that
glycosylated CREB is generally protected from dynamic removal of O-GlcNAc under
basal conditions.  Different populations of CREB (e.g., within different parts of the cell,
or on different promoters) may be differentially regulated by OGT/O-GlcNAcase, an
attractive possibility given the multiple interacting partners of both enzymes, which may
affect their localization and substrate specificity.57,58
In addition to studying the quantification of individual O-GlcNAc proteins, we
have also developed the first quantitative proteomic assays of O-GlcNAc glycosylation.
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O-GlcNAc dynamics were assayed by a chemoenzymatic strategy that facilitated both the
discovery and quantification of O-GlcNAc peptides from cultured neurons and the
mammalian brain.  In contrast to other approaches, such as lectin affinity
chromatography,29 antibody affinity26 or BEMAD,26 the approach is applicable to the
study of O-GlcNAc dynamics both on intact proteins and at specific sites of modification.
Moreover, the approach does not rely on metabolic labeling28 and thus is amenable to
both tissues and whole organisms.
Our proteomic approach featured the use of a simple, efficient and commercially
available isotopic label, which had previously been shown to quantify changes in protein
expression.36  Reductive amination of lysines with formaldehyde and NaCNBH3, or their
deuterated counterparts, proceeds quantitatively within minutes and shows no side
reaction or significant ‘isotopic effect’ during LC-MS.  Because the strategy does not
require cell division for incorporation32 it is  particularly useful for the study of
postmitotic cells, such as neurons and tissue.  Here, it was readily coupled with our
chemoenzymatic strategy to specifically quantify enriched O-GlcNAc glycosylated
peptides cultured neurons and brain tissue.
In our initial experiments we examined the strategy on PUGNAc-treated neuronal
lysate.  PUGNAc was one of the first O-GlcNAcase inhibitors described, and has been
used extensively for the study of O-GlcNAc.59  We showed that it could significantly
elevate endogenous O-GlcNAc levels in neurons.  In order to identify affected proteins,
we isolated O-GlcNAc peptides from both basal and treated cells and  examined peptides
for changes in glycosylation by orbitrap LC-MS analysis.  Interestingly, many peptides
did not show an elevation in O-GlcNAc levels in response to PUGNAc treatment.  This
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may be due to the localization and targeting of the O-GlcNAcase58 or the constitutive
nature of glycosylation for some protein targets.
In order to identify dynamically regulated peptides, we employed two modes of
sequencing, CAD MS/MS analysis followed by multistage MS or ETD MS/MS.  We had
previously described that the biotin-ketone tag provides a unique signature by CAD
MS/MS,  which allows unambiguous characterization of O-GlcNAc peptides.10  Peptides
displaying the unique signature can then be targeted for sequencing by MS4 analysis.  In
contrast to CAD, ETD fragmentation does not release the tagged O-GlcNAc group and
can be used to narrow down or identify exact sites of glycosylation within peptides.37
The peptide backbone is directly fragmented even in the presence of the PTM so
identification can be made directly from MS/MS analysis on an ion trap mass
spectrometer.   We found ETD to be highly effective for the fragmentation of higher
charged species ([M+4H]4+ and above) but less effective for [M+3H]3+ and [M+2H]2+
species.  This was particularly pronounced for tagged O-GlcNAc peptides bearing the
bulky biotin group and two carbohydrates, and may be due to inadequate charge to mass
distribution, which is necessary for effective ETD fragmentation.*  Our efforts to resolve
these issues with the use of endoproteinase Lys-C to generate larger, and more highly
charged peptide fragments were hampered by the high rate of false positives when
searching highly charged ETD fragment ions by the database querying program
SEQUEST.  Advances in programs to query ETD data, such as the publicly available
OMSSA program (http://pubchem.ncbi.nlm.nih.gov/omssa/) should help address this
issue.  In addition, the generation of a cleavable biotinylated linker, which would restore
                                                 
* Effective ETD fragmention relies on high charge to mass distribution.  For example, doubly
charged peptides typically yield poor fragmentation compared with more highly charged species.
(J. Coon. Personal Communication, 2006).
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the lone O-GlcNAc group after affinity capture, may help ETD sequencing of less-highly
charged glycosylated peptides.  With further development, we envision that the ETD
strategy will become a powerful tool for the identification of O-GlcNAc glycosylated
peptides and the mapping of O-GlcNAc glycosylation sites.
Using a combination of CAD and ETD, we sequenced 7 of the O-GlcNAc
peptides that undergo significant increases in glycosylation upon PUGNAc treatment.  In
addition, we identified another peptide by ETD that was not observed in the orbitrap MS
analysis and thus could not be quantified.  Among the identified proteins undergoing
reversible glycosylation was the enzyme O-GlcNAcase.  Inhibition of O-GlcNAcase
using PUGNAc led to a robust increase in OGA glycosylation at Ser-405, suggesting that
OGT may be capable of regulating the activity of its antagonizing enzyme.  This finding
is consistent with a recent report that the two enzymes form a stable association as a gene
transcription regulatory complex, which requires a region of OGA that encompasses the
identified glycosylation site.60
In addition, we identified several proteins involved in mRNA binding and
transport.  Such processes are of particular interest in neurons, where regulated transport
of mRNA from the cell body to dendrites and local translation of mRNA are involved in
the strengthening of individual synapses to give rise to synaptic plasticity.61 In particular,
reversible O-GlcNAc glycosylation occurred on the zinc finger RNA-binding protein,
which is associated with staufen2 granules in neurons and may be important in the early
stages of RNA translocation from the nucleus to the dendrites.62  We also identified a
dynamically glycosylated peptide from the C-terminal domain of nucleoporin 153, which
is necessary for docking and trafficking of mRNA.50  The presence of reversible and
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potentially regulatory sites of glycosylation on proteins involved in RNA transport
supports an expanded role for O-GlcNAc glycosylation in translational control and may
have important consequences for neuronal signaling and synaptic plasticity.
In order to investigate the potential contribution of O-GlcNAc glycosylation to
neuronal communication, we examined the effects of excitatory neuronal stimulation on
O-GlcNAc levels in the brain.  We demonstrated for the first time that O-GlcNAc
glycosylation is regulated in vivo by robust excitatory stimulation.  The O-GlcNAc levels
on several proteins increased upon treatment of rats with the glutamate analogue kainic
acid and returned to basal levels as the behavioral effects of the treatment dissipated.
Using our quantitative proteomics strategy, we found that EGR-1, an immediate early
gene and transcription factor important for long-term memory formation63 and cell
survival, undergoes a 10-fold increase in glycosylation.64  As the site of glycosylation
resides in the N-terminal transactivation domain of EGR-1, one possibility is that O-
GlcNAc may influence the transactivation potential of EGR-1 and modulate the
expression of genes such as the synapsins and proteasome components, which play
critical roles in synaptic plasticity.65
We also observed an increase in O-GlcNAc glycosylation on the translation factor
eIF4G upon kainic acid stimulation.  The observation that eIF4G is reversibly
glycosylated in neurons is consistent with an emerging role for O-GlcNAc in regulation
of the stress response.22  As kainic acid treatment induces excitotoxicity in addition to
synaptic potentiation and suppressed translation is a known marker for neuronal
excitoxicity,66 the potential regulation of eIF4G by O-GlcNAc glycosylation may
represent a stress-induced response.  It will be important to examine whether other
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cellular stresses induce glycosylation of eIF4G and other proteins to modulate translation
and neuronal survival.  Consistent with this possibility, other components of the
translational machinery have been shown to be regulated by O-GlcNAc glycosylation,
including p67, which binds to the eukaryotic initiation factor 2α  (eIF2α ) in its
glycosylated form and promotes protein synthesis by preventing inhibitory
phosphorylation of eIF2α.55
Notably, our studies indicate that only a fraction of the O-GlcNAc-modified
proteins undergo dynamic glycosylation in response to specific stimuli.  Similar
heterogeneous responses have been observed in the case of phosphorylation.  For
example, kainic acid stimulation exerts bidirectional effects on the phosphorylation state
of proteins, both enhancing and inhibiting phosphorylation in a substrate-dependent
manner.67,68   These results suggest that OGT and OGA are subject to complex cellular
regulation analogous to that of kinases and phosphatases, such as the influence of
interacting partners, subcellular targeting and post-translational modifications (including
our observation of reversible glycosylation on OGA itself).  The cycling of O-GlcNAc on
certain substrates, coupled with more inactive, perhaps constitutive, forms of O-GlcNAc
glycosylation, may allow for the finely-tuned, selective regulation of protein function in
response to neuronal stimuli.
The ability of O-GlcNAc to respond to specific extracellular stimuli also suggests
a potential role for the modification in mediating neuronal communication.  This notion is
supported by the identification of a growing number of O-GlcNAc glycosylated proteins
involved in neuronal signaling and synaptic plasticity.10  In the present study, we further
expand the O-GlcNAc proteome of the brain to include proteins involved in synaptic
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vesicle trafficking, including Rab3 GEP, a protein involved in neurotransmitter release,
and phosphatidylinositol clathrin protein, which mediates synaptic vesicle endocytosis.
In keeping with recent work by Vosseller29 and colleagues, we also find that the synaptic
Ras GTPase activating protein SynGAP, which plays a critical role in AMPA (alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor trafficking and synapse
formation, is glycosylated.
Finally, our work highlights the emergent interplay between O -GlcNAc
glycosylation and phosphorylation.  For example, we identified a glycosylated peptide on
the protein Bassoon, 1402SPSTSSTIHSYGQPPTTANYGSQTEELPHAPSGPAGSGR1440
that was likewise shown to be phosphorylated by phospho-proteomic methods.69  In
addition, we also identified a glycosylated peptide in the axonal guidance protein CRMP-
2,  which is known to be phosphorylated at two residues within the identified
glycopeptide.  Interestingly, when hyperphosphorylated within the residues of this
peptide, CRMP-2 appears as a component of the neurofibrillary tangles (NFTs)
associated with Alzheimer’s disease.70  This is reminiscent of the microtubule-associated
protein tau, which is also O -GlcNAc glycosylated, but which exists in
hyperphosphorylated form in the AD brain.71   Deciphering the mechanisms that regulate
the interplay of glycosylation and phosphorylation for these two and other proteins may
have important ramifications for the study of Alzheimer’s disease and other neurological
disorders.
Overall, we have shown that O-GlcNAc is both reversible in neurons and
dynamic in the brain in response to robust neuronal stimulation. Understanding the
mechanisms by which kainic acid administration modulates O-GlcNAc levels will be an
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important next step in understanding O-GlcNAc regulation in the brain.  In addition, the
chemoenzymatic approach should prove useful for studying O-GlcNAc dynamics in
response to stimuli such as behavioral and memory training protocols, or other modes of
excitotoxicity that might identify O-GlcNAc as a mediator of the stress response in
neuronal tissue.  Although we have only begun to understand the processes that regulate
O-GlcNAc, this strategy should serve as a valuable tool in the study of this PTM, as well
as in identifying its role within the rapidly expanding network of PTMs that govern cell
function.
5.5 Experimental Methods
Preparation of HIT-T15 Cell Extracts
HIT-T15 cells were cultured in 37 oC humidified air with 5% CO2 in DMEM
supplemented with fetal bovine serum (10%), penicillin (100 U/mL) and streptomycin
(100 µg/mL).  Nine hours prior to lysis, the culture medium was supplemented with 10
mM glucosamine (500 mM stock in 100 mM HEPES pH 7.4) or 100 µM PUGNAc (10
mM stock in ddH20) (Toronto research chemicals).  Six hours prior to lysis 10 µM
forskolin (Alexis biochemicals) (50 mM stock in DMSO) was added to the culture
medium.  After treatment, cells from a 100 mm dish were trypsinized and pelleted.  The
pellet was resuspended in 0.1 mL of boiling lysis buffer (1% SDS with protease inhibitor
cocktail Complete, Roche), sonicated for 3 × 3 sec, and boiled for 8 min. After
centrifugation at 21,500 × g for 5 min, the supernatant was collected as denatured HIT-
T15 extract.
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Chemoenzymatic Labeling of Proteins from HIT-T15 cells
 One volume of denatured HIT-T15 extract was diluted five-fold with 100 mM HEPES
pH 7.9, 20% Triton-X100, 5 M NaCl, 100 mM MnCl2, 25 mM adenosine 5’-diphosphate,
25X Complete protease inhibitor cocktail and 250 mM phenylmethylsulfonyl fluoride
(PMSF) to a final concentration of 0.2% SDS, 10 mM HEPES pH 7.9, 1.8% Triton-
X100, 100 mM NaCl, 8 mM MnCl2, 1.25 mM adenosine 5’-diphosphate, 1X Complete
protease inhibitor cocktail and 1 mM PMSF.  Diluted extract was then supplemented with
10 mM analogue 1 and Y289L GalT to final concentrations of 0.5mM analogue 1 and 20-
40 ng/µL Y289L GalT.  The reaction mixture was incubated at 4 oC for 12 h, and
dialyzed into buffer A (10 mM HEPES pH 7.9, 5 M urea) 3 × 4 h at 4 ºC.  Following
dialysis, the sample was acidified to pH 4.8 by adding of 2.78 M NaOAc pH 3.9 to a final
concentration of 50 mM and mixed for 10 min.  Pepstatin was added to a final
concentration of 5 µg/mL and the aminooxy biotin derivative (30 mM stock in ddH20,
Dojindo) was then added to a final concentration of 2.75 mM.  After incubation at room
temperature for 20 h, the sample dialyzed into CREB IP buffer (10 mM HEPES pH 7.5,
100 mM KCl, 1 mM EDTA and 0.2% Triton-X100, 1 mM PMSF ) 2 × 2 h and 1 × 12 h
at 4 ºC.
CREB Immunoprecipitation
Dialyzed HIT-T15 cell extract was supplemented with protease inhibitors (1X Complete
protease inhibitor cocktail, 1 mM PMSF), and  protein concentration was assayed by
BCA assay (Pierce).  Protein concentration was adjusted for control and experimental
samples with excess CREB IP buffer such that the concentrations and total amounts of
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lysate for immunoprecipitation were identical.  Lysates were pre-cleared with protein A
sepharose beads (30 µL/100 µg of protein) for 2 h at 4 oC.  After centrifugation by table-
top centrifuge, the supernatant was collected and incubated with CREB antibody (rabbit
polyclonal, Upstate Biotechnology) (1.5 µg/100 µg of proteins) for 4 h at 4 oC.  Extracts
and antibody were then incubated with 30 µL protein A sepharose for 1-1.5 h at 4 ºC.
Flowthrough was removed and beads were washed 3 × 5min with 1 mL CREB IP buffer
at 4 ºC,  3 × 5 min with 1 mL PBS at 4 ºC,  and 1 × 5 min with 1 mL 50mM Na2HPO4 pH
7.5 at 4 ºC. After washing, the beads were boiled for 2 × 3 min in 3.5 volumes of 1×
SDS-PAGE loading buffer (beads were briefly vortexed after the first three minutes and
reboiled). After centrifugation at 2,000 × g for 1 min, the supernatant was collected as the
captured material.
Western Blotting
Captured material from CREB immunoprecipitation was resolved by SDS-PAGE and
transferred to nitrocellulose membranes.  Membranes were blocked for 1 h at RT in 5%
Milk, PBS-T(0.05%), followed by incubation with anti-CREB antibody (mouse
monoclonal, Chemicon International) at 1:1000 dilution in blocking buffer for 1 h at RT.
Blots were then rinsed in PBS-T(0.05%) and washed 3 × 5 min in PBS-T(0.05%), then
incubated with G anti-M-HRP IgG secondary antibody at a 1:10,000 dilution in blocking
buffer for 1 h at RT. Blots were then rinsed in PBS-T(0.05%), washed 2 × 15 min in
PBS-T(0.05%) and 3 × 5min in PBS-T(0.05%) and developed by chemiluminescence and
exposure to film.  Following exposure to film, blots were stripped for 45 min at 60 ºC in
250 mL of stripping buffer (2% SDS, 5 mM Na2HPO4 pH 7.5, 2 mM β-mercaptoethanol)
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and reprobed with Streptavidin-HRP as follows: blots were blocked for 1 h at RT in 5%
BSA TBS-T(0.1%) then incubated with Streptavidin-HRP (Pierce) at a 1:25,000 dilution
in TBS-T(0.1%) for 1 h at RT (unstripped blots were incubated in Streptavidin-HRP at a
concentration of 1:50,000).  Blots were subsequently rinsed with TBS-T(0.1%) and
washed 2 ×  15 min, 3 ×  5 min in TBS-T(0.1%) before exposure to film by
chemiluminescence.
Animal Care and Kainic Acid Administration
Male Long Evans rats from Charles River laboratories (7 week-old, 190-200 g) were
injected with 10-11 mg/kg kainic acid (axxora, San Diego CA) (neutralized with NaOH
and sterile-filtered).  Kainic acid (5 mg/mL concentration) was administrated to the
peritoneum and animals were housed separately, on paper towel bedding and closely
monitored for behavioral changes.  Peak of seizure activity (usually ~1.5 h post-injection)
was marked by shaking, rearing posture and significant frothing by mouth.  Animals were
sacrificed at three time points post-injection, with paired animals demonstrating similar
kainic-acid induced behavior. First, 1 h after onset of seizure, while animals were still
displaying seizure behavior.  Second, ~4.5 after onset of seizure activity, when animals
had begun to display characteristics of controls (responsiveness to cage tapping).  Third,
~8.5 h after onset of seizure activity, at which point animals were largely
indistinguishable from controls and were responsive to cage tapping, and were eating,
and resting.  At these time points, animals were decapitated and brains immediately
dissected for cortices, hippocampi and cerrebella, on dry ice.  Brains were flash frozen in
liquid N2  and stored at – 80  ºC until further use.   Control animals were treated
identically, except that they were peritoneally injected with phosphate-buffered saline.
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The animal protocol was approved by the Institutional Animal Care and Use Committee
at Caltech, and all procedures were performed in accordance with the Public Health
Service Policy on Humane Care and Use of Laboratory Animals.
Preparation of Rat Cortical Extract from Seized Animals
The cortices of control and seized  Long Evans rats (Charles River Laboratories) were
weighed frozen, allowed to briefly thaw on ice, and sliced by razor blade into three
portions.  They were subsequently lysed into 5 volumes of homogenization buffer by 4-5
strokes of manual dounce homogenization on ice, and 8 strokes of mechanical
homogenization at 700 rpm at 4 ºC.  Homogenate was fractionated into nuclear and S100
cytoplasmic components as described by Dignam et al,72 except that Complete protease
inhibitor cocktail tablets (Roche, Indianapolis IN), phosphatase inhibitors, 10 µM
PUGNAc (Toronto Research Chemicals) and the hexosaminidase inhibitor 50 mM
GlcNAc73 were added to the buffers.  In some cases, crude nuclear pellets from seized
and control animals were washed (with homogenization buffer not containing PUGNAc
or GlcNAc) and lysed directly into boiling 1% SDS, by sonication.  Prior to labeling,
cytoplasmic extracts and nuclei not lysed directly into SDS were dialyzed into 20 mM
HEPES pH 7.9, 0.1 M KCl, 0.2 mM EDTA, 0.2% Triton X-100, 0.5mM (PMSF)
phenymethylsulfonylfluoride.  Before labeling, portions of the nuclear and cytoplasmic
samples were removed for Western blotting with the anti-O-GlcNAc CTD110.6 antibody
(Covance) or the anti-EGR-1 antibody (Cell Signaling).
Preparation of Cortical Culture. Cortical neuronal cultures were prepared using a
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modified version of the Goslin and Banker 74 protocol. Embryos at the E18/E19 stage
were obtained from timed-pregnant Sprague-Dawley rats, and the cortex from each
embryo was dissected. In some cases, two to three animals were combined in one mixed
preparation, in which cases volumes below were appropriately scaled. All the cortices
from one preparation were transferred to a 15 mL conical tube containing 4.5 mL of ice-
cold Calcium and Magnesium Free-Hank’s Balanced Salt Solution (CMF-HBSS)
(Gibco). Trypsin (2.5%, no EDTA; Gibco) was added to 5 mL, and the tissue was
digested for 15 min at 37 °C.  The trypsin solution was removed and the tissue rinsed
with 5 mL of warm CMF-HBSS 3×. The tissue was then dissociated in 5 mL of CMF-
HBSS by passing through a 2 mL serological pipet 5× and a P1000 pipet tip 20×. Tissue
was allowed to settle, and supernatant was filtered.  Settled material was dissociated  in 5
mL of fresh CMF-HBSS by passing through a P1000 pipet tip 10× and undissociated
tissue was removed by filtration.  The cells were counted with a hemacytometer and
plated on 100 mM culture dishes, which had been previously coated with 0.1 mg/mL
sterile-filtered poly-D,L-Lysine (Sigma) in 50 mM Na2B4O7 pH 10.  Cells were plated at
a concentration of 8-12 X106 cells/100 mM dish in 500 µL Eagle’s Medium (MEM)
(Gibco) supplemented with 10% Fetal bovine serum (Gibco) and penicillin (100
U/mL)/streptomycin (100 µg/mL). (Gibco).  After 30 min, cells were supplemented with
10 mL of Neurobasal Medium (Gibco) containing 1 × b27 serum-free supplement
(Gibco), 2 mM L-glutamine (Gibco), 1X antibiotic/antimycotic (Gibco), penicillin (100
U/mL)/streptomycin (100 U/mL) (Gibco) and 500 µM kyneuric acid (in 1 N NaOH).
Cells were maintained for 4 days  at 5% CO2/ 95% O2 at 37 ºC and media was replaced
on the second day and just before PUGNAc treatment.
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PUGNAc (Toronto research chemicals) (10 mM solution) was added to a final
concentration of 100 µM.  After 12 h of incubation, cells were trypsinized and pelleted.
After removing media by aspiration the pellet was washed in 1 mL of HEPES-buffered
Saline  and lysed as described by Dignam et al,72 with the following modifications.
Complete protease inhibitor cocktail tablets, phosphatase inhibitors, 10 µM PUGNAc and
the hexosaminidase inhibitor 50 mM GlcNAc73 were added to the buffers. Crude nuclear
pellets were washed (with homogenization buffer not containing PUGNAc or GlcNAc)
and lysed directly into boiling 1% SDS by sonication for 3 × 3 sec.  After centrifugation
at 21,500 × g for 5 min, the supernatant was collected as denatured nuclear extract.  Prior
to labeling, cytoplasmic extracts were dialyzed into 20 mM HEPES pH 7.9, 0.1 M KCl,
0.2 mM EDTA, 0.2% Triton X-100, 0.5mM PMSF.  Basal neurons were treated
identically except that water rather than PUGNAc was added to neuronal culture.
Chemoenzymatic Labeling of Neuronal and Brain Extracts
 α-Crystallin, 5 mg/mL (a ~ 1:1 mixture of A and B crystallin), (Sigma) was denatured in
1% SDS with 25 mM DTT, boiled for 5 min and added to extracts prior to labeling (6.5-
11µg).  OGT ( 0.8 mg/mL in 50 mM NaH2PO4 pH 7.5, 1 mM DTT, 20% glycerol) from
sf9 cells39 was denatured in 1% SDS with 25mM DTT, boiled for 5 min and added to
extracts prior to labeling (0.8-2 µg).  Extracts (500 µg-3 mg; 1-3 mg/mL) containing α-
Crystallin and OGT standard proteins were supplemented with 5 mM MnCl2, 0.5 mM
ketone probe, and Y289L GalT (60 ng/µL), with 1× Complete protease inhibitors and 1
mM PMSF and incubated for 12-14 h at 4 °C.   Denatured extracts, in 1% SDS,  were
first diluted 5-fold with 100 mM HEPES pH 7.9,  5 M NaCl and 20% Triton-X100 to a
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final concentration of 10 mM HEPES pH 7.9, 100 mM NaCl and 1.8% Triton-X100.
Following enzymatic labeling, extracts were dialyzed into denaturing buffer (5 M urea,
10 mM HEPES pH 7.5; 3 × 3 h). The pH was adjusted with 2.7 M NaOAc pH 3.9 (final
concentration 50 mM, pH 4.8).  Aminooxy biotin (30 mM) was added to a final
concentration of 2.75 mM, and the reactions were incubated for 20-24 h at RT.  Extracts
were dialyzed (2 × 2 h, 1× 10 h) into 7 M urea, 10mM HEPES pH 7.5 at RT followed by
2 M urea, 50 mM NH4HCO3 pH 8 (3 × 3 h) at 4  ºC.
Proteolytic Digestion
Dialyzed extracts were reduced in 10 mM DTT (500 mM stock in 50 mM NH4HCO3 pH
8) for 1 h at RT, alkylated in 20mM iodoacetamide (500 mM stock in 50 mM NH4HCO3
pH 8) for 1 h at RT, and  incubated with 20 mM DTT for 1 h at RT to  react with excess
iodoacetamide.  The extract solution was then centrifuged at 15,000 rpm for 5 min to
remove any insoluble material.  Protein concentration was measured via Biorad assay.
Control and experimental extracts were adjusted to identical volumes/protein
concentrations with excess  2 M urea, 50 mM NH4HCO3 pH 8 and then diluted with 50
mM NH4HCO3 pH 8  to a final urea concentration of 1M.  Sequencing-Grade Trypsin
(Promega) was added to a final extract: trypsin ratio of 20:1. Trypsin concentration was
always maintained above 0.01 mg/mL and digestion was carried out in a water bath at 37
ºC for 12-14 h.
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Dimethyl Labeling
Digested extracts were desalted using a Sep-Pak C18 cartridge (1 cc bed volume; Waters)
as follows:  cartridges were equilibrated with 1 mL of 0.1% AcOH in water, and acidified
extracts were loaded onto cartridges.  Cartridges were washed with 1.5 mL water and
peptides were eluted in 500 µL of 60% aqueous CH3CN, concentrated by speedvac to a
volume of 50 µL, and diluted with 450 µL of 1 M HEPES pH 7.5.  To begin the
reactions, the samples were mixed with 40 µL of a 600 mM stock of NaCNBH3 or
NaCNBD3 (Sigma) in water, followed by 40 µL of 4% aqueous formaldehyde
(Mallinckrodt Chemicals) or 40 µL of 4% aqueous formaldehyde-d2 (Sigma).  The
reactions were briefly vortexed, allowed to proceed for 10 min at room temperature, and
then quenched by acidification with 100% AcOH to a pH <4.5.  Dimethylated peptides
were desalted using a Sep-Pak C18 cartridge (1 cc bed volume) as described above and
the eluents (500 µL in 60% aqueous CH3CN, 0.1% AcOH) were concentrated by
speedvac to a volume of 100 µL.
Cation Exchange and Avidin Chromatography
Cation exchange chromatography (Applied Biosystems) was performed on dimethylated
peptides as described by the manufacturer, except that peptides were eluted with a step
gradient of 100 mM, 250 mM, and 350 mM KCl in 5 mM KH2PO4 containing 25%
CH3CN.  Fractionated peptides were enriched via avidin chromatography (Applied
Biosystems) as follows: peptides were loaded onto the avidin column as described by the
manufacturer and washed with 2 mL of 2X PBS (1X PBS final concentration: 10.1 mM
Na2HPO4, 1.76 mM KH2PO4,, 137 mM NaCl, 2.7 mM KCl, pH 7.4), 2 mL of 1X PBS,
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1.5 mL of manufacturer wash buffer 2 and 1 mL of ddH20.  Avidin-enriched peptides
were eluted as described by the manufacturer.
Orbitrap LC-MS Analysis of Avidin-Enriched Biotinylated Peptides
Automated nanoscale reversed-phase HPLC/ESI/MS was performed as described in
previous chapters.  Approximately 1/5 of the avidin-enriched peptides from each cation
exchange fraction was loaded onto a 360 µm O.D. X 75 µm I.D. precolumn packed with
4 cm of 5 µm Monitor C18 particles (Column Engineering) at a flow rate of 4 µL/min.
After desalting, the vent was closed and peptides eluted to a 360 µm O.D. X 75 µm I.D.
analytical column with integrated emitter tip (10 cm of 5 µm C18, ca. 5 µm tip).  The
chromatographic profile was from 100% solvent A (0.1% aqueous AcOH) to 50%
solvent B (0.1% AcOH in CH3CN) in 30 min.  The flow rate through the analytical
column was approximately 100 nL/min.  For data-dependent experiments, the mass
spectrometer was programmed to record a full-scan ESI mass spectrum (m/z 650-2000,
ions detected in orbitrap mass spectrometer with a resolution set to 100000) followed by
five data-dependent MS/MS scans (relative collision energy = 35%; 3.5 Da isolation
window).  Precursor ion masses for candidate glycosylated peptides were identified by a
computer algorithm (Charge Loss Scanner; developed in-house with Visual Basic 6.0)
that inspected product ion spectra for peaks corresponding to losses of the ketogalactose-
biotin and GlcNAc-ketogalactose-biotin moieties.  Up to eight candidate peptides at a
time were analyzed in subsequent targeted MS4 experiments to derive sequence
information.
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For all MS experiments, the electrospray voltage was set at 1.8 kV and the heated
capillary was maintained at 250 °C.  For database analysis to identify O-GlcNAc
proteins, Bioworks Browser 3.2SR1 (ThermoElectron) software was used to create files
from MS4 data and ETD MS/MS data.  These files were then directly queried, using the
SEQUEST algorithm (ThermoElectron), against amino acid sequences in the NCBI
rat/mouse protein database.
Quantification was conducted by generating single ion chromatograms from the
orbitrap MS scans for candidate O-GlcNAc peptides.  Peak areas of isotopic clusters were
derived using Xcalibur 1.4 software (ThermoElectron) and relative ratios were
normalized against the mean relative ratio of standard peptides. Mean values, standard
deviations and confidence intervals were calculated using the program Excel on log-
transformed ratios and reported in the original scale as previously described. 75  Standard
peptide ratios were tested for goodness of fit to the log-normal distribution via the
Kolmogorov-Smirnov test and were used to determine the confidence with which
changes in experimental peptides could be detected.  Experimental peptide ratios were
normalized against the slope of the linear regression produced by the heavy versus light
forms of standard peptides within experiments.  Where applicable, paired t-test was
performed on normalized, log-transformed peptide ratios to determine significance.
MS/MS experiments by ETD were conducted on a modified LTQ mass
spectrometer.  A chemical ionization source was added to the rear side of the LTQ to
allow for the introduction of fluoranthene radical anions for ETD reactions.  For data-
dependent experiments, the mass spectrometer was programmed to record a full-scan ESI
mass spectrum (m/z 650-2000) followed by five data-dependent MS/MS scans (70-100
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ms ETD activation; 3.5 Da isolation window).  In some cases, targeted MS/MS was
conducted on up to eight candidate peptides that had demonstrated the signature
ketogalactose-biotin loss during CAD MS/MS.  All sequenced peptides were manually
verified, and annotated CAD and ETD spectra will be presented in a published
manuscript.
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Appendix I
Exploring O-GlcNAc Dynamics from Neuron Culture and the Brain
AI.1 Background and Introduction
Several lines of evidence suggest that O-GlcNAc glycosylation, like
phosphorylation, is a dynamic  modification. As described in Chapter 5, early studies
suggested that O-GlcNAc is a highly dynamic modification, with a turnover rate that
exceeds that of the protein backbone.1  Moreover, O-GlcNAc levels in lymphocyte cells
were shown be responsive to mitogens.2  Evidence also suggests that O-GlcNAc levels
can rapidly respond (within minutes) to ligand binding on neutrophils.3  Finally, O -
GlcNAc levels in mammalian cells showed marked upregulation in response to numerous
cell stresses, and perturbation of the O-GlcNAc machinery decreased cell survival in
response to stress.4 In cultured cerebellar neurons, O-GlcNAc levels of cytoskeletal-
associated proteins were shown to respond reciprocally to PKA and PKC activators and
inhibitors, highlighting the apparent antagonism between the two modifications, in some
contexts.5  In addition, okadaic acid, an inhibitor of protein phosphatase-2A (PP2A) (and
less robustly protein phosphatase-1) (PP1)6 was shown to downregulate O-GlcNAc levels
in a neuroblastoma cell line.7 Finally, O-GlcNAc levels are decreased in the Alzheimer’s
brain, which may be a reflection of the altered glucose uptake/metabolism associated
with Alzheimer’s disease.8  Interestingly, perturbing O-GlcNAc levels with the inhibitor
PUGNAc induces phosphorylation of the microtubule associated protein tau, at many
sites.  As hyperphosphorylated tau has been implicated in the pathology of Alzheimer’s
disease, researches have speculated that perturbations in O-GlcNAc in the Alzheimer’s
brain is one of the mechanisms by which tau may become dysfunctional. The interplay of
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O-GlcNAc and phosphorylation on tau underscores the relationship between the
modifications (Chapter 1 and Chapter 5), which may have important consequences for
cell function
Our studies have been focused on understanding O-GlcNAc in neuronal tissue.
As such , we investigated stimuli that might activate or repress O-GlcNAc glycosylation,
as well the relationship between O-GlcNAc and phosphorylation in neurons.  We found
that global O-GlcNAc levels, as monitored by the anti-O-GlcNAc antibody CTD110.6,
could readily be manipulated by PUGNAc and glucosamine, a precursor of UDP-GlcNAc
in neuronal tissue, suggesting that O-GlcNAc is reversible in these cells.  In addition, we
found that O-GlcNAc levels were responsive to the PP1/PP2A inhibitor calyculin A
within a matter of minutes, suggesting that phosphorylation pathways can impact O-
GlcNAc and may be involved in its regulation.
AI.2 Characterizing  O-GlcNAc Dynamics in Adult Hippocampal Slices
For our initial studies, we assayed O-GlcNAc dynamics in hippocampal slices,
choosing this region of the brain for its particularly significant role in processes such as
learning and memory and its reported high abundance of the O-GlcNAc enzymes.9 As
Table AI.1 shows, the majority of stimuli had no reproducible effect on O-GlcNAc levels
as monitored by the anti-O-GlcNAc antibody CTD110.6.  PUGNAc and glucosamine
both elevated O-GlcNAc levels suggesting that O-GlcNAc is dynamic and reversible in
acute slice preparations.  Moreover, we did find a pronounced effect on O-GlcNAc levels
by the PKA inhibitor H89.
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Table AI.1. Pharmacological treatment of adult hippocampal slices can modulate O-GlcNAc
levels as measured by O-GlcNAc antibody Western blotting
H89 appeared to activate O-GlcNAc glycosylation on several proteins, as seen
after fractionation into a cytosolic (S2) and nuclear fraction.  SDS lysis of coordinately
treated slices shows only a subtle change in O-GlcNAc on high molecular weight
proteins (Figure AI.1) suggesting that whole-cell lysis may mask compartmentalized
changes in glycosylation in the cell.
Figure AI.1.  The PKA inhibitor H89 upregulates O-GlcNAc levels in hippocampal slices as
observed by CTD110.6 Western blot of adult acute hippocampal slice lysate.
H89 (20 µM, 1 h)
MW
(kDa)
+ + +
250
160
105
75
50
30
CTD110.6
Nuclear S2
Whole Cell
Lysate
Known Target Cell Observed
Stimulus of Stimulus Fractionation Time Effect Control
15/20 mM Gluocsamine UDP-GlcNAc Whole-Cell 3 h upregulation –
levels SDS
200µM PUGNAc O-GlcNAcase Whole-Cell 3 h upregulation –
inhibition SDS
Glucose (5mM versus 10mM) UDP-GlcNAc Whole-Cell SDS 3 h no change –
50mM Forskolin cAMP pathway Whole-Cell 5 min&10min no change phospho-GlUR1 (s845)
PKA activation SDS
Okadaic acid PP2A Whole-Cell 3 h no change phospho-tau (s212)
0.1µM inhibition SDS
Genistein 100µM tyrosine kinase Whole-Cell SDS 1.5 h no change –
inhibition Nuclear/S2
H89 20µM PKA inhibition Whole-Cell SDS 1 h no change –
Nuclear/S2 upregulation/upregulation
KCl depolarization Whole-Cell SDS 30 min  no change –
mutliple pathways
Lavendustin A 10µM tyrosine kinase Whole-Cell SDS 1 h no change –
inhibition
PD98059 50µM MEK inhibition Whole-Cell SDS 50 min no change –
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The mechanism by which H89 might elevate O-GlcNAc levels is unclear.  Notably, PKA
is known to inhibit the activity of Glutamine:fructose-6-phosphate amidotransferase
(GFAT), the rate-limiting enzyme in glucosamine synthesis.10 By blocking PKA activity,
H89 may influence UDP-GlcNAc levels and the activity of OGT toward certain
substrates.  Comparison of fractionated tissue after H89 treatment and concurrent
repression of GFAT with the inhibitor azaserine11 should help address whether the effect
is specifically due to elevation of UDP-GlcNAc levels.
AI.3 Characterizing O-GlcNAc Dynamics in Cortical Culture
Previous studies on O-GlcNAc had shown that phosphorylation pathways could regulate
glycosylation levels in cytoskeletal fractions of cultured cerebellar neurons 5.  Here, we
asked if similar effects could be observed for mixed cortical/hippocampal neurons in
culture.
Table AI.2. Pharmacological treatment of neuronal cortical culture can modulate O-GlcNAc
levels as measured by O-GlcNAc antibody CTD110.6 Western blotting
Glucose Known Target Cell Observed
Concentration (mM) Stimulus of Stimulus Fractionation Time Effect Control
25mM 10 mM Gluocsamine UDP-GlcNAc Whole Cell 3 h/6h/9h upregulation –
levels SDS
25mM 100 µM PUGNAc O-GlcNAcase Whole Cell 9h/12h/24h upregulation –
inhibition SDS
25mM 50µM Forskolin cAMP pathway Whole Cell 1.5 h no change phospho-GlUR1 (s845)
PKA activation SDS phospho-CREB(s133)
25mM Calyculin 0.03 µM PP2A S2/P2 15 min/1 h downregulation phospho-CREB(s133)
inhibition Whole Cell SDS
25mM Orthovanadate 10mM tyrosine phosphatase Whole Cell SDS 2 h no change –
inhibition
25mM H89 10µM PKA inhibition Whole Cell SDS 1.5 h no change phospho-CREB(s133)
phospho-GLUR1(s845)
25mM 50 mM KCl depolarization Whole Cell SDS 2 min  no change phospho-CREB(s133)
5mM/7.5mM/20mM 50 mM KCl depolarization Whole Cell SDS 30 s/1min/5min/30min/1h  no change phospho-CREB(s133)
25mM Calcium Ionophore A23187 multiple pathways Nuc/S2/P2 1.5 min no change phospho-CREB(s133)
5mM Calcium Ionophore A23187 multiple pathways Whole Cell SDS  1/2/5/10 min no change phospho-CREB(s133)
25mM NMDA 100µM multiple pathways Whole Cell SDS 2 min/1h no change phospho-CREB(s133)
25mM NMDA 20µM/200µM Nuclear/S2/P2 3 min no change phospho-CREB(s133)
25mM PDBU 5µM PKC activation Whole Cell SDS 5 min no change phospho-GlUR1 (s831)
25mM Insulin 0.02µM multiple pathways Whole Cell SDS 15 min/3h/12h no change phospho-Akt(s473)
25mM Insulin Growth Factor-1 0.02µM multiple pathways Whole Cell SDS 15 min/3h/12h no change phospho-Akt(s473)
25mM PD98059 10µM MEK inhibition Whole Cell SDS 1 h no change –
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Our results with cortical culture suggest that as with hippocampal slices, O-GlcNAc
levels can respond dynamically to glucosamine and PUGNAc treatment.  Varying
glucose concentration produced ambiguous effects, in some cases producing subtle
differences in O-GlcNAc levels by CTD110.6 Western blotting.  Finally, as shown in
Figure AI.2, the PP1/PP2A inhibitor calyculin A was able to significantly downregulate
O-GlcNAc levels on several prominent protein bands as quickly as 15 min after
treatment.
Figure AI.2. Pharmacological treatment of neuronal cortical culture with the phosphatase
inhibitor calyculin A decreases O-GlcNAc glycosylation as observed by CTD110.6
Western blotting.  Neuronal Fractions probed include total cellular homogenate (H0),
cytosol (S2) and Nuclear. Western blotting of phosphorylated CREB from the sample
samples shows the expected increase in phosphorylation with calyculin A treatment.
AI.4 Characterization of O-GlcNAc Cycling at Synaptosomes
The O-GlcNAc enzymes are very abundant at nerve terminal synaptosomes, particularly
in the presynaptic cytosol.12  Moreover, our own work (Chapter 4) has identified a
number of modified proteins in the synaptosome, many of which are involved in synaptic
0.03µM calyculin A
CTD110.6
+
++
–
––
H0 S2 Nuclear
75
50
35
105
250
160
mw(kDa)
pCREB(S133)
Nuclear
+–
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vesicle cycling and presynaptic scaffolding.  To investigate the dynamics of O-GlcNAc
in synaptosomes, we fractionated adult rat cortices and isolated synaptosomes.  Intact
synaptosomes were then treated with a variety of pharmacological stimuli.  O-GlcNAc
levels on SDS-lysed synaptosomes were monitored with the CTD110.6 antibody.  As
described in Table AI.3, we tested a number of stimuli, including PUGNAc, none of
which reproducibly  produced changes in O-GlcNAc glycosylation. O-GlcNAc may be
constitutive on the bands detected in SDS lysis of the synaptosomal fraction.  Therefore,
it will be important to test the effect of these stimuli on fractionated synaptosomes, as
SDS lysis may be masking effects on cytosolic O-GlcNAc proteins.
Table AI.3. The effect of pharmacological stimuli on O -GlcNAc levels of  cortical
synaptoneurosomes as monitored by SDS-lysis of treated synaptosomes and subsequent
CTD110.6 Western blotting
AI.4 Implications and Future Directions
Overall, we found that O-GlcNAc levels can respond directly to the UDP-GlcNAc
precursor glucosamine and the O-GlcNAcase inhibitor PUGNAc in both neuronal culture
and hippocampal slices.  This supports a dynamic cycling of O-GlcNAc in neuronal
tissue.  We also found that O-GlcNAc  levels could respond to perturbations in
phosphorylation pathways, specifically to the PKA inhibitor H89 in hippocampal slices
Known Target Observed
Stimulus of Stimulus Effect Time Control
50 µM PUGNAc O-GlcNAcase no change 1 h/2 h –
200µM inhibition 1 h
5 µM/10 µM/50 µM Forskolin cAMP pathway no change 15 min phospho-synapsin(s9)
PKA activation 15 min
0.25 µM Calyculin A  PP2A/PP1 no change 10 min phospho-synapsin(s9)
inhibition
2.5 µM/5 µM KN-62 CaMKII no change 5 min phospho-synapsin(s9)
inhibition
H89 100µM PKA inhibition no change 15 min/1 h phospho-synapsin(s9)
50 mM KCl depolarization  no change 30 sec/1 min/5 min phospho-synapsin(s9)
10 min/30 min/1 h
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and the protein phosphatase (PP1 and PP2A) inhibitor calyculin A in cultured cortical
neurons.
Although previous studies on cerebellar neurons had indicated that O-GlcNAc
levels are significantly downregulated with short treatments of the calcium ionophore
A23187,5 we found no such effect on cortical neurons.  This may be due to technical
variation. The cerebellar neuron study used an O-GlcNAc antibody coupled to an ElISA
assay that has been reported to detect other carbohydrate epitopes.13  Alternatively,  there
may be differences in O-GlcNAc regulation in the cortex versus the cerebellum
Several additional studies may address the findings reported in this appendix.  In
vitro glycosylation assays with immunoprecipitated OGT have successfully been used to
detect changes in enzyme activity in response to cellular stimuli.4  Those studies would
be important to do on slices or neuron culture.  Although we could not detect changes in
glycosylation within synaptosomes, this may reflect difficulties in detecting such changes
from unfractionated material.  It will be useful to repeat some of these stimulations and
fractionate synaptosomes into the components that showed greatest enrichment of the O-
GlcNAc enzymes (i.e., the synaptosomal cytosol).12  Moreover, in vitro activity assays
for both enzymes after stimulation will likewise offer insight into O-GlcNAc regulation
in this  compartment.
Several studies suggest that O-GlcNAc may play a fundamental role in the stress
response.14  With the exception of our study with kainic acid discussed in Chapter 5, this
has not been addressed in neuronal tissue.  It will be important to examine changes in O-
GlcNAc in response to neuronal stresses such as hypoxia and excitotoxicity both on the
level of enzyme activity and O-GlcNAc glycosylation.  Finally, ongoing developments in
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the chemoenzymatic strategy (as described in Chapter 2) should allow for direct
chemiluminescent or fluorescent detection of tagged O-GlcNAc proteins.  We envision
that this methodology will have significant benefits in sensitivity  and scope over the
CTD110.6 antibody and will be useful for studying O-GlcNAc dynamics both by
Western blot and through in-gel fluorescent detection.
AI.5: Experimental Methods
Preparation of Hippocampal Slices
8-10 week old Sprague-Dawley rats (Charles River Laboratories) were sacrificed (with
C02 for 1-1.5 min) and decapitated. Brains were removed and rinsed with ice-cold Krebs
bicarbonate buffer (124 mM NaCl, 4 mM KCl, 26 mM NaHCO3, 1.5 mM CaCl2, 1.25
mM KH2PO4, 1.5 mM MgSO4, and 10 mM D-glucose, pH 7.4), which was buffered with
5% CO2/95% O2 that had been aerated for at least 30 min before use.  Cerebella were
removed by razor blade and 400 µM coronal slices of cerebral cortices were prepared by
vibratome (Leica). During slicing, brains were immersed in Krebs bicarbonate buffer,
chilled by ice-water bath.  Hippocampi were dissected out of slices and placed into 2 mL
polypropylene tubes containing chilled Krebs bicarbonate buffer.  Buffer was
immediately removed and replaced with fresh solution, and slices were incubated for 30
min at 30 ºC with constant bubbling of 5% CO2/95% O2. Incubation buffer was removed
and new buffer, containing the pharmacological agents described in Table AI.1 were
added to slices.  All pharmacological agents were purchased from Alexis biochemicals
except PUGNAc (Toronto research chemicals) and glucosamine-HCL (Sigma).  KCl
depolarization experiments were conducted in Krebs bicarbonate buffer except  that NaCl
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concentration was 55 mM and KCl concentration was 60 mM.  Treatment was stopped by
removal of the slice from treatment buffer via glass pipet.  Slices were immediately flash
frozen in liquid N2 and stored at –80 ºC until further use.  Each experimental slice was
paired with a control slice from the opposing hemisphere.  Control slices were treated
identically except that pharmacological agents were replaced with the same volume of
vehicle (DMSO, ddH20, or 100mM HEPES pH 7.4 for glucosamine).
For whole cell SDS lysis, slices were lysed in boiling 1% SDS, with protease
inhibitors, sonicated for 3 sec and boiled for 8 min.  Slices were kept on dry ice until the
addition of boiling SDS.  For fractionation, two slices were homogenized by mechanical
homogenization for 5 strokes at 700 rpm in 300 µL of homogenization buffer (0.32 M
sucrose, phosphatase inhibitors, protease inhibitors, 10 µM PUGNAc, 50 mM
glucosamine). Centrifugation at 800 × g for 10 min produced the nuclear pellet, which
was washed one time in homogenization buffer and lysed directly into boiling 1% SDS
by sonication.  Supernatant (S1) was spun at 16,000 × g for 15 min to produce the S2 and
P2 fractions.
Preparation of Cortical Culture
Cortical neuronal cultures were prepared as described in experimental methods of
Chapter 5.  Neurons were grown in 100 mM dishes (8-15X 106 cells/dish) or in 6-well 35
mM plates (2-4 X 106 cells/dish) pre-coated with poly-D,L-lysine (Sigma).  Media was
replaced 12 h before addition of pharmacological agents, which were added directly to
culture dishes/wells.  Neurons were generally grown for 7-10 days before
pharmacological treatment.  To specifically assess the effect of glucose concentration on
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O-GlcNAc levels, neurons were grown in  minimum essential media (MEM) (Gibco)
containing 10% fetal calf serum (FCS) (Gibco), 1X N2-supplement (Gibco) 1 mM
pyruvate, and 5 mM glucose. For different concentrations of glucose, media was
supplemented with sterile-filtered glucose (1 M) to final concentrations as described in
the text.
For SDS lysis of short pharmacological treatments (≤3 h), treatments were
stopped by aspiration of the media and 1% SDS (with protease inhibitors, phosphatase
inhibitors and 10 µM PUGNAc) was added directly to dishes/wells (250 µL/well of a 6-
well dish).  Neurons were scraped into lysis buffer, drawn up with a plastic P1000 pipet
(cut at the tip) and sonicated for 2 × 3 sec.  Lysate was boiled for 8 min and centrifuged
for 5 min at 15,000 × g to remove insoluble material.  For SDS lysis of prolonged
treatments (≥3 h) in 100 mM dishes, media was removed and neurons were trypsinized,
pelleted and frozen at –80 ºC until future use.  Pellets were kept on dry ice until lysis in
boiling 1% SDS with protease inhibitors, phosphatase  inhibitors and 10 µM PUGNAc.
S2/P2 fractionation was conducted on neurons grown in 100 mM dishes.
Treatment was stopped by media aspiration. Plates were quickly washes with 1 mL of
ice-cold HEPES-buffered Saline and lysed by scraping into 500-800 µL of ice-cold lysis
buffer (0.32 M sucrose, 10 mM HEPES pH 7.4 containing protease inhibitors,
phosphatase inhibitors, 10 µM PUGNAc and 50 mM GlcNAc).  Scraped cells were
homogenized  by manual dounce homogenization for 5 strokes on ice followed by
mechanical homogenization for 5 strokes at 700 rpm.   A portion of the lysate was saved
as homogenate (H0) and the rest was centrifuged for 10 min at 800 × g. The resultant
nuclear pellet was washed one time with lysis buffer (with no PUGNAc or GlcNAc) and
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then lysed directly in boiling 1% SDS.  The supernatant (S1) was centrifuged for 15 min
at 16,000 × g yielding  the S2 supernatant and the P2 pellet.  P2 pellets were washed one
time with 10% sucrose and lysed directly into boiling 1% SDS.
Synaptosome Treatment and Lysis
Intact Synaptosomes were prepared as described in the experimental methods of Chapter
4.  After rinsing in pre-incubation buffer as described, synaptosomes were diluted in
incubation buffer (10 mM HEPES pH 7.4, 10 mM Glucose, 4.8 mM KCl, 1.2 mM
Na2HPO4, 2.4 mM MgSO4, 132 mM NaCl, 1.1 mM CaCl2, 0.1 mM EGTA), at a volume
of 750-1000 µL per brain originally used for extract preparation.   Synaptosomes were
split into portions, in eppendorf tubes, for experiments and  incubated by rocking at 37 ºC
for 15 min.  (Typically, 6 experiments, each with a control, were conducted from 8 rats.)
After 15 min, synaptosomes were diluted 2-fold with incubation buffer containing
pharmacological agents or an equal volume of vehicle and incubated for the prescribed
time.  In the case of depolarization experiments synaptosomes were diluted two-fold with
10 mM HEPES pH 7.4, 10 mM Glucose, 105 mM KCl, 1.2 mM Na2HPO4, 2.4 mM
MgSO4, 32 mM NaCl, 1.1 mM CaCl2, 0.1 mM EGTA, such that the final concentration of
NaCl was 82 mM and final KCl concentration was 55 mM15.  Incubations were stopped
by placing tubes on ice. Eppendorf tubes were immediately centrifuged by pulse
centrifugation for 15 sec (in a refrigerated centrifuge) to collect synaptosomes.
Incubation buffer was removed by pipet and synaptosomes immediately lysed by addition
of boiling 1% SDS with protease inhibitors.  Synaptosomal extract was sonicated for 3 ×
3 sec and boiled for 8 min.  Synaptosomal extracts were spun at 15,000 × g for  5min to
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remove insoluble material.
CTD110.6 Western Blotting
Blots were blocked for 1 h in 5% BSA, TBS-T(0.1%) and incubated with the CTD110.6
antibody (Covance) for 1 h at RT or o/n for 10-12 h at 4 ºC at a concentration of 1:2500-
1:5000 in blocking buffer.  Blots were rinsed with  TBS-T(0.1%), washed 3 × 5 min and
incubated with secondary antibody, (GαM IgG-HRP, Pierce) at a concentration of
1:10,000 at RT for 1 h.  Blots were subsequently rinsed with TBS-T(0.1%), washed 2 ×
15 min and 3 × 5 min and developed by chemiluminescence.
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Appendix II
Identification of O-GlcNAc Glycosylation Sites: Application to
Endogenous Proteins and Exploration of Fluorous Enrichment Strategies
AII.1 Background and Introduction
In Chapter 3 we highlighted methodology for identification of glycosylation sites
from individual proteins.  Glycosylation site mapping is a particularly important endeavor
as it helps to establish the functional significance of the O-GlcNAc modification.
Mapping sites to  particular domains of proteins  advances research into the mechanisms
by which O-GlcNAc may alter protein-protein interaction,1 protein stability,2 or protein
activity.3
In Chapter 3 we demonstrated that the chemoenzymatic strategy allows the facile
isolation and identification of  O-GlcNAc peptides  from purified proteins such as CREB,
OGT and ΔfosB and the low-stoichiometry protein α-crystallin.  Here, we discuss our
efforts to extend this approach to individual endogenous proteins or proteins transfected
at low levels into neuronal culture.  This presents a formidable task given the lack of
consensus sequence for OGT, the low-abundance of many targets, and the
substoichiometric nature of the modification.4  We also demonstrate the versatility of the
chemoenzymatic approach by demonstrating non-biotin streptavidin techniques for
isolation of O-GlcNAc peptides.
AII.1 O-GlcNAc Site Identification on Low Abundance Proteins from Cells
To investigate the applicability of site identification for endogenous proteins, we
chemoenzymatically labeled HIT-T15 pancreatic cell lysate and immunoprecipitated
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CREB.  Control samples were treated identically except that the enzyme β1,4-
galactosyltransferase Y289L was not added to reactions.  As Figure AII.1 shows, only
CREB that was immunoprecipitated from lysates labeled with both the enzyme and
analogue 1 displayed a signal by streptavidin Western blotting.
Figure AII.1. Endogenous O-GlcNAc glycosylated CREB is chemoenzymatically tagged and
immunoprecipitated from HIT-T15 pancreatic cell lysate.
A fraction of the chemoenzymatically tagged lysate was run on an SDS-PAGE gel
and silver stained, revealing two discrete bands in the molecular weight vicinity of CREB
(Figure AII.2A).  In-gel trypsin digestion followed by liquid-chromatography mass
spectrometry (LC-MS) revealed that the upper band corresponded to CREB (sequence
coverage in Figure AII.2B).
Figure AII.2. (A) Silver stain of endogenous CREB immunoprecipitated from
chemoenzymatically tagged  HIT-T15 pancreatic cell lysate. (B) LC-MS/MS sequence coverage
of in-gel tryptic digest of the marked band. Sequencing revealed that this band contained peptides
corresponding to CREB. Peptides found by LC-MS are highlighted in yellow, including the
peptide known to contain the O-GlcNAc site (highlighted in blue).
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Although we identified the peptide known to contain the O-GlcNAc site, avidin
enrichment of the digested CREB peptides did not reveal any  O-GlcNAc-modified
species.  Because we did not see the modified peptide in the avidin chromatography input
we must conclude that it is of considerably lower abundance (and thus stoichiometry)
than the unmodified peptide.
Concurrently with CREB, we applied a similar strategy to neuronal lysates that
had been transected with a Flag-tagged MeCP2.  We had previously shown that the
transcriptional repressor MECP2 is an O-GlcNAc protein (Chapter 3) but the site of
modification is unknown.  We chemoenzymatically labeled neuronal lysate and
immunoprecipitated using an anti-Flag antibody (Figure AII.3A).  We found two bands
that had a molecular weight close to that reported for MECP2 and analyzed both by LC-
MS. As shown in figure AII.3B, we were able to identify the lower band as MeCP2.
However, as with CREB, avidin enrichment of the digested peptides did not reveal an O-
GlcNAc-modified species.
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Figure AII.3. Immunoprecipitation and LC-MS/MS sequence coverage of Flag-tagged MeCP2
isolated from neuron culture.  (A) Silver Stain of chemoenzymatically-tagged and Flag-
immunoprecipitated lysate reveals two bands in the molecular weight vicinity of the
transcriptional repressor MeCP2. (B) LC-MS/MS of the in-gel tryptic digest of both bands reveals
that the bottom band corresponds to MeCP2 as demonstrated by the identified peptides.
Several methodological adjustments may make identification of the O-GlcNAc
site from very low-abundance proteins such as CREB and neuron-transfected or
endogenous MeCP2 technically feasible.  First, in-gel digestion is known to incur loss
and it may be replaced with on-bead proteolytic digestion.  Second, our avidin
enrichment strategy currently utilizes a large (0.2 mL, Applied Biosystems) affinity
cartridge that includes an 800 µL elution step.  The eluent is then dried by vacuum
centrifugation before LC-MS.  This approach is effective for O-GlcNAc glycosylated
peptides isolated from >1 µg of protein, or from complex mixtures, but may induce
significant loss for low-abundance material.  Therefore, it may be useful to add carrier
species in picomolar abundance (such as biotinylated peptides, or digested purified O-
GlcNAc proteins such as OGT) when analyzing endogenous proteins.  In addition, it may
be effective to pack monomeric avidin (commercially available from several sources)
into microcapillary columns for improved sensitivity.
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Finally, one advantage of the chemoenzymatic approach is the versatility of the
ketone ‘handle,’ which may be exploited to tag O-GlcNAc with other molecules besides
biotin for affinity purification.  To address some of the problems described with biotin-
streptavidin, we explored the use of a fluorous-aminooxy group for fluorous-affinity
chromatography and enrichment of O-GlcNAc peptides, with some success.
AII.3 Coupling the Chemoenzymatic Strategy with Fluorous Affinity
Chromatography
Highly fluorinated or ‘fluorous’ compounds have been exploited for a number of
separation and enrichment strategies in both organic synthesis5 and more recently in mass
spectrometry of peptides.6  Because of the selectivity of the fluorine-fluorine interaction,
fluorous compounds can be readily separated from a mixture by solid-phase extraction
over fluorous-functionalized silica gel  (fluorous solid-phase extraction (FSPE)) .  In
order to overcome some of the limitations of streptavidin enrichment described above, we
explored the utility of FSPE for the enrichment of O-GlcNAc glycosylated peptides that
had been tagged with a fluorous compound. We used a commercially available fluorous-
aminooxy  nucleophile, 2-Aminooxy-N-(3-perfluorolhexyl)propyl-acetamide (Fluorous
Technologies, Inc, Pittsburgh PA), to tag keto-galactose labeled O-GlcNAc transferase
(OGT).  After in-gel trypsin digestion, fluorous-O-GlcNAc peptides were specifically
enriched via FSPE and analyzed in-line with mass spectrometry.   Because fluorous
peptides could be specifically enriched in a microcapillary column in-line with the mass
spectrometer, we did not need to manually collect eluent or conduct additional reverse-
192
phase chromatography to detect O-GlcNAc peptides.  Enrichment of a representative
OGT peptide is shown in Figure AII.4
Figure AII.4. FSPE enrichment of tagged O-GlcNAc peptides from OGT.  The total ion
chromatogram (TIC) of trypsin-digested OGT as it eluted from the FSPE column onto the mass
spectrometer shows a region of enriched, fluorous-tagged O-GlcNAc peptides.  MS/MS analysis
of one of these peptides shows the characteristic signature loss of the fluorous-ketogalactose
group and fluorous-ketogalactose-GlcNAc.  Representative b and y ions are shown from the MS4
sequencing of this peptide, which was identified as 390ISPTFADAYSNMoxGNTLK406 of OGT.
Notably, we detected all the O-GlcNAc peptides of OGT that had been identified by
biotinylation and streptavidin enrichment (Chapter 3) and additionally found that the
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peptides 421AIQINPAFADAHSNLASIHK440 and 390ISPTFADAYSNMoxGNTLK406
were doubly O-GlcNAc modified.
We investigated the fluorous strategy on several other proteins such as the
transcription factor ΔfosB (Chapter 3) and CREB as well as on complex mixtures.
However, we were confronted with several problems.  First, the fluorous compound
necessitates organic solvent for solvation.  We found that protein lysates were most stable
in commixtures of THF/water.  However, care had to be taken as ketone byproducts form
in THF that compete for oxime formation.  We addressed some of these problems by
digesting proteins directly after enzymatic addition of the ketogalactose group.  Digested
peptides were subsequently labeled with the fluorous-aminooxy, (peptides are stable in
organic/aqueous co-mixtures such as EtOH/water, forgoing the need for THF).  To
remove excess fluorous-aminooxy, we used Zwitterionic-HILIC chromatography
(SeQuant).  However, we had difficulty implementing the methodology, reproducibly, for
complex mixtures.
However, as demonstrated with OGT, the strategy may be useful for single
proteins as the enrichment step is conducted within microcapillary columns, in-line with
mass spectrometry.  This forgoes the large volumes and unnecessary handling and drying
steps of avidin enrichment and may increase the recovery of O-GlcNAc peptides from
low-abundance, low-stoichiometry proteins.
AII.3: Experimental Methods
Chemoenzymatic Labeling of HIT-TI5 cells and Immunoprecipitation of CREB
HIT-T15 cells were cultured, chemoenzymatically labeled and CREB
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immunoprecipitated as described in Chapter 5.  600µg of lysate was chemoenzymatically
labeled for Western blot analysis and 3.8 mg was labeled for mass spectrometry analysis.
To immunoprecipitate CREB from lysate for mass spectrometry, 50 µL of protein A
sepharose (Pierce) and 7.5 µg of anti-CREB antibody (rabbit polyclonal, Upstate
Biotechnology) were used.  SDS-PAGE of immunoprecipitated proteins was conducted
with 4-12%  Bis-Tris gels (Invitrogen).
Chemoenzymatic Labeling of Neuronal Cell Lysate and Immunoprecipitation of
Flag-Tagged MeCP2
Harvested and frozen embryonic cortical neurons, which had been transfected with an N-
terminal Flag construct of MeCP2 and treated with 10 mM glucosamine for 6 h were
provided by J. Zellhoefer from Yi Sun’s Laboratory at UCLA.  Pellets were lysed in 1%
boiling SDS and chemoenzymatically labeled as described in Chapter 3.  One milligram
of lysate was used for mass spectrometry analysis.  After biotinylation, labeled lysates
were dialyzed into Flag-IP buffer (0.05 M Tris pH 7.4, 100 mM NaCl, 5 mM EDTA,
0.2% NP-40) 1× 12 h,  and 2 × 3 h at 4 ºC.  One hundred microliters of Flag-agarose
beads (Sigma) were washed with 1 mL Flag-IP buffer 3× and incubated with labeled
lysate for 2 h at 4 ºC by inversion.  Flowthrough was removed by centrifugation on a
table-top centrifuge.  Beads were washed 3× with Flag-IP buffer, 3× with TBS (50 mM
Tris-HCl, 150 mM NaCl, pH 7.4) and 1× with 50 mM Na2HPO4 pH 7.4 at 4 ºC. Captured
proteins were eluted by boiling beads in 150 µL of 2X SDS-PAGE loading dye for 2 ×
3min (beads were briefly vortexed after the first 3 min incubation). SDS-PAGE was
conducted with 7% Tris-Acetate gels (Invitrogen).
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Western Blotting
Streptavidin western blotting and anti-CREB western blotting were performed as
described in the experimental methods of Chapter 5. Flag immunoprecipitates were
blocked for 1 h at RT in 5% milk-TBS-T(0.1%), and incubated with the anti-Flag
antibody (mouse monoclonal, Sigma) at a concentration  of 1:2000, in blocking buffer,
for 1 h at RT.  Blots were subsequently rinsed in TBS-T(0.1%) and washed 3 × 5 min in
TBS-T(0.1%).  Blots were incubated with a GαM IgG secondary antibody at a
concentration of 1:10,000 in blocking buffer for 1 h at RT.  They were subsequently
rinsed in TBS-T(0.1%), washed 2 ×  15 min and 3 ×  5 min and developed via
chemiluminescence.
Silver Stain, In-Gel Digestion and LC-MS of CREB and MeCP2
SDS-PAGE gels were silver stained with a variantion of the methods described by
Shevchenko et al.,7 and Blum et al.8  Gels were fixed for 30 min in 50% MeOH/10%
AcOH.  Solution was removed and gels were fixed in 5% MeOH/1% AcOH for 15 min,
then rinsed with 50% MeOH for 1 min.  Gels were then washed for 3 × 10 min with
ddH20, then sensitized for 90 sec with 20 mg/100 mL of Na2S2O3•5H20.  Gels were then
rinsed for  3 × 30 sec in ddH20, and silver stained with AgNO3 (200 mg/100 mL) for 30
min. After rinsing 3 × 30 sec in ddH20, gels were developed in Na2CO3 (6 g/100 mL),
37% formaldehyde (50 µL/100 mL), Na2S2O3•5H20 (from the sensitization step, 2
mL/100 mL).  Development proceeded until bands at the appropriate molecular weight of
CREB and MeCP2 were visualized and stopped by removal of the development solution
and addition of 6% AcOH, in water.  After rinsing in ddH20, putative CREB and MeCP2
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bands were excised from silver-stained gels.  Gel pieces were cut into 5-6 pieces with a
razor blade and incubated with destain solution (K3Fe(CN)6 0.4 g/200mL in 0.2 g/L
Na2S2O3•5H20) for 15 min with shaking (or until gel pieces turned yellow).  Gel pieces
were washed 4-5 times for 15 min each with ddH20 until pieces were transparent. Gel
pieces were reduced, alkylated and trypsin digested as described in Chapter 3.
LC-MS and avidin enrichment on digested peptides was performed as described
for CREB/OGT in the experimental methods of Chapter 3.
Chemoenzymatic (Fluorous) Labeling and LC/MS of OGT
 Baculovirus preparation and protein expression were performed as described previously.1
OGT (10 µg) (in a mixture with CREB (2 µg)) in 20 mM HEPES pH 7.9, 100 mM KCl,
0.2 mM EDTA, 15% glycerol was supplemented with 5 mM MnCl2. Analogue 1 and
Y289L GalT were added to final concentrations of 500 µM and 40 ng/µL, respectively.
Following incubation at 12 h at 4 °C, the reactions were diluted 3-fold with 9M urea, 2.7
M NaOAc pH 3.9, neat THF and 2-Aminooxy-N-(3-perfluorolhexyl)propyl-acetamide
(Fluorous Technologies, Inc, Pittsburgh PA) dissolved in neat THF (final concentration
3.8 M urea, 50 mM NaOAc, 20% THF, 3 mM 2-Aminooxy-N-(3-perfluorolhexyl)propyl-
acetamide, final pH 4.8) and incubated with gentle shaking for 20-24 h at 23 °C. Tagged
OGT was resolved by SDS-PAGE and the protein was excised and digested from a
Coomassie-stained gel as described in Chapter 3.
Automated nanoscale liquid chromatography and tandem mass spectrometry (LC-
MS/MS) were conducted using a ThermoElectron Surveyor HPLC and  LCQDecaXP+
mass spectrometer along with a variation of the “vented column” approach described by
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Licklider et al.9  Labeled digests were combined with an equal volume of 50% methanol
with 10 mM ammonium formate and loaded onto fluorous analytical columns with
integrated ESI emitter tips (360 um OD x 75 um ID fused silica, 5 um tip) packed with 5
cm Fluoroflash media (FTI, Pittsburgh, PA).  Peptides were eluted into the
LCQDecaXP+ ion trap mass spectrometer (ThermoElectron Corp, San Jose, CA) using
an HPLC gradient (50% B for 2 min, then 50%-95% B in 10 minutes, A = 0.1M acetic
acid with 10 mM ammonium acetate, B = 0.1M acetic acid in methanol with 10 mM
ammonium formate).  The mass spectrometer was operated in data dependent mode such
that the top 3 ions in each MS scan was subjected to MS/MS (relative collision energy =
35%).  Higher-order MS analyses involved an MS precursor scan followed by targeted
MS4 scans of those masses that specifically demonstrated loss of the ketone-fluorous
moiety and ketone-fluorous-GlcNAc moiety in the MS/MS analysis. MS4 data were used
to search against an OGT sequence database using SEQUEST.10 For all experiments, the
spray voltage was 1.8 kV and the capillary temperature was 150 ºC.
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